

The effects of lowering LDL cholesterol with simvastatin in patients with
chronic kidney disease (Study of Heart and Renal Protection): a
placebo-controlled trial

Lancet, The

377, 2181-2192

DOI: [10.1016/s0140-6736\(11\)60739-3](https://doi.org/10.1016/s0140-6736(11)60739-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) <i>TJ ETQq0 0 0</i> <i>igBT /Overlock 10 T</i>	10.0	2,331
3	Secondary dyslipidaemia. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2011, 53, 317-323.	0.2	0
4	Lipid lowering in patients with chronic kidney disease: a SHARP turn in the wrong direction?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 858-861.	3.1	5
5	The Year in Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2011, 58, 779-791.	1.2	7
6	Chronic Kidney Disease and Cardiovascular Therapeutics. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1162-1164.	1.2	5
7	Current developments in lipid-lowering therapy for the patient with chronic kidney disease. <i>Clinical Lipidology</i> , 2011, 6, 693-702.	0.4	0
8	Inflammation as a risk factor and target for therapy in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 662-668.	1.0	102
9	SHARP: a stab in the right direction in chronic kidney disease. <i>Lancet, The</i> , 2011, 377, 2153-2154.	6.3	16
10	Prevention of cardiovascular disease in adult recipients of kidney transplants. <i>Lancet, The</i> , 2011, 378, 1419-1427.	6.3	234
11	Benefits of lowering cholesterol in chronic kidney disease. <i>Lancet, The</i> , 2011, 378, 1375.	6.3	0
12	Benefits of lowering cholesterol in chronic kidney disease. <i>Lancet, The</i> , 2011, 378, 1376.	6.3	0
13	Benefits of lowering cholesterol in chronic kidney disease. <i>Lancet, The</i> , 2011, 378, 1376.	6.3	0
14	Benefits of lowering cholesterol in chronic kidney disease. <i>Lancet, The</i> , 2011, 378, 1376-1377.	6.3	2
15	Benefits of lowering cholesterol in chronic kidney disease – Authors' reply. <i>Lancet, The</i> , 2011, 378, 1377-1378.	6.3	1
16	Mild and moderate pre-dialysis chronic kidney disease is associated with increased coronary artery calcium. <i>Vascular Health and Risk Management</i> , 2011, 7, 719.	1.0	22
17	Lipid-lowering therapy: who can benefit. <i>Vascular Health and Risk Management</i> , 2011, 7, 525.	1.0	31
18	IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rlsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. <i>Archives of Medical Science</i> , 2011, 6, 984-992.	0.4	46
19	State of the art papers Lipids, blood pressure, kidney – what was new in 2011?. <i>Archives of Medical Science</i> , 2011, 6, 1055-1066.	0.4	63

#	ARTICLE	IF	CITATIONS
22	Combination therapy for dyslipidemia. <i>Current Opinion in Cardiology</i> , 2011, 26, 420-423.	0.8	6
23	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Yearbook of Medicine</i> , 2011, 2011, 190-193.	0.1	46
24	Protecting the kidneys in lupus nephritis. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 529-546.	0.3	11
26	Implications of the Frequent Hemodialysis Networkâ€Daily Trial. <i>Seminars in Dialysis</i> , 2011, 24, 621-628.	0.7	3
27	A SHARP Study, But With Blunted Conclusions. <i>Seminars in Dialysis</i> , 2011, 24, 684-685.	0.7	1
28	HDL: who needs it?. <i>International Journal of Clinical Practice</i> , 2011, 65, 1111-1113.	0.8	4
29	The ezetimibe Jonah: the trials and tribulations of an unlucky drug. <i>International Journal of Clinical Practice</i> , 2011, 65, 1207-1208.	0.8	22
30	The Polypill - multiple drug combinations are not the answer. <i>International Journal of Clinical Practice</i> , 2011, 65, 1113-1114.	0.8	1
31	Impact of CKD on Coronary Artery Calcifications. <i>American Journal of Kidney Diseases</i> , 2011, 58, 503-505.	2.1	1
32	Impact of Ezetimibe Coadministered With Statins on Cardiovascular Events Following Acute Coronary Syndrome: A 3-Year Population-Based Retrospective Cohort Study in Taiwan. <i>Clinical Therapeutics</i> , 2011, 33, 1120-1131.	1.1	14
33	Efficacy of Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients With or Without Obesity. <i>Combination Products in Therapy</i> , 2011, 1, 1.	1.1	3
34	Familial Hypercholesterolemia: Present and Future Management. <i>Current Cardiology Reports</i> , 2011, 13, 527-536.	1.3	40
35	Early detection of CKD: the benefits, limitations and effects on prognosis. <i>Nature Reviews Nephrology</i> , 2011, 7, 446-457.	4.1	68
36	The Role of Statins in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2011, 34, 195-202.	1.4	37
38	The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients: the rosuvastatin monotherapy looks to be insufficient. <i>Current Medical Research and Opinion</i> , 2011, 27, 1959-1960.	0.9	7
39	Intestinal sterol transporters and cholesterol absorption inhibition. <i>Current Opinion in Lipidology</i> , 2011, 22, 467-478.	1.2	24
40	Hyperlipidaemia and cardiovascular disease - Back to basics. <i>Current Opinion in Lipidology</i> , 2011, 22, 509-511.	1.2	4
41	Growing Evidence Showing Association of Chronic Kidney Disease and Coronary Artery Disease Should Impact Clinical Practice. <i>Cardiology</i> , 2011, 120, 209-210.	0.6	0

#	ARTICLE	IF	CITATIONS
42	Lowering LDL cholesterol reduces atherosclerotic risk in patients with chronic kidney disease. <i>Nature Reviews Cardiology</i> , 2011, 8, 424-424.	6.1	1
43	n-3 polyunsaturated fatty acids, lipids and lipoproteins in end-stage renal disease. <i>Clinical Lipidology</i> , 2011, 6, 563-576.	0.4	7
44	Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 987-997.	0.6	6
45	Lipid-lowering in CKD— at the SHARP end of the evidence?. <i>Nature Reviews Nephrology</i> , 2011, 7, 609-611.	4.1	2
46	Health Literacy Associated With Blood Pressure but not Other Cardiovascular Disease Risk Factors Among Dialysis Patients. <i>American Journal of Hypertension</i> , 2012, 25, 348-353.	1.0	46
47	Republished: How to reduce sudden cardiac death in patients with renal failure. <i>Postgraduate Medical Journal</i> , 2012, 88, 418-424.	0.9	0
48	Screening for Chronic Kidney Disease: Preventing Harm or Harming the Healthy?. <i>PLoS Medicine</i> , 2012, 9, e1001345.	3.9	11
49	Serum triglycerides and risk for death in Stage 3 and Stage 4 chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3228-3234.	0.4	17
50	Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients. <i>Cholesterol</i> , 2012, 2012, 1-7.	1.6	49
51	Physiological role of hepatic NPC1L1 in human cholesterol and lipoprotein metabolism: New perspectives and open questions. <i>Journal of Lipid Research</i> , 2012, 53, 2253-2255.	2.0	5
52	Stroke and Renal Dysfunction. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 305-311.	0.7	12
53	Can cardiovascular risk in dialysis patients be decreased?. <i>Nature Reviews Nephrology</i> , 2012, 8, 72-74.	4.1	6
54	Carotid Intima-Media Thickness in Children with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1930-1937.	2.2	93
56	Prevention of cardiovascular disease after renal transplantation. <i>Current Opinion in Organ Transplantation</i> , 2012, Publish Ahead of Print, 393-400.	0.8	28
57	Statins and noncardiac vascular disease. <i>Current Opinion in Cardiology</i> , 2012, 27, 392-397.	0.8	22
58	Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 334-340.	1.0	44
59	Chronic kidney disease 10 years on. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 607-611.	1.0	5
60	The fats of life in diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2012, 12, 216-220.	0.6	3

#	ARTICLE	IF	CITATIONS
61	Vascular Disease, ESRD, and Death: Interpreting Competing Risk Analyses. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1606-1614.	2.2	40
62	Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates. <i>Circulation</i> , 2012, 126, 617-663.	1.6	255
63	Lipid-Modifying Therapies and Risk of Pancreatitis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 804.	3.8	140
64	CKD, Plasma Lipids, and Common Carotid Intima-Media Thickness: Results from the Multi-Ethnic Study of Atherosclerosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1777-1785.	2.2	28
65	Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 205-215.	0.9	15
66	Statins and Lipid-Lowering Strategies in PD. <i>Contributions To Nephrology</i> , 2012, 178, 106-110.	1.1	3
67	Statin Therapy Is Associated with Decreased Small, Dense Low-Density Lipoprotein Levels in Patients Undergoing Peritoneal Dialysis. <i>Contributions To Nephrology</i> , 2012, 178, 111-115.	1.1	10
68	Multiple comparisons, interaction effects, and statistical inference: lessons from chronic kidney disease progression among blacks. <i>Kidney International</i> , 2012, 81, 516-519.	2.6	1
70	Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2872-2879.	0.4	45
71	Current drug development challenges in chronic kidney disease (CKD)—identification of individualized determinants of renal progression and premature cardiovascular disease (CVD). <i>Nephrology Dialysis Transplantation</i> , 2012, 27, iii81-iii88.	0.4	13
72	Should statin therapy be expanded in patients with CKD?. <i>Nature Reviews Nephrology</i> , 2012, 8, 440-441.	4.1	1
73	Should we use fibrates in patients with diabetes and mild CKD?. <i>Nature Reviews Nephrology</i> , 2012, 8, 201-202.	4.1	4
74	Progression, prediction, populations and possibilities. <i>Nature Reviews Nephrology</i> , 2012, 8, 70-72.	4.1	3
75	Current views on the management of atherosclerotic renovascular disease. <i>Annals of Medicine</i> , 2012, 44, S98-S110.	1.5	4
76	Ischemic Heart Disease in Patients Undergoing Dialysis. <i>Hospital Practice (1995)</i> , 2012, 40, 33-39.	0.5	4
77	Searching for new care models for chronic kidney disease. <i>Kidney International</i> , 2012, 82, 621-623.	2.6	4
79	What is the real meaning of increased serum plant sterol concentrations?. <i>British Journal of Nutrition</i> , 2012, 108, 943-945.	1.2	2
80	Can LDL-cholesterol targets be achieved in a population at high risk? Results of the non-interventional study ACT II. <i>Current Medical Research and Opinion</i> , 2012, 28, 1447-1454.	0.9	7

#	ARTICLE	IF	CITATIONS
81	Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?. <i>Future Cardiology</i> , 2012, 8, 813-817.	0.5	3
82	Effect of High-Dose Statin Versus Low-Dose Statin Plus Ezetimibe on Endothelial Function. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012, 17, 357-365.	1.0	25
83	Adiponectin in renal disease – a review of the evidence as a risk factor for cardiovascular and all-cause mortality. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2012, 49, 218-231.	2.7	4
84	Statins in the management of dyslipidemia associated with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2012, 8, 214-223.	4.1	46
85	Do patients with CKD benefit from lipid-lowering therapy?. <i>Nature Reviews Nephrology</i> , 2012, 8, 684-685.	4.1	0
86	The question of primary lipid nephrotoxicity. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2614-2615.	0.4	0
87	How to reduce sudden cardiac death in patients with renal failure. <i>Heart</i> , 2012, 98, 335-341.	1.2	7
88	Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2012, 367, 2482-2494.	13.9	805
89	Stage of chronic kidney disease and severity of coronary heart disease manifestation. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 457-460.	0.9	14
90	Therapeutic options for statin-intolerant patients. <i>Current Medical Research and Opinion</i> , 2012, 28, 345-349.	0.9	5
91	Impact of the apolipoprotein B/apolipoprotein A-I ratio on renal outcome in immunoglobulin A nephropathy. <i>Scandinavian Journal of Urology and Nephrology</i> , 2012, 46, 148-155.	1.4	12
92	Sudden Cardiac Death in Hemodialysis Patients: A Comprehensive Care Approach to Reduce Risk. <i>Blood Purification</i> , 2012, 33, 183-189.	0.9	25
93	Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease. <i>Clinical Medicine Insights: Cardiology</i> , 2012, 6, CMC.S4324.	0.6	94
94	Established and Emerging Approaches for the Management of Dyslipidaemia. <i>Scientifica</i> , 2012, 2012, 1-14.	0.6	2
95	Statins for Renal Patients: A Fiddler on the Roof?. <i>International Journal of Nephrology</i> , 2012, 2012, 1-7.	0.7	4
96	Socio-Economic Disparities in the Distribution of Cardiovascular Risk in Chronic Kidney Disease Stage 3. <i>Nephron Clinical Practice</i> , 2013, 122, 58-65.	2.3	8
97	CKD and Sudden Cardiac Death. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1929-1939.	3.0	113
98	Statins and kidney disease. <i>Current Opinion in Cardiology</i> , 2012, 27, 429-440.	0.8	9

#	ARTICLE	IF	CITATIONS
99	Association of Race with Cumulative Exposure to Statins in Dialysis. <i>American Journal of Nephrology</i> , 2012, 36, 90-96.	1.4	7
100	Comorbid Heart Failure and Renal Impairment: Epidemiology and Management. <i>CardioRenal Medicine</i> , 2012, 2, 281-297.	0.7	18
101	Care of the Patient after Renal Allograft Failure: Managing the Present and Planning for the Future. <i>American Journal of Nephrology</i> , 2012, 36, 348-354.	1.4	10
102	Statin Therapy and the Risk of Intracerebral Hemorrhage. <i>Stroke</i> , 2012, 43, 2149-2156.	1.0	266
103	Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. <i>Clinical Trials</i> , 2012, 9, 113-124.	0.7	34
104	Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe. <i>European Heart Journal</i> , 2012, 33, 2939-2945.	1.0	39
105	Serendipity of post-hoc surrogate marker research. <i>European Heart Journal</i> , 2012, 33, 2897-2898.	1.0	1
106	A carpenter with tricuspid regurgitation. <i>European Heart Journal</i> , 2012, 33, 2945-2945.	1.0	0
107	Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1396-1402.	0.4	42
108	Ongoing gaps in CKD and CVD care: re-evaluating strategies for knowledge dissemination. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1282-1284.	0.4	6
109	Clinically silent myocardial infarctions in the CKD community. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3387-3391.	0.4	9
110	American Association of Clinical Endocrinologistsâ€™™ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: Executive Summary. <i>Endocrine Practice</i> , 2012, 18, 269-293.	1.1	61
111	Statin-Induced Myotoxicity: Pharmacokinetic Differences among Statins and the Risk of Rhabdomyolysis, with Particular Reference to Pitavastatin. <i>Current Vascular Pharmacology</i> , 2012, 10, 257-267.	0.8	44
112	The Singapore General Hospital Peritoneal Dialysis Programme from 2000â€™“2008. <i>Proceedings of Singapore Healthcare</i> , 2012, 21, 132-139.	0.2	4
113	Cardiovascular assessment of patients with advanced kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3370-3371.	0.4	0
115	Charmed With a Name. <i>American Journal of the Medical Sciences</i> , 2012, 344, 258-260.	0.4	1
116	Statins and acute lung injury. <i>Critical Care Medicine</i> , 2012, 40, 1661-1663.	0.4	2
119	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Yearbook of Endocrinology</i> , 2012, 2012, 68-71.	0.0	2

#	ARTICLE	IF	CITATIONS
120	Lipid-Lowering Therapy in Persons With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2012, 157, 251.	2.0	146
121	Cholesterol Metabolism in Patients With Hemodialysis in the Presence or Absence of Coronary Artery Disease. <i>Circulation Journal</i> , 2012, 76, 1980-1986.	0.7	21
122	Effects of Rosuvastatin and Atorvastatin on Renal Function. <i>Circulation Journal</i> , 2012, 76, 1259-1266.	0.7	26
123	Ezetimibe Improves Endothelial Function and Inhibits Rho-Kinase Activity Associated With Inhibition of Cholesterol Absorption in Humans. <i>Circulation Journal</i> , 2012, 76, 2023-2030.	0.7	29
124	How to Use Ezetimibe as an Anti-Atherogenic Agent via Inhibition of Rho-Kinase. <i>Circulation Journal</i> , 2012, 76, 1836-1837.	0.7	4
125	Ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein, decreases cholesteryl ester transfer protein in type 2 diabetes mellitus. <i>Endocrine Journal</i> , 2012, 59, 1077-1084.	0.7	2
126	Randomised-controlled trials in chronic kidney disease - a call to arms!. <i>International Journal of Clinical Practice</i> , 2012, 66, 913-915.	0.8	7
127	Contribution of High Flux Membranes to the Therapy of Uremia-Associated Dyslipidemia. <i>Therapeutic Apheresis and Dialysis</i> , 2012, 16, 595-599.	0.4	5
128	Emphasizing Statin Safety in the Hospitalized Patient: A Review. <i>American Journal of Medicine</i> , 2012, 125, 845-853.	0.6	20
129	Impacts of estimated glomerular filtration rate on coronary atherosclerosis and plaque composition before and during statin therapy in patients with normal to mild renal dysfunction: Subanalysis of the TRUTH study. <i>Nephrology</i> , 2012, 17, 628-635.	0.7	3
130	Lipid Disorders in Uremia and Dialysis. <i>Contributions To Nephrology</i> , 2012, 178, 100-105.	1.1	21
131	Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: A retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program. <i>Atherosclerosis</i> , 2012, 221, 471-477.	0.4	13
132	Management of Hyperglycemia, Dyslipidemia, and Albuminuria in Patients With Diabetes and CKD: A Systematic Review for a KDOQI Clinical Practice Guideline. <i>American Journal of Kidney Diseases</i> , 2012, 60, 747-769.	2.1	87
133	Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. <i>Lancet, The</i> , 2012, 380, 807-814.	6.3	601
134	Chronic kidney disease: a coronary heart disease equivalent?. <i>Lancet, The</i> , 2012, 380, 783-785.	6.3	10
135	Arterial calcification and bone physiology: role of the bone-vascular axis. <i>Nature Reviews Endocrinology</i> , 2012, 8, 529-543.	4.3	260
136	Clinical assessment and management of dyslipidemia in patients with chronic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2012, 16, 522-529.	0.7	27
137	Insulin Resistance in Patients Undergoing Peritoneal Dialysis: Can We Improve It?. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 441-443.	1.3	2

#	ARTICLE	IF	CITATIONS
138	Colesterol de las lipoproteínas de baja densidad <70mg/dl en la enfermedad renal crónica. ¿Ficción o realidad?. Clínica E Investigación En Arteriosclerosis, 2012, 24, 284-288.	0.4	0
139	Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: Cause or association?. Atherosclerosis, 2012, 223, 86-94.	0.4	107
140	Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis, 2012, 223, 251-261.	0.4	203
141	Identical LDL-cholesterol lowering but non-identical effects on NF- κ B activity: High dose simvastatin vs combination therapy with ezetimibe. Atherosclerosis, 2012, 223, 190-196.	0.4	24
142	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis, 2012, 223, 1-68.	0.4	414
144	Medical options to fight mortality in end-stage renal disease: a review of the literature. Nephrology Dialysis Transplantation, 2012, 27, 4298-4307.	0.4	25
145	Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis. Journal of the American College of Cardiology, 2012, 60, 2372-2379.	1.2	172
146	Utility of Biomarkers and Imaging in the Development of Drugs for the Treatment of Coronary Atherosclerosis. Canadian Journal of Cardiology, 2012, 28, 687-692.	0.8	2
147	High-Density Lipoproteins. Journal of the American College of Cardiology, 2012, 60, 2380-2383.	1.2	38
149	A Decade After the KDOQI CKD Guidelines: Impact on Research. American Journal of Kidney Diseases, 2012, 60, 701-704.	2.1	7
150	Avoiding Harm in Peritoneal Dialysis Patients. Advances in Chronic Kidney Disease, 2012, 19, 171-178.	0.6	9
151	Ezetimibe â€“ a new approach in hypercholesterolemia management. Pharmacological Reports, 2012, 64, 997-998.	1.5	5
152	Papel de la lipotoxicidad en el desarrollo de la lesión renal en el síndrome metabólico y el envejecimiento. Dialisis Y Trasplante, 2012, 33, 89-96.	0.4	1
153	A Decade After the KDOQI CKD Guidelines: Impact on the Cardiovascular Diseaseâ€“CKD Paradigm. American Journal of Kidney Diseases, 2012, 60, 710-712.	2.1	15
154	Chronic kidney disease. Lancet, The, 2012, 379, 165-180.	6.3	1,463
155	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 2012, 33, 1635-1701.	1.0	5,247
156	American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocrine Practice, 2012, 18, 1-78.	1.1	386
157	Is combination therapy an effective way of reaching lipid goals in Type 2 diabetes mellitus?. Expert Review of Clinical Pharmacology, 2012, 5, 43-54.	1.3	3

#	ARTICLE	IF	CITATIONS
158	Effects of lipid-lowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients without and with chronic kidney disease: a randomized trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3540-3546.	0.4	13
159	Regression of vascular calcification in chronic kidney disease â€“ feasible or fantasy? A review of the clinical evidence. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 560-572.	1.1	23
160	Ezetimibe/Simvastatin: A Guide to its Clinical Use in Hypercholesterolemia. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 49-56.	1.0	12
161	Cardio-Renal Syndrome Type 4: Epidemiology, Pathophysiology and Treatment. <i>Seminars in Nephrology</i> , 2012, 32, 40-48.	0.6	30
162	South African Dyslipidaemia Guideline Consensus Statement:. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2012, 17, 155-165.	0.4	30
163	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). <i>European Journal of Preventive Cardiology</i> , 2012, 19, 585-667.	0.8	359
164	Diagnostic criteria for renovascular disease: where are we now?. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2657-2663.	0.4	28
165	Cholesterol Synthesis, Cholesterol Absorption, and Mortality in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 943-948.	2.2	47
166	Sudden Cardiac Death in Dialysis: Do Current Guidelines for Implantable Cardioverter Defibrillator Therapy Apply to Patients with End-stage Kidney Disease?. <i>Seminars in Dialysis</i> , 2012, 25, 272-276.	0.7	6
167	Are Dialysate Sodium Levels Too High?. <i>Seminars in Dialysis</i> , 2012, 25, 277-283.	0.7	13
168	Accuracy and Limitations of the Diagnosis of Malnutrition in Dialysis Patients. <i>Seminars in Dialysis</i> , 2012, 25, 423-427.	0.7	36
169	Clinical benefits of ezetimibe use: is absence of proof, proof of absence?. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1985-1988.	0.9	14
171	The SHARP trial: Lessons learnt; answers and more questions!. <i>International Journal of Cardiology</i> , 2012, 156, e6.	0.8	0
172	Caveats to aggressive lowering of lipids by specific statins. <i>International Journal of Cardiology</i> , 2012, 154, 97-101.	0.8	21
173	Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. <i>Journal of Clinical Lipidology</i> , 2012, 6, 180-191.	0.6	19
174	Cross-Sectional Survey to Assess the Status of Lipid Management in High-Risk Patients With Dyslipidemia: Clinical Impact of Combination Therapy With Ezetimibe. <i>Current Therapeutic Research</i> , 2012, 73, 1-15.	0.5	18
175	Clinical Efficacy and Tolerability of Ezetimibe in Combination With Atorvastatin in Japanese Patients With Hypercholesterolemiaâ€”Ezetimibe Phase IV Randomized Controlled Trial in Patients With Hypercholesterolemia. <i>Current Therapeutic Research</i> , 2012, 73, 16-40.	0.5	11
176	A Case Study of Singleâ€”Pill Combination Therapy: The Ezetimibe/Simvastatin Combination for Treatment of Hyperlipidemia. <i>ChemMedChem</i> , 2012, 7, 1882-1894.	1.6	5

#	ARTICLE	IF	CITATIONS
177	Diagnosis and treatment of coronary artery disease in hemodialysis patients evaluated for transplant. <i>Transplantation Research</i> , 2012, 1, 3.	1.5	5
178	Chronic Kidney Disease—A Challenge for All Ages. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2401.	3.8	16
179	Dyslipidemia: Management Using Optimal Lipid-Lowering Therapy. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1368-1381.	0.9	28
182	Japanese Society for Dialysis Therapy Guidelines for Management of Cardiovascular Diseases in Patients on Chronic Hemodialysis. <i>Therapeutic Apheresis and Dialysis</i> , 2012, 16, 387-435.	0.4	109
183	Japanese Society for Dialysis Therapy Guidelines for Management of Cardiovascular Diseases in Patients on Chronic Hemodialysis. <i>Therapeutic Apheresis and Dialysis</i> , 2012, 16, 384-386.	0.4	3
184	Ezetimibe reduces intimal hyperplasia in rabbit jugular vein graft. <i>Journal of Vascular Surgery</i> , 2012, 56, 1689-1697.	0.6	8
185	Effects of Fibrates in Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2061-2071.	1.2	148
186	LDL Cholesterol: The Lower the Better. <i>Medical Clinics of North America</i> , 2012, 96, 13-26.	1.1	73
187	Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 667-676.	1.9	36
188	Mechanisms and Treatment of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1917-1928.	3.0	225
189	BÃ©nÃ©ficice cardiovasculaire des statines dans le haut risque vasculaire. <i>Archives of Cardiovascular Diseases Supplements</i> , 2012, 4, 259-267.	0.0	0
190	Lipid-Lowering Therapy in Individuals With CKD: Lessons Learned From SHARP. <i>American Journal of Kidney Diseases</i> , 2012, 59, 170-173.	2.1	7
191	Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates. <i>Journal of the American College of Cardiology</i> , 2012, 60, 434-480.	1.2	328
192	Renal Function and Effect of Statin Therapy on Cardiovascular Outcomes in Patients Undergoing Coronary Revascularization (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). <i>American Journal of Cardiology</i> , 2012, 110, 1568-1577.	0.7	33
194	Management of dyslipidemia in CKD, dialysis and renal transplant recipient. <i>Clinical Queries Nephrology</i> , 2012, 1, 191-197.	0.2	0
195	Chronic kidney disease and its adverse cardiovascular associations. <i>Clinical Queries Nephrology</i> , 2012, 1, 183-190.	0.2	0
196	Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expression: A novel anti-atherosclerotic mechanism. <i>Pharmacological Research</i> , 2012, 66, 536-543.	3.1	32
199	Complications and characteristics of patients referred to a joint diabetes renal clinic in Ireland. <i>Irish Journal of Medical Science</i> , 2012, 181, 549-553.	0.8	3

#	ARTICLE	IF	CITATIONS
200	European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). International Journal of Behavioral Medicine, 2012, 19, 403-488.	0.8	224
201	Guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica (versión 2012). Revista Espanola De Cardiologia, 2012, 65, 937.e1-937.e66.	0.6	30
202	Comentarios a la guía de práctica clínica de la ESC sobre prevención de la enfermedad cardiovascular (versión 2012). Un informe del Grupo de Trabajo del Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología. Revista Espanola De Cardiologia, 2012, 65, 869-873.	0.6	22
203	Comments on the ESC Guidelines on Cardiovascular Disease Prevention (Version 2012). A Report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. Revista Espanola De Cardiologia (English Ed), 2012, 65, 869-873.	0.4	2
204	Treatment Targets in the Management of Dyslipidemias: Which Targets in Whom?. Current Cardiology Reports, 2012, 14, 692-700.	1.3	3
205	Geographic Variation in HMG-CoA Reductase Inhibitor Use in Dialysis Patients. Journal of General Internal Medicine, 2012, 27, 1475-1483.	1.3	4
206	Treatment of chronic kidney disease. Kidney International, 2012, 81, 351-362.	2.6	141
207	KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. American Journal of Kidney Diseases, 2012, 60, 850-886.	2.1	1,095
208	Benefits and Harms of Statin Therapy for Persons With Chronic Kidney Disease. Annals of Internal Medicine, 2012, 157, 263.	2.0	293
209	Screening for Chronic Kidney Disease. , 2012, , .		1
210	Ezetimibe therapy: mechanism of action and clinical update. Vascular Health and Risk Management, 2012, 8, 415.	1.0	169
211	Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis. Journal of Atherosclerosis and Thrombosis, 2012, 19, 299-315.	0.9	67
212	Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins. World Journal of Nephrology, 2012, 1, 184.	0.8	25
213	Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review. International Journal of Nephrology and Renovascular Disease, 2012, 5, 165.	0.8	3
214	Ezetimibe Ameliorates Early Diabetic Nephropathy in db/db Mice. Journal of Atherosclerosis and Thrombosis, 2012, 19, 608-618.	0.9	17
215	Antioxidant Therapy for Diabetic Kidney Disease. , 0, , .		1
216	Cost effective prescribing in cardiovascular disease. Practice Nursing, 2012, 23, 488-492.	0.1	0
217	Novel Treatments in Diabetic Nephropathy. Current Hypertension Reviews, 2012, 8, 71-78.	0.5	0

#	ARTICLE	IF	CITATIONS
218	South African Dyslipidaemia Guideline Consensus Statement. South African Medical Journal, 2012, 102, 178.	0.2	24
219	Chronic kidney disease in acute coronary syndromes. World Journal of Nephrology, 2012, 1, 134.	0.8	37
220	Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials. Current Pharmaceutical Design, 2012, 18, 1519-1530.	0.9	349
221	New Insights into the Assembly and Metabolism of ApoB-Containing Lipoproteins from in vivo Kinetic Studies: Results on Healthy Subjects and Patients with Chronic Kidney Disease. , 2012, , .		0
222	High burden and unmet patient needs in chronic kidney disease. International Journal of Nephrology and Renovascular Disease, 2012, 5, 151.	0.8	50
223	Editorial [Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough?]. Current Vascular Pharmacology, 2012, 10, 173-177.	0.8	11
224	Ezetimibe Ameliorates Atherosclerotic and Inflammatory Markers, Atherogenic Lipid Profiles, Insulin Sensitivity, and Liver Dysfunction in Japanese Patients with Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2012, 19, 532-538.	0.9	33
225	The ezetimibe controversy “ can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?. Expert Opinion on Pharmacotherapy, 2012, 13, 1469-1480.	0.9	10
226	Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nature Reviews Nephrology, 2012, 8, 362-369.	4.1	143
227	Niacin in Cardiovascular Disease: Recent Preclinical and Clinical Developments. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 582-588.	1.1	42
228	LDL cholesterol targets “ how low to go?. Current Opinion in Lipidology, 2012, 23, 265-270.	1.2	6
232	The Role of Statin Therapy for Primary Prevention: What is the Evidence?. Current Atherosclerosis Reports, 2012, 14, 167-174.	2.0	5
233	The Role of Intravascular Ultrasound in the Determination of Progression and Regression of Coronary Artery Disease. Current Atherosclerosis Reports, 2012, 14, 175-185.	2.0	10
234	Approach to Cardiovascular Disease Prevention in Patients With Chronic Kidney Disease. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 391-413.	0.4	10
235	What Are the Best Biomarkers and Definitions for Chronic Kidney Disease and How Well Do They Relate to Cardiovascular Risk?. Current Cardiovascular Risk Reports, 2012, 6, 155-163.	0.8	1
236	Identification and Treatment of Women with Familial Hypercholesterolemia. Current Cardiovascular Risk Reports, 2012, 6, 196-204.	0.8	0
238	Effect on Short- and Long-Term Major Adverse Cardiac Events of Statin Treatment in Patients With Acute Myocardial Infarction and Renal Dysfunction. American Journal of Cardiology, 2012, 109, 1425-1430.	0.7	12
239	Recent Clinical Studies of the Effects of Lipid-Modifying Therapies. American Journal of Cardiology, 2012, 110, 15A-26A.	0.7	36

#	ARTICLE	IF	CITATIONS
240	LXR ¹ activation increases intestinal cholesterol absorption, leading to an atherogenic lipoprotein profile. <i>Journal of Internal Medicine</i> , 2012, 272, 452-464.	2.7	24
241	Dyslipidemia and Its Therapeutic Challenges in Renal Transplantation. <i>American Journal of Transplantation</i> , 2012, 12, 1975-1982.	2.6	67
242	Safety profile of statins alone or combined with ezetimibe: a pooled analysis of 27 studies including over 22,000 patients treated for 6-24 weeks. <i>International Journal of Clinical Practice</i> , 2012, 66, 800-812.	0.8	17
243	CHRONIC KIDNEY DISEASE, DIABETES MELLITUS AND CARDIOVASCULAR DISEASE: RISKS AND COMMONALITIES. <i>Journal of Renal Care</i> , 2012, 38, 4-11.	0.6	22
244	HOW TO IDENTIFY AND MANAGE DIABETES MELLITUS AFTER RENAL TRANSPLANTATION. <i>Journal of Renal Care</i> , 2012, 38, 125-137.	0.6	4
245	LIPID-LOWERING THERAPY IN CHRONIC KIDNEY DISEASE: IS THERE A ROLE FOR EZETIMIBE?. <i>Journal of Renal Care</i> , 2012, 38, 138-146.	0.6	5
247	Ezetimibe alone or in combination with pitavastatin prevents kidney dysfunction in 5/6 nephrectomized rats fed high-cholesterol. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 379-388.	1.5	13
248	Prevalence and predictors of abnormal arterial function in statin-treated type 2 diabetes mellitus patients. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 349-357.	1.5	5
249	Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis. <i>European Journal of Clinical Investigation</i> , 2012, 42, 693-701.	1.7	10
250	Regression of left ventricular mass following conversion from conventional hemodialysis to thrice weekly in-centre nocturnal hemodialysis. <i>BMC Nephrology</i> , 2012, 13, 3.	0.8	30
253	Can simvastatin improve erectile function and health-related quality of life in men aged ≥ 40 years with erectile dysfunction? Results of the Erectile Dysfunction and Statins Trial [ISRCTN66772971]. <i>BJU International</i> , 2013, 111, 324-333.	1.3	26
254	Cardiovascular disease in chronic kidney disease: untying the Gordian knot. <i>International Journal of Clinical Practice</i> , 2013, 67, 14-31.	0.8	62
255	Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON). <i>American Journal of Nephrology</i> , 2013, 37, 212-222.	1.4	82
256	Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 341-346.	0.8	23
257	Antiplatelet Therapy for Preventing Stroke in Patients with Chronic Kidney Disease. <i>Contributions To Nephrology</i> , 2013, 179, 119-129.	1.1	12
258	Reasons for the Lack of Salutary Effects of Cholesterol-Lowering Interventions in End-Stage Renal Disease Populations. <i>Blood Purification</i> , 2013, 35, 31-36.	0.9	22
259	Treatment of idiopathic membranous nephropathy. <i>Nature Reviews Nephrology</i> , 2013, 9, 443-458.	4.1	104
260	Magnitude of discordance between registry data and death certificate when evaluating leading causes of death in dialysis patients. <i>BMC Medical Research Methodology</i> , 2013, 13, 51.	1.4	9

#	ARTICLE	IF	CITATIONS
261	Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass. <i>BMC Nephrology</i> , 2013, 14, 149.	0.8	23
262	Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001–2010. <i>BMC Nephrology</i> , 2013, 14, 132.	0.8	67
263	The natural history of, and risk factors for, progressive Chronic Kidney Disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol. <i>BMC Nephrology</i> , 2013, 14, 95.	0.8	37
264	Renal involvement in autoimmune connective tissue diseases. <i>BMC Medicine</i> , 2013, 11, 95.	2.3	100
265	Efficacy of statin treatment after endovascular therapy for isolated below-the-knee disease in patients with critical limb ischemia. <i>Cardiovascular Intervention and Therapeutics</i> , 2013, 28, 374-382.	1.2	21
266	Statin Use and Calcific Uremic Arteriopathy: A Matched Case-Control Study. <i>American Journal of Nephrology</i> , 2013, 37, 325-332.	1.4	65
267	Management of cardiovascular disease in patients with kidney disease. <i>Nature Reviews Cardiology</i> , 2013, 10, 261-273.	6.1	98
268	Medical Management of Stable Coronary Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2013, 15, 313.	2.0	6
269	Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy. <i>Current Cardiology Reports</i> , 2013, 15, 397.	1.3	31
270	Chronic Kidney Disease as a Coronary Artery Disease Risk Equivalent. <i>Current Cardiology Reports</i> , 2013, 15, 340.	1.3	120
271	Pharmacologic Management of Chronic Reno-Cardiac Syndrome. <i>Current Heart Failure Reports</i> , 2013, 10, 54-62.	1.3	14
273	Common sources and composition of phytosterols and their estimated intake by the population in the city of São Paulo, Brazil. <i>Nutrition</i> , 2013, 29, 865-871.	1.1	29
274	The lipid story in chronic kidney disease: a long story with a happy end?. <i>International Urology and Nephrology</i> , 2013, 45, 1273-1287.	0.6	4
275	LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?. <i>Drugs</i> , 2013, 73, 293-301.	4.9	20
276	Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management. <i>Drugs</i> , 2013, 73, 327-339.	4.9	190
277	Pharmacotherapies for lipid modification: beyond the statins. <i>Nature Reviews Cardiology</i> , 2013, 10, 560-570.	6.1	35
278	Anti-Inflammatory Interventions in End-stage Kidney Disease: A Randomized, Double-Blinded, Controlled and Crossover Clinical Trial on the Use of Pravastatin in Continuous Ambulatory Peritoneal Dialysis. <i>Archives of Medical Research</i> , 2013, 44, 633-637.	1.5	17
279	Elevated interleukin-12 and interleukin-18 in chronic kidney disease are not associated with arterial stiffness. <i>Cytokine</i> , 2013, 64, 39-42.	1.4	25

#	ARTICLE	IF	CITATIONS
280	Residual Dyslipidemia Among United States Adults Treated With Lipid Modifying Therapy (Data from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 112, 373-379.	0.7	30
281	All at sea: new lipid-lowering drug trials continue to disappoint. International Journal of Clinical Practice, 2013, 67, 595-598.	0.8	3
282	The beneficial effects of statins in patients undergoing hemodialysis. International Journal of Cardiology, 2013, 168, 4155-4159.	0.8	7
283	Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers. American Heart Journal, 2013, 166, 373-380.e2.	1.2	45
284	Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis. Evidence-Based Medicine, 2013, 18, 175-176.	0.6	0
285	Fenofibrate and the kidney: an overview. European Journal of Clinical Investigation, 2013, 43, 522-531.	1.7	46
286	A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?. International Journal of Cardiology, 2013, 168, 5437-5447.	0.8	66
287	New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. European Heart Journal, 2013, 34, 1783-1789.	1.0	90
288	Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial. Nephrology Dialysis Transplantation, 2013, 28, 1874-1888.	0.4	24
289	Assessment of Low-Density Lipoprotein Targets. Angiology, 2013, 64, 411-416.	0.8	11
290	Lipid-Lowering Agents. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 401-411.	1.0	28
291	Chronic kidney disease and statin therapy: to treat or not to treat?. European Heart Journal, 2013, 34, 1772-1774.	1.0	3
292	Dyslipidemia. Canadian Journal of Diabetes, 2013, 37, S110-S116.	0.4	15
293	The Management of Dyslipidemia in CKD: New Analyses of an Expanding Dataset. American Journal of Kidney Diseases, 2013, 61, 371-374.	2.1	8
294	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	1.0	1,758
295	RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale. Lipids in Health and Disease. 2013. 12. 142.	1.2	4
296	DyslipidÃ©mie. Canadian Journal of Diabetes, 2013, 37, S484-S491.	0.4	1
297	Altered Lipid Metabolism and Serum Lipids in Kidney Disease and Kidney Failure. , 2013, , 31-48.		1

#	ARTICLE	IF	CITATIONS
298	Relationship between Icodextrin use and decreased level of small low-density lipoprotein cholesterol fractioned by high-performance gel permeation chromatography. <i>BMC Nephrology</i> , 2013, 14, 234.	0.8	3
299	Efficacy of combination of Ezetimibe 10Âmg and rosuvastatin 2.5Âmg versus rosuvastatin 5Âmg monotherapy for hypercholesterolemia in patients with type 2 diabetes. <i>Lipids in Health and Disease</i> , 2013, 12, 137.	1.2	39
300	Low-Density Lipoprotein Cholesterol: How Low Can We Go?. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 225-232.	1.0	10
301	Diastolic function is a strong predictor of mortality in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2013, 14, 280.	0.8	61
302	Are there differences in LDL-C target value attainment in Austrian federal states? Yes!. <i>Wiener Medizinische Wochenschrift</i> , 2013, 163, 528-535.	0.5	3
303	Triologue Plus. <i>Acta Diabetologica</i> , 2013, 50, 989-998.	1.2	2
304	HMG-CoA Reductase Inhibitors in Chronic Kidney Disease. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 385-398.	1.0	4
305	Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega-3 polyunsaturated fatty acid ethyl esters. <i>Clinical Lipidology</i> , 2013, 8, 329-344.	0.4	5
306	Chronic Kidney Disease in the Elderly. <i>Clinics in Geriatric Medicine</i> , 2013, 29, 611-624.	1.0	19
307	Demystifying the management of hypertriglyceridaemia. <i>Nature Reviews Cardiology</i> , 2013, 10, 648-661.	6.1	92
309	Pharmacokinetic and Pharmacodynamic Profile of Rosuvastatin in Patients with End-Stage Renal Disease on Chronic Haemodialysis. <i>Clinical Drug Investigation</i> , 2013, 33, 233-241.	1.1	10
310	Strategies to Lower Low-Density Lipoprotein Cholesterol in Metabolic Syndrome: Averting the Diabetes Risk. <i>Metabolic Syndrome and Related Disorders</i> , 2013, 11, 149-151.	0.5	7
311	Current Ways of Treating Dyslipidemias to Prevent Atherosclerosis. <i>Therapeutic Apheresis and Dialysis</i> , 2013, 17, 125-129.	0.4	1
312	Statins of high versus low cholesterolâ€lowering efficacy and the development of severe renal failure. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 583-592.	0.9	29
313	Stroke in Dialysis and Chronic Kidney Disease. <i>Blood Purification</i> , 2013, 36, 179-183.	0.9	54
316	Slowing progression of chronic kidney disease. <i>Kidney International Supplements</i> , 2013, 3, 372-376.	4.6	42
317	Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2013, 34, 1807-1817.	1.0	156
318	Heart Disease and Stroke Statisticsâ€2013 Update. <i>Circulation</i> , 2013, 127, e6-e245.	1.6	4,387

#	ARTICLE	IF	CITATIONS
319	Chapter 5: Referral to specialists and models of care. <i>Kidney International Supplements</i> , 2013, 3, 112-119.	4.6	38
320	Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3-4: A randomized controlled trial. <i>Nephrology</i> , 2013, 18, 26-35.	0.7	25
321	Cardiovascular disease: Prevention and treatment in renal transplant recipients. <i>Clinical Queries Nephrology</i> , 2013, 2, 184-196.	0.2	0
322	Statins and Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 109-118.	2.4	75
323	Incremental Lowering of Low-Density Lipoprotein Cholesterol With Ezetimibe 20 mg vs 10 mg Daily in Patients Receiving Concomitant Statin Therapy. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1395-1399.	0.8	4
324	Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1250-1258.	1.2	47
326	Quantitative and qualitative pleiotropic differences between Simvastatin single and Vytorin combination therapy in hypercholesterolemic subjects. <i>Atherosclerosis</i> , 2013, 231, 411-420.	0.4	14
327	Différences régionales chez les 987 diabétiques de type 2 de la cohorte française GAD% RODIAB à l'inclusion. <i>Medicine Des Maladies Metaboliques</i> , 2013, 7, 563-571.	0.1	0
328	Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 799-801.	1.2	6
329	Proprotein convertase subtilisin/kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment. <i>Atherosclerosis</i> , 2013, 226, 459-465.	0.4	51
330	Comparative effectiveness of coronary artery bypass grafting and percutaneous coronary intervention for multivessel coronary disease in a community-based population with chronic kidney disease. <i>American Heart Journal</i> , 2013, 165, 800-808.e2.	1.2	32
332	Risk factors for atherosclerosis in patients with chronic kidney disease: recognition and management. <i>Current Opinion in Pharmacology</i> , 2013, 13, 192-199.	1.7	31
334	High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. <i>Atherosclerosis</i> , 2013, 227, 118-124.	0.4	38
335	PANACEA or much a do about nothing: Effect of a statin and ezetimibe on postprandial lipaemia and endothelial function in the metabolic syndrome. <i>Atherosclerosis</i> , 2013, 227, 32-34.	0.4	0
336	Effect of Ezetimibe on Major Atherosclerotic Disease Events and All-Cause Mortality. <i>American Journal of Cardiology</i> , 2013, 111, 532-539.	0.7	15
337	Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. <i>Atherosclerosis</i> , 2013, 230, 322-329.	0.4	40
338	Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2013, 7, 306-315.	1.0	23
339	The demise of calcium-based phosphate binders. <i>Lancet, The</i> , 2013, 382, 1232-1234.	6.3	14

#	ARTICLE	IF	CITATIONS
340	Even Mild Kidney Dysfunction Is an Important Cardiovascular Risk Predictor: Implications and Challenges. Canadian Journal of Cardiology, 2013, 29, 1371-1373.	0.8	1
341	Regulatory science in Europe: the case of schizophrenia trials. Lancet, The, 2013, 382, 1234-1235.	6.3	8
342	Effect of an L-Carnitine-Containing Peritoneal Dialysate on Insulin Sensitivity in Patients Treated With CAPD: A 4-Month, Prospective, Multicenter Randomized Trial. American Journal of Kidney Diseases, 2013, 62, 929-938.	2.1	42
343	HPS2-THRIVE results: Bad for niacin/laropiprant, good for ezetimibe?. Atherosclerosis, 2013, 229, 449-450.	0.4	12
344	Impact of Adding Ezetimibe to Statin to Achieve Low-Density Lipoprotein Cholesterol Goal (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf American Journal of Cardiology, 2013, 111, 1557-1562.	0.7	10
346	Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?. Current Atherosclerosis Reports, 2013, 15, 290.	2.0	3
347	Pharmacologic Interactions of Multidrug Therapy for Dyslipidemia. Current Atherosclerosis Reports, 2013, 15, 303.	2.0	1
348	Beyond Statins: Lipid Management to Reduce Cardiovascular Risk. Pharmacotherapy, 2013, 33, 754-764.	1.2	13
349	Triglyceride levels, pancreatitis and choice of lipid-modifying therapy. Expert Review of Gastroenterology and Hepatology, 2013, 7, 193-195.	1.4	5
350	Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney International Supplements, 2013, 3, 91-111.	4.6	38
352	2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2013, 29, 151-167.	0.8	680
353	The Metabolic Syndrome and Cancer. , 2013, , 55-61.		4
354	A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs. Drugs, 2013, 73, 1025-1054.	4.9	30
355	Diagnostic, suivi biologique de lâ€™insuffisance rÃ©nale chronique et prise en charge de lâ€™insuffisance rÃ©nale chronique terminale. Revue Francophone Des Laboratoires, 2013, 2013, 59-73.	0.0	3
356	Management of Coronary Atherosclerosis and Acute Coronary Syndromes in Patients With Chronic Kidney Disease. Current Problems in Cardiology, 2013, 38, 165-206.	1.1	11
357	The USRDS. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 845-851.	2.2	119
358	LDL cholesterol in CKDâ€™to treat or not to treat?. Kidney International, 2013, 84, 451-456.	2.6	49
359	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapyâ€™A meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacological Research, 2013, 72, 35-44.	3.1	90

#	ARTICLE	IF	CITATIONS
360	Targets, trends, excesses, and deficiencies: refocusing clinical investigation to improve patient outcomes. <i>Kidney International</i> , 2013, 83, 1001-1009.	2.6	14
361	Chronic kidney disease: global dimension and perspectives. <i>Lancet</i> , The, 2013, 382, 260-272.	6.3	3,135
362	Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. <i>Lancet</i> , The, 2013, 382, 339-352.	6.3	1,613
363	HDL function and cardiovascular risk: Debate continues. <i>Atherosclerosis</i> , 2013, 229, 38-41.	0.4	2
364	Risk Factors and Prevention, Including Hyperlipidemia. , 2013, , 405-418.		0
365	Cardiovascular Complications in Patients with Renal Disease. , 2013, , 687-700.		0
366	The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia. <i>Current Cardiology Reports</i> , 2013, 15, 391.	1.3	9
367	Rosuvastatin calcium in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1215-1227.	0.9	17
368	HIV and Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 511-523.	1.2	234
369	Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol. <i>European Journal of Clinical Investigation</i> , 2013, 43, 413-426.	1.7	55
370	-374 T/A RAGE Polymorphism Is Associated with Chronic Kidney Disease Progression in Subjects Affected by Nephrocardiovascular Disease. <i>PLoS ONE</i> , 2013, 8, e60089.	1.1	11
371	Beyond cholesterol reduction, the pleiotropic effects of statins: is their use in cancer prevention hype or hope?. <i>Clinical Lipidology</i> , 2013, 8, 273-277.	0.4	2
372	Association between LDL-C and Risk of Myocardial Infarction in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 979-986.	3.0	114
373	Clinical significance of subclinical carotid atherosclerosis and its relationship with echocardiographic parameters in non-diabetic chronic kidney disease patients. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 96.	0.7	10
374	The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early effects. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 240-247.	0.7	11
375	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2013, 7, 561-565.	0.6	147
376	Predictive Value of Cardiac Computed Tomography and the Impact of Renal Function on All Cause Mortality (from Coronary Computed Tomography Angiography Evaluation for Clinical Outcomes). <i>American Journal of Cardiology</i> , 2013, 111, 1563-1569.	0.7	9
377	Safety and Efficacy of Statins in Patients With End-Stage Renal Disease. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1321-1329.	0.9	10

#	ARTICLE	IF	CITATIONS
379	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2013, 29, 435-451.	0.9	36
381	Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. <i>European Heart Journal</i> , 2013, 34, 354-363.	1.0	38
382	Statins in patients with chronic kidney disease – an attempt at recommendations. <i>Current Medical Research and Opinion</i> , 2013, 29, 1419-1422.	0.9	9
383	The Oxford Renal (OxRen) cross-sectional study of chronic kidney disease in the UK. <i>BMJ Open</i> , 2013, 3, e004265.	0.8	7
384	Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renegal in New Dialysis trial. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2586-2595.	0.4	39
385	Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. <i>BMJ Open</i> , 2013, 3, e002764.	0.8	11
386	No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. <i>Kidney International</i> , 2013, 84, 989-997.	2.6	54
387	Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1579-1589.	0.4	94
390	The Cardiorenal Syndrome: What the Cardiologist Needs to Know. <i>Cardiology</i> , 2013, 126, 175-186.	0.6	20
392	Chapter 2: Pharmacological cholesterol-lowering treatment in adults. <i>Kidney International Supplements</i> , 2013, 3, 271-279.	4.6	16
393	Chapter 5: Triglyceride-lowering treatment in adults. <i>Kidney International Supplements</i> , 2013, 3, 284-285.	4.6	4
394	Chronic Kidney Disease, Plasma Lipoproteins, and Coronary Artery Calcium Incidence. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 652-658.	1.1	34
395	Determinants of Cardiovascular Risk in Haemodialysis Patients: Post hoc Analyses of the AURORA Study. <i>American Journal of Nephrology</i> , 2013, 37, 144-151.	1.4	29
396	Management of diabetic kidney disease: Recent advances. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 55.	0.2	6
397	Altering Serum Lipids to Reduce Progression of Chronic Kidney Disease. , 2013, , 241-248.		0
398	Effect of Obesity and the Metabolic Syndrome on Incident Kidney Disease and the Progression to Chronic Kidney Failure. , 2013, , 445-456.		1
399	Blue Toe Syndrome after the Discontinuation of Statin Therapy in a Patient on Chronic Hemodialysis. <i>Nephrology Research & Reviews</i> , 2013, 5, 1-3.	0.2	1
400	Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. <i>BMJ</i> , The, 2013, 347, f5680-f5680.	3.0	209

#	ARTICLE	IF	CITATIONS
401	Initial Implementation of a Web-Based Consultation Process for Patients With Chronic Kidney Disease. <i>Annals of Family Medicine</i> , 2013, 11, 151-156.	0.9	53
402	Low Protein Nitrogen Appearance as a Surrogate of Low Dietary Protein Intake Is Associated with Higher All-Cause Mortality in Maintenance Hemodialysis Patients ^{1&#x2013;3} . <i>Journal of Nutrition</i> , 2013, 143, 1084-1092.	1.3	32
403	Arterial disease in chronic kidney disease. <i>Heart</i> , 2013, 99, 365-372.	1.2	119
404	Evidence-Based Cardiology in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1934-1943.	3.0	44
405	Adverse effects of systemic glucose absorption with peritoneal dialysis. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 663-668.	1.0	22
406	Update on the detection and treatment of atherogenic low-density lipoproteins. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2013, 20, 140-147.	1.2	14
407	Lipoprotein Kinetics in Male Hemodialysis Patients Treated with Atorvastatin. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1319-1326.	2.2	2
408	Statins and beyond: Concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 99-114.	0.9	7
409	Associations of baseline characteristics with evolution of eGFR in a referred chronic kidney disease cohort. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 915-924.	0.2	14
410	Mild Renal Dysfunction and Metabolites Tied to Low HDL Cholesterol Are Associated With Monocytosis and Atherosclerosis. <i>Circulation</i> , 2013, 127, 988-996.	1.6	51
411	Importance of high-density lipoprotein quality. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 259-265.	1.0	14
412	Effects of Rosuvastatin With or Without Ezetimibe on Clinical Outcomes in Patients Undergoing Elective Vascular Surgery. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 5-12.	1.0	32
414	Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: A nationwide observational study from the Swedish National Diabetes Register. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 520-529.	0.9	74
415	Dyslipidemia in Patients with Chronic and End-Stage Kidney Disease. <i>CardioRenal Medicine</i> , 2013, 3, 165-177.	0.7	26
416	Changes in Body Weight and Subsequent Mortality. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1640-1642.	2.2	2
417	Association of Cholesterol Levels with Mortality and Cardiovascular Events among Patients with CKD and Different Amounts of Proteinuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1915-1926.	2.2	6
418	The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. <i>Clinical Lipidology</i> , 2013, 8, 13-41.	0.4	23
419	Drugs for Elevated Low-Density Lipoprotein Cholesterol. , 2013, , 421-433.		0

#	ARTICLE	IF	CITATIONS
420	Prevention and Management of Cardiovascular Disease in Kidney Disease and Kidney Failure. , 2013, , 123-135.		0
421	Is Lipid Management Effective for All Stages of CKD. Blood Purification, 2013, 35, 26-30.	0.9	12
422	New therapies to reduce low-density lipoprotein cholesterol. Current Opinion in Cardiology, 2013, 28, 452-457.	0.8	22
423	Role of Dyslipidemia in Patients With Chronic Kidney Disease. Postgraduate Medicine, 2013, 125, 28-37.	0.9	4
424	Statin Improves Flow-Mediated Vasodilation in Chronic Kidney Diseases. International Journal of Hypertension, 2013, 2013, 1-9.	0.5	9
425	South African Dyslipidaemia Guideline Consensus Statement. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2013, 55, 9-18.	0.2	3
426	Observational study of ezetimibe discontinuation in primary care practices in the UK. Current Medical Research and Opinion, 2013, 29, 1737-1745.	0.9	0
427	Renoprotective strategies in lupus nephritis: beyond immunosuppression. Lupus, 2013, 22, 1267-1273.	0.8	21
428	Effect of metabolic syndrome on clinical outcomes of non-diabetic peritoneal dialysis patients in India. Nephrology, 2013, 18, 657-664.	0.7	9
429	Doubling up: maximising statin therapy as opposed to adding other drugs for cardiovascular disease prevention. International Journal of Clinical Practice, 2013, 67, 391-393.	0.8	0
430	Novel drugs and intervention strategies for the treatment of chronic kidney disease. British Journal of Clinical Pharmacology, 2013, 76, 536-550.	1.1	38
431	New approaches to assessing cardiovascular risk. Trends in Urology & Men's Health, 2013, 4, 37-42.	0.2	0
432	Familial hypercholesterolaemia in children and adolescents: A new paediatric model of care. Journal of Paediatrics and Child Health, 2013, 49, E263-72.	0.4	24
433	CHALLENGES TO ADVANCING THE EVIDENCE BASE FOR NEPHROLOGY: THE TIME IS RIGHT FOR COLLABORATION. Journal of Renal Care, 2013, 39, 191-193.	0.6	0
434	A fixed protocol for outpatient clinic routines in the care of patients with severe renal failure. Renal Failure, 2013, 35, 845-854.	0.8	3
435	Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. Expert Opinion on Investigational Drugs, 2013, 22, 1411-1423.	1.9	19
436	Dyslipidemia Is Associated With Tunneled Cuffed Catheter-Related Central Venous Thrombosis in Hemodialysis Patients: A Retrospective, Multicenter Study. Artificial Organs, 2013, 37, E155-61.	1.0	8
438	Instrumental variable analysis. Nephrology Dialysis Transplantation, 2013, 28, 1694-1699.	0.4	22

#	ARTICLE	IF	CITATIONS
439	A Clinician's Guide to the <scp>ABCs</scp> of Cardiovascular Disease Prevention: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. <i>Clinical Cardiology</i> , 2013, 36, 383-393.	0.7	45
440	The Role of Statins in Diabetes Treatment. <i>Diabetes Spectrum</i> , 2013, 26, 156-164.	0.4	8
442	Optimal use of lipid-altering therapy: guidelines versus evidence. <i>Clinical Lipidology</i> , 2013, 8, 269-272.	0.4	0
443	Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2013, 158, 825.	2.0	2,404
444	Landmark Lipid-Lowering Trials in the Primary Prevention of Cardiovascular Disease. <i>Clinical Cardiology</i> , 2013, 36, 516-523.	0.7	19
445	Polyunsaturated fatty acyl-coenzyme As are inhibitors of cholesterol biosynthesis in zebrafish and mice. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 1365-77.	1.2	15
448	HMG CoA reductase inhibitors (statins) for dialysis patients. <i>The Cochrane Library</i> , 2014, 2014, CD004289.	1.5	54
449	Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. <i>Vascular Health and Risk Management</i> , 2013, 9, 617.	1.0	71
450	Dyslipidemia, Kidney Disease, and Cardiovascular Disease in Diabetic Patients. <i>Review of Diabetic Studies</i> , 2013, 10, 88-100.	0.5	89
451	Effect of shared care on blood pressure in patients with chronic kidney disease: a cluster randomised controlled trial. <i>British Journal of General Practice</i> , 2013, 63, e798-e806.	0.7	30
453	Intestinal and Hepatic Niemann-Pick C1-Like 1. <i>Diabetes and Metabolism Journal</i> , 2013, 37, 240.	1.8	27
454	Interrelationship between Chronic Kidney Disease and Risk of Cardiovascular Diseases. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2013, 11, 38-43.	0.4	9
455	Cardiovascular disease in end-stage renal disease. <i>Journal of the Korean Medical Association</i> , 2013, 56, 576.	0.1	3
456	Prevention of Chronic Kidney Disease and Subsequent Effect on Mortality: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e71784.	1.1	19
457	Role of Statins in Coronary Artery Disease. <i>Chonnam Medical Journal</i> , 2013, 49, 1.	0.5	30
458	Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. <i>Vascular Health and Risk Management</i> , 2013, 9, 719.	1.0	28
459	Statin Use in Patients with Diabetes and Kidney Disease: The Japanese Experience. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 407-424.	0.9	15
460	Management of Familial Hypercholesterolemia: A Review of the Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Managed Care Pharmacy</i> , 2013, 19, 139-149.	2.2	88

#	ARTICLE	IF	CITATIONS
461	Cardiovascular Disease in Hemodialysis Patients. , 0, , .		1
462	Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 123-133.	0.9	75
463	Lipid Abnormalities in Hemodialysis Patients. , 0, , .		2
464	Effects of Adding Ezetimibe to Fluvastatin on Kidney Function in Patients with Hypercholesterolemia: a Randomized Control Trial. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 245-256.	0.9	8
465	Association Between Renal Vasculature Changes and Generalized Atherosclerosis: An Autopsy Survey. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 99-107.	0.9	6
466	Dyslipidemia in women: etiology and management. <i>International Journal of Women's Health</i> , 2014, 6, 185.	1.1	57
467	Current and emerging treatment options for the elderly patient with chronic kidney disease. <i>Clinical Interventions in Aging</i> , 2014, 9, 191.	1.3	33
468	How do We Manage Coronary Artery Disease in Patients with CKD and ESRD?. <i>Electrolyte and Blood Pressure</i> , 2014, 12, 41.	0.6	15
469	The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in renal disease. <i>International Journal of Nephrology and Renovascular Disease</i> , 2014, 7, 123.	0.8	3
470	Tinzaparin Provides Lower Lipid Profiles in Maintenance Hemodialysis Patients: A Cross-Sectional Observational Study. <i>Scientific World Journal, The</i> , 2014, 2014, 1-9.	0.8	3
471	Coronary artery calcification in chronic kidney disease: An update. <i>World Journal of Cardiology</i> , 2014, 6, 115.	0.5	35
472	Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update. <i>Current Cardiology Reviews</i> , 2014, 9, 331-339.	0.6	156
473	Clinical implications of statin therapy in patients undergoing hemodialysis. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 703-710.	0.5	6
474	Total and low-density lipoprotein cholesterol in high-risk patients treated with atorvastatin monotherapy in the United Kingdom: analysis of a primary-care database. <i>Current Medical Research and Opinion</i> , 2014, 30, 655-665.	0.9	9
475	Lipid mediators in diabetic nephropathy. <i>Fibrogenesis and Tissue Repair</i> , 2014, 7, 12.	3.4	54
476	The Endoplasmic Reticulum Coat Protein II Transport Machinery Coordinates Cellular Lipid Secretion and Cholesterol Biosynthesis. <i>Journal of Biological Chemistry</i> , 2014, 289, 4244-4261.	1.6	41
477	Dyslipidemias and chronic kidney disease: a focus on pathogenesis and treatment. <i>Clinical Lipidology</i> , 2014, 9, 673-681.	0.4	3
478	Long-Term Outcomes after Dialysis-Requiring Acute Kidney Injury. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	34

#	ARTICLE	IF	CITATIONS
479	An Update on Coronary Artery Disease and Chronic Kidney Disease. International Journal of Nephrology, 2014, 2014, 1-9.	0.7	59
480	Reasons for Discontinuation of Lipid-Lowering Medications in Patients with Chronic Kidney Disease. CardioRenal Medicine, 2014, 4, 225-233.	0.7	11
481	Genomics and Pharmacogenomics of Lipid-Lowering Therapies. , 2014, , 715-746.		0
482	Statins stabilize the renal function of IgA nephropathy. Renal Failure, 2014, 36, 356-360.	0.8	13
483	Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrology Dialysis Transplantation, 2014, 29, 400-405.	0.4	26
484	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention. Journal of the American Heart Association, 2014, 3, e001098.	1.6	24
487	Implementation of a CKD Checklist for Primary Care Providers. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1526-1535.	2.2	44
488	Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease. European Journal of Clinical Investigation, 2014, 44, 276-284.	1.7	26
489	Long-Term Risk of Coronary Events after AKI. Journal of the American Society of Nephrology: JASN, 2014, 25, 595-605.	3.0	262
490	Cholesterol Treatment Patterns and Cardiovascular Clinical Outcomes Associated with Colesevelam HCl and Ezetimibe. Drugs and Aging, 2014, 31, 683-694.	1.3	4
491	Risk of Metabolic Complications in Kidney Transplantation After Conversion to mTOR Inhibitor: A Systematic Review and Meta-Analysis. American Journal of Transplantation, 2014, 14, 2317-2327.	2.6	91
492	Diseases of Renal Microcirculation: Diabetic Nephropathy. , 2014, , 1-34.		2
493	Combination Therapy with Statins. Endocrinology and Metabolism Clinics of North America, 2014, 43, 993-1006.	1.2	1
494	Prevalence and management of chronic kidney disease in primary care patients in the UK. International Journal of Clinical Practice, 2014, 68, 1110-1121.	0.8	25
495	Heart Disease and Stroke Statistics—2014 Update. Circulation, 2014, 129, e28-e292.	1.6	4,522
496	HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. The Cochrane Library, 2014, , CD007784.	1.5	141
497	New cholesterol guidelines: Worth the wait?. Cleveland Clinic Journal of Medicine, 2014, 81, 11-19.	0.6	25
498	Dialysis method Alters the Expression of MicroRNA-33a and Its Target Genes ABCA1, ABCG1 in THP-1 Macrophages. Therapeutic Apheresis and Dialysis, 2014, 18, 44-50.	0.4	10

#	ARTICLE	IF	CITATIONS
499	<sc>KHAâ€CARI</sc> commentary on the <sc>KDIGO C</sc>linical <sc>P</sc>ractice <sc>G</sc>uideline for <sc>L</sc>ipid <sc>M</sc>anagement in <sc>C</sc>hronic <sc>K</sc>idney <sc>D</sc>isease. Nephrology, 2014, 19, 663-666.	0.7	11
500	Statins do not improve cardiovascular outcomes for dialysis patients. Evidence-Based Medicine, 2014, 19, 89-89.	0.6	0
501	How is the Heart Best Protected in Chronic Dialysis Patients?. Seminars in Dialysis, 2014, 27, 325-328.	0.7	2
502	Critical Appraisal of the SHARP Trial: The Results May Be Dull. Clinical Therapeutics, 2014, 36, 2112-2117.	1.1	2
503	Nurse Practitioner Care Improves Renal Outcome in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2014, 25, 390-398.	3.0	90
504	Effects of Lowering LDL Cholesterol on Progression of Kidney Disease. Journal of the American Society of Nephrology: JASN, 2014, 25, 1825-1833.	3.0	142
505	Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EVALUATION Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. Journal of the American Heart Association, 2014, 3, e001363.	1.6	105
506	Treatment of albuminuria due to diabetic nephropathy: recent trial results. Clinical Investigation, 2014, 4, 327-341.	0.0	1
507	Cardiovascular disease prevention. Acta Clinica Belgica, 2014, 69, 407-411.	0.5	79
508	Efficacy and safety of ezetimibe plus atorvastatin therapy. Clinical Lipidology, 2014, 9, 441-470.	0.4	7
509	Of heart and kidney: a complicated love story. European Journal of Preventive Cardiology, 2014, 21, 840-846.	0.8	11
510	Cardiovascular Risk Assessment Before and After Kidney Transplantation. Cardiology in Review, 2014, 22, 153-162.	0.6	43
511	Updated management of chronic kidney disease in patients with diabetes. JAAPA: Official Journal of the American Academy of Physician Assistants, 2014, 27, 17-22.	0.1	5
512	Diagnosis and Treatment of Diabetic Kidney Disease. American Journal of the Medical Sciences, 2014, 347, 406-413.	0.4	33
513	Carotid Intima-media Thickness. American Journal of Therapeutics, 2014, 21, 535-539.	0.5	2
514	Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease. Current Opinion in Nephrology and Hypertension, 2014, 23, 578-585.	1.0	28
515	Do patients with chronic kidney disease get optimal cardiovascular risk reduction?. Current Opinion in Nephrology and Hypertension, 2014, 23, 267-274.	1.0	7
516	Statins in Chronic Kidney Disease: Cardiovascular Risk and Kidney Function. Postgraduate Medicine, 2014, 126, 29-36.	0.9	16

#	ARTICLE	IF	CITATIONS
517	The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1061-1073.	0.4	25
518	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 133-173.	0.9	173
519	Potential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney disease. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 53-59.	0.9	2
520	Meta-Analysis of Lipid-Lowering Therapy in Maintenance Dialysis Patients. <i>Nephron Clinical Practice</i> , 2014, 124, 209-217.	2.3	15
521	Treatment patterns, risk factor control and functional capacity in patients with cardiovascular and chronic kidney disease in the cardiac rehabilitation setting. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1125-1133.	0.8	10
522	Hyperlipidemia as a Risk Factor for Progression of CKD in Nondiabetics. , 2014, , 27-44.		1
523	Formulation of Treatment Recommendations for Statins. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 305.	3.8	0
524	Dyslipidemias. , 2014, , 137-146.		1
525	Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1554-1562.	0.4	84
526	Chronic aspirin and statin therapy in patients with impaired renal function and acute coronary syndromes: results from the IN-ACS Outcome Registry. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 214-221.	0.8	7
527	Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 19.	0.7	28
528	LDL Cholesterol Affects Clinical Outcomes in Incident Hemodialysis Patients During the Early Stages of Dialysis. <i>Blood Purification</i> , 2014, 38, 131-139.	0.9	5
529	Endoplasmic Reticulum Stress Effector CCAAT/Enhancer-binding Protein Homologous Protein (CHOP) Regulates Chronic Kidney Disease-induced Vascular Calcification. <i>Journal of the American Heart Association</i> , 2014, 3, e000949.	1.6	49
530	Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 265-268.	0.7	70
531	Pathophysiology of Chronic Kidney Disease. , 2014, , 448-457.		1
532	Cardiac Function and Cardiovascular Disease in Chronic Kidney Disease. , 2014, , 488-496.		1
533	Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease. , 2014, 24, 65-71.		7
534	Medication among patients with type 1 diabetes and predialytic renal disease. <i>Diabetes Research and Clinical Practice</i> , 2014, 103, 510-515.	1.1	0

#	ARTICLE	IF	CITATIONS
535	Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel. <i>Canadian Journal of Cardiology</i> , 2014, 30, 377-380.	0.8	27
536	General Approach to the Diagnosis and Management of Glomerular Diseases. , 2014, , 1-13.		0
537	Metabolic syndrome in children with chronic kidney disease and after renal transplantation. <i>Pediatric Nephrology</i> , 2014, 29, 203-216.	0.9	26
538	Treatment and impact of dyslipidemia in diabetic nephropathy. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 201-205.	0.7	25
539	Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 704-710.	0.7	10
541	Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: Prevention and treatment. <i>Transplantation Reviews</i> , 2014, 28, 37-46.	1.2	59
542	Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 291-295.	0.7	11
543	Residual macrovascular risk in 2013: what have we learned?. <i>Cardiovascular Diabetology</i> , 2014, 13, 26.	2.7	149
544	Cardiometabolic Impact of Non-Statin Lipid Lowering Therapies. <i>Current Atherosclerosis Reports</i> , 2014, 16, 390.	2.0	5
545	Lipoproteins and Diabetic Nephropathy. <i>Contemporary Diabetes</i> , 2014, , 279-299.	0.0	0
546	About Randomised Clinical Trials Related to Lipoproteins in Diabetes Mellitus. <i>Contemporary Diabetes</i> , 2014, , 329-346.	0.0	0
547	Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes. <i>Contemporary Diabetes</i> , 2014, , 435-453.	0.0	0
548	Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2014, 64, 40-48.	2.1	55
549	Targeting inflammation: New therapeutic approaches in chronic kidney disease (CKD). <i>Pharmacological Research</i> , 2014, 81, 91-102.	3.1	104
550	Joint British Societiesâ€™ consensus recommendations for the prevention of cardiovascular disease (JBS3). <i>Heart</i> , 2014, 100, ii1-ii67.	1.2	441
551	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. <i>Journal of Clinical Lipidology</i> , 2014, 8, 29-60.	0.6	289
552	Cardiorenal Syndrome. <i>Heart Failure Clinics</i> , 2014, 10, 251-280.	1.0	115
554	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 63, 696-697.	1.2	0

#	ARTICLE	IF	CITATIONS
555	The endothelial glycocalyx: Scratching the surface for cardiovascular disease in kidney failure. <i>Atherosclerosis</i> , 2014, 235, 56-57.	0.4	10
556	Lipid-Lowering Guidelines and Statin Use in CKD: A Time for Change. <i>American Journal of Kidney Diseases</i> , 2014, 63, 736-738.	2.1	2
557	Potential Effects of Reclassifying CKD as a Coronary Heart Disease Risk Equivalent in the US Population. <i>American Journal of Kidney Diseases</i> , 2014, 63, 753-760.	2.1	13
558	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiología</i> , 2014, 67, 136.e1-136.e56.	0.6	15
559	Dyslipidemia in Diabetes Mellitus and Chronic Kidney Disease. , 2014, , 141-152.		0
560	Therapeutic approaches to diabetic nephropathy—beyond the RAS. <i>Nature Reviews Nephrology</i> , 2014, 10, 325-346.	4.1	152
561	Plant sterols from foods in inflammation and risk of cardiovascular disease: A real threat?. <i>Food and Chemical Toxicology</i> , 2014, 69, 140-149.	1.8	50
563	Cardiovascular Complications of Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 273-280.	0.6	181
564	Sudden cardiac death and diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 573-579.	1.2	30
565	Pharmacogenomics, Lipid Disorders, and Treatment Options. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 36-47.	2.3	26
566	Statin Therapy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry). <i>American Journal of Cardiology</i> , 2014, 113, 621-625.	0.7	14
567	Cardiovascular complications after transplantation: Treatment options in solid organ recipients. <i>Transplantation Reviews</i> , 2014, 28, 47-55.	1.2	30
568	Evidence of Comparative Effectiveness Without Evidence of Effectiveness: The Case of Phosphate Binders in CKD. <i>American Journal of Kidney Diseases</i> , 2014, 63, 13-15.	2.1	1
569	Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. <i>Atherosclerosis</i> , 2014, 232, 224-230.	0.4	116
570	Results of the 4D study: ten years of follow-up?. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 274-277.	0.7	4
571	Epidemiology of dyslipidemia in chronic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 185-188.	0.7	10
572	What is the Role of Lipid Measurements in End-Stage Renal Disease?. <i>Seminars in Dialysis</i> , 2014, 27, 549-552.	0.7	0
573	Risk of Sudden Cardiac Death in Chronic Kidney Disease. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 222-231.	0.8	27

#	ARTICLE	IF	CITATIONS
574	Achieving lipid targets in primary care settings. <i>Current Medical Research and Opinion</i> , 2014, 30, 1971-1974.	0.9	4
575	Novel effective drugs for diabetic kidney disease? or not?. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 571-601.	1.0	15
576	The thyroid receptor β 2 modulator GC-1 reduces atherosclerosis in ApoE deficient mice. <i>Atherosclerosis</i> , 2014, 237, 544-554.	0.4	15
577	Chronic Kidney Disease and Stroke. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 500-508.	0.6	39
578	The Management of Acute Coronary Syndromes in Patients With Chronic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 472-479.	0.6	7
579	The Interplay Between CKD, Sudden Cardiac Death, and Ventricular Arrhythmias. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 480-488.	0.6	45
580	Incidence of Cancer and Mortality in Patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Trial. <i>American Journal of Cardiology</i> , 2014, 114, 1518-1522.	0.7	21
581	Effect of High-Dose Atorvastatin on Renal Function in Subjects With Stroke or Transient Ischemic Attack in the SPARCL Trial. <i>Stroke</i> , 2014, 45, 2974-2982.	1.0	29
582	HDL in CKD: How Good Is the "Good Cholesterol"? <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 871-874.	3.0	15
585	Statins for microvascular complications" all but the kidney. <i>Nature Reviews Nephrology</i> , 2014, 10, 680-681.	4.1	1
586	Treatment of Dyslipidemia and Cardiovascular Outcomes: The Journey So Far"Is This the End for Statins?. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 192-205.	2.3	20
587	Relation of Serum Lipids and Lipoproteins with Progression of CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1190-1198.	2.2	124
588	High serum cholesterol: a missed risk factor for chronic kidney disease mortality. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 613-614.	5.5	3
589	Review of Clinical Practice Guidelines for the Management of LDL-Related Risk. <i>Journal of the American College of Cardiology</i> , 2014, 64, 196-206.	1.2	52
590	Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1415-1422.	0.4	74
591	Impact of Drug Policy on Regional Trends in Ezetimibe Use. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 589-596.	0.9	8
593	High serum cholesterol: a missed risk factor for chronic kidney disease mortality"Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 614.	5.5	1
594	Defining the Natural History of Uremic Cardiomyopathy in Chronic Kidney Disease. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 703-714.	2.3	92

#	ARTICLE	IF	CITATIONS
595	Implications of Kidney Disease in the Cardiac Patient. <i>Interventional Cardiology Clinics</i> , 2014, 3, 317-331.	0.2	0
596	Artificial metabolism-inspired photoelectrochemical probing of biomolecules and cells. <i>Journal of Materials Chemistry A</i> , 2014, 2, 15752-15757.	5.2	11
597	A Current Approach to Statin Intolerance. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 74-80.	2.3	16
598	Statins in chronic kidney disease and kidney transplantation. <i>Pharmacological Research</i> , 2014, 88, 62-73.	3.1	22
599	LDL cholesterol: controversies and future therapeutic directions. <i>Lancet, The</i> , 2014, 384, 607-617.	6.3	229
600	Estimated glomerular filtration rate. <i>BMJ, The</i> , 2014, 348, g264-g264.	3.0	16
601	Combination therapy in dyslipidemia: Where are we now?. <i>Atherosclerosis</i> , 2014, 237, 319-335.	0.4	39
602	Prevalence, determinants, and management of chronic kidney disease in Karachi, Pakistan - a community based cross-sectional study. <i>BMC Nephrology</i> , 2014, 15, 90.	0.8	52
603	The VITAH Trial Vitamin D supplementation and cardiac autonomic tone in hemodialysis: a blinded, randomized controlled trial. <i>BMC Nephrology</i> , 2014, 15, 129.	0.8	11
604	Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2014, 59, e96-e138.	2.9	254
605	Measuring the quality of renal care: things to keep in mind when selecting and using quality indicators. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1460-1467.	0.4	25
606	A Summary and Critical Assessment of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Filling the Gaps. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1257-1278.	1.4	35
608	Chronic kidney disease induced dysfunction of high density lipoprotein. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 251-254.	0.7	13
609	Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 257-260.	0.7	9
610	In vivo kinetic studies to further understand pathogenesis of abnormal lipoprotein metabolism in chronic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 261-264.	0.7	8
611	The kidney and lipids: preface. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 180-184.	0.7	0
612	Inflammatory stress reduces the effectiveness of statins in the kidney by disrupting HMGCoA reductase feedback regulation. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1864-1878.	0.4	10
613	The Ebbs and Flows in the Development of Cholesterol-Lowering Drugs: Prospects for the Future. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 64-73.	2.3	13

#	ARTICLE	IF	CITATIONS
614	New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 493-503.	0.9	150
615	Preventing the progression of chronic kidney disease: two case reports and review of the literature. <i>International Urology and Nephrology</i> , 2014, 46, 2167-2174.	0.6	4
616	Discordance in Lipid Measurements: Can we Capitalize to Better Personalize Cardiovascular Risk Assessment and Treatment?. <i>Current Cardiovascular Risk Reports</i> , 2014, 8, 1.	0.8	1
617	Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial: a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25Âmg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomised controlled trial. <i>Trials</i> , 2014, 15, 160.	0.7	29
618	Comparison of the Efficacy and Safety Profile of Morning Administration of Controlled-release Simvastatin Versus Evening Administration of Immediate-release Simvastatin in Chronic Kidney Disease Patients With Dyslipidemia. <i>Clinical Therapeutics</i> , 2014, 36, 1182-1190.	1.1	12
619	Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. <i>European Heart Journal</i> , 2014, 35, 1996-2000.	1.0	34
620	Drug development: how academia, industry and authorities interact. <i>Nature Reviews Nephrology</i> , 2014, 10, 602-610.	4.1	4
621	Cardiovascular Disease Prevention in CKD. <i>American Journal of Kidney Diseases</i> , 2014, 64, 326-328.	2.1	3
622	Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody. <i>Future Cardiology</i> , 2014, 10, 183-199.	0.5	38
623	Diagnosis and Treatment of Glomerular Diseases in Elderly Patients. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 228-246.	0.6	13
624	Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angiography and ultrasound: The ZIPANGU study. <i>Journal of Cardiology</i> , 2014, 64, 501-507.	0.8	8
625	Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk Factors. <i>Diabetes Care</i> , 2014, 37, 1660-1667.	4.3	68
626	The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 369-385.	2.2	32
627	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. <i>American Heart Journal</i> , 2014, 168, 205-212.e1.	1.2	93
628	Intestinal Cholesterol Absorption and Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2014, 63, 695-696.	1.2	7
629	The Roads Less Traveled? Diverging Research and Clinical Priorities for Dialysis Patients and Those With Less Severe CKD. <i>American Journal of Kidney Diseases</i> , 2014, 63, 124-132.	2.1	8
630	KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. <i>American Journal of Kidney Diseases</i> , 2014, 63, 713-735.	2.1	1,249
631	Are Renin-Angiotensin-Aldosterone System Inhibitors Lifesaving in Chronic Kidney Disease?. <i>Journal of the American College of Cardiology</i> , 2014, 63, 659-660.	1.2	5

#	ARTICLE	IF	CITATIONS
632	Overcoming toxicity and side-effects of lipid-lowering therapies. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 439-452.	2.2	41
634	Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2014, 8, 107-116.	0.6	31
635	Kidney Disease Guideline Profusion and Confusion: Unintended Consequences of Different Perspectives and Definitions. <i>American Journal of Kidney Diseases</i> , 2014, 63, 749-752.	2.1	4
636	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. <i>Lancet, The</i> , 2014, 383, 1831-1843.	6.3	341
637	KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. <i>Kidney International</i> , 2014, 85, 1303-1309.	2.6	452
638	Managing advanced chronic kidney disease: A primary care guide. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 289-299.	0.6	10
639	Critical review of non-statin treatments for dyslipoproteinemia. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 359-371.	0.6	6
640	Meta-Analysis of the Effect of Statins on Renal Function. <i>American Journal of Cardiology</i> , 2014, 114, 562-570.	0.7	48
641	Lipid lowering in liver and chronic kidney disease. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 339-352.	2.2	9
642	High-density lipoprotein in uremic patients: metabolism, impairment, and therapy. <i>International Urology and Nephrology</i> , 2014, 46, 27-39.	0.6	10
643	Renal and Vascular Protective Effects of Ezetimibe in Chronic Kidney Disease. <i>Internal Medicine</i> , 2014, 53, 307-314.	0.3	12
644	Dyslipidemia in chronic kidney disease: randomized controlled trial of colestilan versus simvastatin in dialysis patients. <i>Clinical Nephrology</i> , 2014, 82, 163-172.	0.4	6
645	2014 Meet-The-Professor: Endocrine Case Management. , 2014, , .		0
646	CVD and type 2 diabetes: The nurse prescriber's role. <i>British Journal of Cardiac Nursing</i> , 2014, 9, 325-329.	0.0	0
647	Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2014, 160, 182-189.	2.0	159
649	Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease. <i>Current Opinion in Lipidology</i> , 2014, 25, 54-60.	1.2	51
650	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 914-919.	2.2	19
651	Separate and Joint Effects of Diabetes Mellitus and Chronic Kidney Disease on the Risk of Acute Coronary Syndrome. <i>Medicine (United States)</i> , 2014, 93, e261.	0.4	9

#	ARTICLE	IF	CITATIONS
652	Predicting hospital admissions by looking backwards: an alternative perspective. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 225-227.	0.4	1
653	HMG CoA reductase inhibitors (statins) for kidney transplant recipients. <i>The Cochrane Library</i> , 2015, 2015, CD005019.	1.5	58
654	Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target. <i>Medicina Clínica (English Edition)</i> , 2015, 145, 67-69.	0.1	0
655	Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. <i>Value in Health</i> , 2015, 18, 1079-1087.	0.1	16
656	Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials. <i>Clinical Cardiology</i> , 2015, 38, 763-769.	0.7	12
657	Lipid Lowering in Patients With Kidney Disease—“Is It Really That Hard?”. <i>Circulation Journal</i> , 2015, 79, 976-977.	0.7	0
658	Differential Effects of Strong and Regular Statins on the Clinical Outcome of Patients With Chronic Kidney Disease Following Coronary Stent Implantation—“The Kumamoto Intervention Conference Study (KICS) Registry”. <i>Circulation Journal</i> , 2015, 79, 1115-1124.	0.7	19
659	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan 2015. <i>Endocrine Practice</i> , 2015, 21, 1-87.	1.1	443
661	The Serum Lipids Levels may be Underestimated in Patients on Hemodialysis. <i>Internal Medicine</i> , 2015, 54, 887-894.	0.3	4
663	Bedside-to-Bench Translational Research for Chronic Heart Failure: Creating an Agenda for Clients who do Not Meet Trial Enrollment Criteria. <i>Clinical Medicine Insights: Cardiology</i> , 2015, 9s1, CMC.S18737.	0.6	5
664	Pathophysiologic and Treatment Strategies for Cardiovascular Disease in End-Stage Renal Disease and Kidney Transplantations. <i>Cardiology in Review</i> , 2015, 23, 109-118.	0.6	25
665	Current Focuses in Serum Lipid Abnormalities in Dialysis Patients. <i>Blood Purification</i> , 2015, 40, 326-331.	0.9	3
666	Current practices in coronary artery disease evaluation of renal transplant candidates prior to renal transplantation. <i>Proceedings of Singapore Healthcare</i> , 2015, 24, 213-218.	0.2	0
668	Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies. <i>Cardiovascular Diabetology</i> , 2015, 14, 60.	2.7	3
669	Improving the odds: ezetimibe and cardiovascular disease. <i>International Journal of Clinical Practice</i> , 2015, 69, 390-395.	0.8	2
670	Interdisciplinary care clinics in chronic kidney disease. <i>BMC Nephrology</i> , 2015, 16, 161.	0.8	38
671	Does pharmacotherapy improve cardiovascular outcomes in hemodialysis patients?. <i>Hemodialysis International</i> , 2015, 19, S40-50.	0.4	1
672	New worldwide lipid guidelines. <i>Current Opinion in Cardiology</i> , 2015, 30, 447-453.	0.8	4

#	ARTICLE	IF	CITATIONS
673	Heparin induces an accumulation of atherogenic lipoproteins during hemodialysis in normolipidemic end-stage renal disease patients. <i>Hemodialysis International</i> , 2015, 19, 360-367.	0.4	5
674	The old is new. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2015, 28, 18-22.	0.1	1
675	HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. <i>Sao Paulo Medical Journal</i> , 2015, 133, 541-542.	0.4	9
676	2015 Korean Guidelines for Management of Dyslipidemia. <i>Journal of Lipid and Atherosclerosis</i> , 2015, 4, 61.	1.1	38
677	Combination pharmacotherapy in lipid management. <i>Journal of the Korean Medical Association</i> , 2015, 58, 745.	0.1	0
678	Increased Proinflammatory Cytokine Production and Decreased Cholesterol Efflux Due to Downregulation of ABCG1 in Macrophages Exposed to Indoxyl Sulfate. <i>Toxins</i> , 2015, 7, 3155-3166.	1.5	30
679	Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. <i>Lipids in Health and Disease</i> , 2015, 14, 45.	1.2	13
680	Type 4 Cardiorenal Syndrome: Diagnosis and Treatment. <i>Nephrology @ Point of Care</i> , 2015, 1, napoc.2015.1467.	0.2	0
681	Strategies for Controlling Blood Pressure and Reducing Cardiovascular Disease Risk in Patients with Chronic Kidney Disease. <i>Ethnicity and Disease</i> , 2015, 25, 515.	1.0	4
682	Type of dyslipidemia and achievement of the LDL-cholesterol goal in chronic kidney disease patients at the University Hospital. <i>Vascular Health and Risk Management</i> , 2015, 11, 563.	1.0	3
683	Target Values of Cardiovascular Risk Factors Are Not Associated with All-Cause Mortality in Patients with Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2015, 10, e0124536.	1.1	3
684	Clinical Efficacy and Safety of Ezetimibe on Major Cardiovascular Endpoints: Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2015, 10, e0124587.	1.1	27
685	Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition. <i>PLoS ONE</i> , 2015, 10, e0142430.	1.1	38
686	Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins. <i>PLoS ONE</i> , 2015, 10, e0138332.	1.1	21
687	A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on Dialysis. <i>International Journal of Nephrology</i> , 2015, 2015, 1-12.	0.7	5
688	Severe Rhabdomyolysis Associated with Simvastatin and Role of Ciprofloxacin and Amlodipine Coadministration. <i>Case Reports in Nephrology</i> , 2015, 2015, 1-4.	0.2	12
689	All for Statins and Statins for All; An Update. <i>Current Pharmaceutical Design</i> , 2015, 22, 18-27.	0.9	19
690	Lipid abnormalities in kidney disease and management strategies. <i>World Journal of Nephrology</i> , 2015, 4, 83.	0.8	43

#	ARTICLE	IF	CITATIONS
691	Is There an Optimal Strategy for Pretransplant Cardiovascular Screening?. <i>Transplantation</i> , 2015, 99, 656-657.	0.5	3
692	Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2328-2339.	3.0	116
694	Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2015, 162, ITC1-ITC16.	2.0	168
695	Intestinal Cholesterol Absorption, Treatment With Atorvastatin, and Cardiovascular Risk in Hemodialysis Patients. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2291-2298.	1.2	34
696	Cholesterol Absorption Inhibitor Ezetimibe: Riskâ€“Benefits and Role in Treating Dyslipidemias. <i>Contemporary Endocrinology</i> , 2015, , 465-481.	0.3	0
697	Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2289-2302.	3.0	39
698	Twenty-five years of statins: where do we go from here?. <i>Clinical Lipidology</i> , 2015, 10, 33-45.	0.4	2
699	What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. <i>BMC Nephrology</i> , 2015, 16, 65.	0.8	82
700	Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial. <i>Kidney International</i> , 2015, 87, 1250-1257.	2.6	46
701	Cholesterol Metabolism and Statin Effectiveness in Hemodialysis Patientsâ€“ —. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2299-2301.	1.2	5
702	Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein. <i>Archives of Medical Research</i> , 2015, 46, 379-391.	1.5	42
703	Statins Can Delay Insulin Use and Reduce Diabetes-related Diseases in Asian Patients With Type 2 Diabetes. <i>Medicine (United States)</i> , 2015, 94, e735.	0.4	1
704	Defining, Treating, and Understanding Chronic Kidney Diseaseâ€“A Complex Disorder. <i>Journal of Clinical Hypertension</i> , 2015, 17, 514-527.	1.0	18
705	Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy. <i>Advances in Therapy</i> , 2015, 32, 1177-1191.	1.3	41
706	Drug therapies to delay the progression of chronic kidney disease. <i>Clinical Medicine</i> , 2015, 15, 550-557.	0.8	10
707	Acute Care QUALiTy in chronic Kidney disease (ACQUATIK): a prospective cohort study exploring outcomes of patients with chronic kidney disease. <i>BMJ Open</i> , 2015, 5, e006987-e006987.	0.8	3
708	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>Journal of Clinical Lipidology</i> , 2015, 9, S1-S122.e1.	0.6	430
709	The past, present and future of lipid-lowering therapy. <i>Clinical Lipidology</i> , 2015, 10, 481-498.	0.4	6

#	ARTICLE	IF	CITATIONS
710	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management. <i>Seminars in Nephrology</i> , 2015, 35, 582-589.e17.	0.6	9
711	Humble kidneys predict mighty heart troubles. <i>Lancet Diabetes and Endocrinology</i> ,the, 2015, 3, 489-491.	5.5	16
712	Is the Guideline Process Replicable and, if Not, What Does This Mean?. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 3-9.	1.6	2
713	Updates in the management of diabetic nephropathy. <i>Clinical Queries Nephrology</i> , 2015, 4, 9-14.	0.2	0
714	High prevalence of chronic kidney disease in Finnish patients with type 2 diabetes treated in primary care. <i>Primary Care Diabetes</i> , 2015, 9, 31-38.	0.9	40
715	Type 2 Diabetes Mellitus, Metabolic Syndrome, and Mixed Dyslipidemia: How Similar, How Different, and How to Treat?. <i>Metabolic Syndrome and Related Disorders</i> , 2015, 13, 1-21.	0.5	26
716	Restoration of Renal Function Does Not Correct Impairment of Uremic HDL Properties. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 565-575.	3.0	37
717	Incremental prognostic value of kidney function decline over coronary artery disease for cardiovascular event prediction after coronary computed tomography. <i>Kidney International</i> , 2015, 88, 152-159.	2.6	18
718	Endocrine and Metabolic Changes Affecting Cardiovascular Disease in Dialysis Patients. , 2015, 25, 223-225.		6
719	Selective Cathepsin S Inhibition Attenuates Atherosclerosis in Apolipoprotein Eâ€“Deficient Mice with Chronic Renal Disease. <i>American Journal of Pathology</i> , 2015, 185, 1156-1166.	1.9	63
720	Lipid Lowering Drugs. , 2015, , 915-929.		0
721	Associations between lipid profiles and MACE in hemodialysis patients with percutaneous coronary intervention: From the FU-Registry. <i>Journal of Cardiology</i> , 2015, 65, 105-111.	0.8	10
722	Ezetimibe/statin combination therapy to treat patients with type 2 diabetes. <i>Atherosclerosis Supplements</i> , 2015, 17, 2-8.	1.2	7
723	Lipid Levels and Renal Function Decline in Pre-Dialysis Patients. <i>Nephron Extra</i> , 2015, 5, 19-29.	1.1	7
724	A nephrology guide to reading and using systematic reviews of randomized trials. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 878-884.	0.4	2
725	Statins and the kidney: friend or foe?. <i>Lancet Diabetes and Endocrinology</i> ,the, 2015, 3, 161-162.	5.5	2
726	Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. <i>Lancet Diabetes and Endocrinology</i> ,the, 2015, 3, 181-190.	5.5	114
727	Updated guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists. <i>Canadian Pharmacists Journal</i> , 2015, 148, 21-28.	0.4	6

#	ARTICLE	IF	CITATIONS
728	Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection. Journal of the American Society of Nephrology: JASN, 2015, 26, 2055-2064.	3.0	204
729	Physiological Actions of PTH and PTHrP IV. , 2015, , 187-201.		1
730	Heart Disease and Stroke Statisticsâ€™2015 Update. Circulation, 2015, 131, e29-322.	1.6	5,963
732	Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The Evaluation Of Cinacalcet HCl Therapy to Lower CardioVascular Events Trial. Journal of the American Heart Association, 2015, 4, .	1.6	31
733	Timeliness in chronic kidney disease and albuminuria identification: a retrospective cohort study. BMC Family Practice, 2015, 16, 18.	2.9	20
734	Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. Internal and Emergency Medicine, 2015, 10, 219-246.	1.0	11
735	Norepinephrine, left ventricular disorders and volume excess in ESRD. Journal of Nephrology, 2015, 28, 729-737.	0.9	4
736	Drug Management in the Elderly Adult With Chronic Kidney Disease: A Review for the Primary Care Physician. Mayo Clinic Proceedings, 2015, 90, 633-645.	1.4	40
737	Primary Prevention of Atherosclerotic Cardiovascular Disease. Annals of Pharmacotherapy, 2015, 49, 484-493.	0.9	9
738	Lipid Management. , 2015, , .		1
739	Baseline Serum Interleukin-6 Predicts Cardiovascular Events in Incident Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2015, 35, 35-42.	1.1	23
740	Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2015, 66, 495-507.	1.2	352
741	The low-density lipoprotein hypothesis: Proven again with the Improved Reduction of Outcomes: Vytorin Efficacy International Trial. Journal of Clinical Lipidology, 2015, 9, 496-497.	0.6	1
743	Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: Multicenter prospective study in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 756-762.	1.1	21
745	Changes over the last decade in carotid atherosclerosis in patients with end-stage kidney disease. Atherosclerosis, 2015, 240, 535-543.	0.4	6
746	Impact of combination therapy with statin and ezetimibe on secondary prevention for post-acute myocardial infarction patients in the statin era. IJC Heart and Vasculature, 2015, 8, 154-160.	0.6	3
747	Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia. Nephron, 2015, 130, 229-238.	0.9	7
749	Statins and Ezetimibe. , 2015, , 25-36.		1

#	ARTICLE	IF	CITATIONS
750	Dermatological Manifestations of Kidney Disease. , 2015, , .		0
751	New Hope for Lipid-Lowering Beyond Statins: Effect of IMPROVE-IT on Understanding and Implementation of Atherosclerosis Prevention. Canadian Journal of Cardiology, 2015, 31, 585-587.	0.8	8
752	Chronic kidney disease and heart disease: after 179 years, do we yet understand the link?. Kidney International, 2015, 88, 11-13.	2.6	9
753	Celebrating 20 years of evidence from the Cochrane Collaboration: what has been the impact of systematic reviews on nephrology?. Nephrology Dialysis Transplantation, 2015, 30, 871-877.	0.4	5
754	Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?. Expert Opinion on Drug Safety, 2015, 14, 1445-1455.	1.0	8
755	Meta-analysis of statin therapy in maintenance dialysis patients. Renal Failure, 2015, 37, 1149-1156.	0.8	14
756	Association of Serum Lipids with Outcomes in Hispanic Hemodialysis Patients of the West versus East Coasts of the United States. American Journal of Nephrology, 2015, 41, 284-295.	1.4	19
757	Cardiovascular complications of chronic kidney disease. Medicine, 2015, 43, 469-473.	0.2	5
758	Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. European Heart Journal, 2015, 36, 1601-1608.	1.0	59
759	Cardiovascular Complications in Diabetic Patients Undergoing Regular Hemodialysis. Angiology, 2015, 66, 225-230.	0.8	10
760	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace, 2015, 17, 1169-1196.	0.7	138
761	A paradigm shift in the treatment of atherosclerosis. Archives of Cardiovascular Diseases, 2015, 108, 337-339.	0.7	1
762	The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal Cancer. Current Treatment Options in Oncology, 2015, 16, 43.	1.3	19
763	Current Treatment of Dyslipidemia: Evolving Roles of Non-Statins and Newer Drugs. Drugs, 2015, 75, 1201-1228.	4.9	18
764	Folic Acid for Stroke Prevention: Time to Revisit Vitamin Therapy in Patients With Kidney Disease?. American Journal of Kidney Diseases, 2015, 66, 942-944.	2.1	1
765	Effect of Membrane Permeability on Cardiovascular Risk Factors and β_2 m Plasma Levels in Patients on Long-Term Haemodialysis: A Randomised Crossover Trial. Nephron, 2015, 129, 269-275.	0.9	10
766	Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease. Atherosclerosis, 2015, 242, 37-44.	0.4	23
767	Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. Atherosclerosis, 2015, 242, 56-64.	0.4	30

#	ARTICLE	IF	CITATIONS
768	Ezetimibe+Statin Combination to Reduce Cardiovascular Events: The Evidence Base. <i>Metabolic Syndrome and Related Disorders</i> , 2015, 13, 327-328.	0.5	0
769	Optimizing Care for Canadians with Diabetic Nephropathy in 2015. <i>Canadian Journal of Diabetes</i> , 2015, 39, 221-228.	0.4	8
770	Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: insights from the Associazione Medici Diabetologi Annals initiative. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1526-1533.	0.4	39
771	Simvastatin+ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study. <i>International Journal of Cardiology</i> , 2015, 190, 20-25.	0.8	22
772	Asociación de simvastatina con ezetimiba como alternativa terapéutica en el control lipídico de enfermos renales crónicos en estadio 3-4. Resultados a un año. <i>Dialisis Y Trasplante</i> , 2015, 36, 1-7.	0.4	0
773	2013 ACC/AHA cholesterol treatment guidelines. <i>Journal of Indian College of Cardiology</i> , 2015, 5, S15-S20.	0.1	0
774	Coronary Artery Calcium Assessment in CKD: Utility in Cardiovascular Disease Risk Assessment and Treatment?. <i>American Journal of Kidney Diseases</i> , 2015, 65, 937-948.	2.1	37
775	Dyslipidemia in Dialysis Patients. <i>Seminars in Dialysis</i> , 2015, 28, 345-353.	0.7	20
776	Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 489-499.	0.6	2
777	Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal. <i>Journal of Medical Economics</i> , 2015, 18, 565-572.	1.0	13
778	Coronary plaque progression of non-culprit lesions after culprit percutaneous coronary intervention in patients with moderate to advanced chronic kidney disease: intravascular ultrasound and integrated backscatter intravascular ultrasound study. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 935-945.	0.7	19
779	Prevention of Heart Failure in Patients with Chronic Kidney Disease. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	0.8	1
780	Tools for Cardiovascular Risk Assessment in Clinical Practice. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	0.8	0
783	Deeper insight into chronic kidney disease-related atherosclerosis: comparative proteomic studies of blood plasma using 2DE and mass spectrometry. <i>Journal of Translational Medicine</i> , 2015, 13, 20.	1.8	25
784	Practical recommendations for the management of hyperlipidemia. <i>Atherosclerosis Supplements</i> , 2015, 18, 194-198.	1.2	25
785	Statins in chronic kidney disease: time to move on?. <i>Nature Reviews Nephrology</i> , 2015, 11, 262-263.	4.1	5
786	The Evolving Understanding of the Contribution of Lipid Metabolism to Diabetic Kidney Disease. <i>Current Diabetes Reports</i> , 2015, 15, 40.	1.7	136
788	Inflammatory Cytokines and Reactive Oxygen Species as Mediators of Chronic Kidney Disease-Related Vascular Calcification. <i>American Journal of Hypertension</i> , 2015, 28, 746-755.	1.0	140

#	ARTICLE	IF	CITATIONS
789	Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease. <i>Pediatric Nephrology</i> , 2015, 30, 2073-2084.	0.9	27
790	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1â€”Full Report. <i>Journal of Clinical Lipidology</i> , 2015, 9, 129-169.	0.6	632
791	Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). <i>Nephrology Dialysis Transplantation</i> , 2015, 30, ii1-ii142.	0.4	113
792	Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1255-1262.	0.9	15
793	Medical Management of Serum Lipids and Coronary Heart Disease. <i>Cardiovascular Medicine</i> , 2015, , 39-55.	0.0	0
794	Vascular Effects of Inflammation and Oxidative Stress in CKD. , 2015, , 51-59.		0
795	Statins and Cardiovascular Primary Prevention in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 732-739.	2.2	49
797	Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge. <i>International Urology and Nephrology</i> , 2015, 47, 805-813.	0.6	14
798	Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome. <i>Circulation</i> , 2015, 131, 1123-1149.	1.6	61
799	Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial. <i>Journal of Cardiology</i> , 2015, 66, 353-358.	0.8	11
800	Current lipid-modifying agents. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1117-1118.	0.9	5
801	Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. <i>Lancet Diabetes and Endocrinology</i> ,the, 2015, 3, 993-1003.	5.5	25
802	Nonstatin Therapies for Management of Dyslipidemia: A Review. <i>Clinical Therapeutics</i> , 2015, 37, 2153-2179.	1.1	39
803	Comparative Effectiveness of Statin Therapy in Chronic Kidney Disease and Acute Myocardial Infarction: A Retrospective Cohort Study. <i>American Journal of Medicine</i> , 2015, 128, 1252.e1-1252.e11.	0.6	7
804	Evidence-based care in a population with chronic kidney disease and acute coronary syndrome. Findings from the Australian Cooperative National Registry of Acute Coronary Care, Guideline Adherence and Clinical Events (CONCORDANCE). <i>American Heart Journal</i> , 2015, 170, 566-572.e1.	1.2	26
805	Nonstatin Low-Density Lipoproteinâ€”Lowering Therapy and Cardiovascular Risk Reductionâ€”Statement From <i>ATVB</i> Council. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2269-2280.	1.1	58
806	Participation in a Structured Weight Loss Program and All-Cause Mortality and Cardiovascular Morbidity in Obese Patients With Chronic Kidney Disease. , 2015, 25, 472-479.		18
807	The IMPROVE-IT study and ezetimibe. <i>British Journal of Community Nursing</i> , 2015, 20, 243-244.	0.2	2

#	ARTICLE	IF	CITATIONS
808	Dyslipidemia in Obesity. , 2015, , 1-18.		1
809	Low dialysate potassium and central arterial pressure waveform. Upsala Journal of Medical Sciences, 2015, 120, 207-212.	0.4	1
811	Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. Current Atherosclerosis Reports, 2015, 17, 72.	2.0	11
812	Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome. Contemporary Endocrinology, 2015, , 137-154.	0.3	0
813	Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation. International Journal of Angiology, 2015, 24, 105-112.	0.2	3
814	Not All Deaths in CKD Are from a Broken Heart. Journal of the American Society of Nephrology: JASN, 2015, 26, 2307-2308.	3.0	0
815	The glycocalyx linking albuminuria with renal and cardiovascular disease. Nature Reviews Nephrology, 2015, 11, 667-676.	4.1	128
816	Alopecias. , 2015, , 159-167.		0
817	Are Statins out in the COLD? The STATCOPE Trial. Canadian Journal of Cardiology, 2015, 31, 970-973.	0.8	6
818	Lowering cholesterol in chronic kidney disease: is it safe and effective?. European Heart Journal, 2015, 36, 2988-2995.	1.0	20
819	Safety and efficacy of ezetimibe: A meta-analysis. International Journal of Cardiology, 2015, 201, 247-252.	0.8	70
820	Primary Care of the Patient with Chronic Kidney Disease. Medical Clinics of North America, 2015, 99, 935-952.	1.1	12
821	Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates. Kidney International, 2015, 88, 1411-1418.	2.6	23
822	Stroke and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management Across Kidney Disease Stages. Seminars in Nephrology, 2015, 35, 311-322.	0.6	71
823	Antilipidemic Drug Therapy Today and in the Future. Handbook of Experimental Pharmacology, 2015, 233, 373-435.	0.9	5
824	Cholesterol Metabolism in CKD. American Journal of Kidney Diseases, 2015, 66, 1071-1082.	2.1	84
825	Dyslipidemia in chronic kidney disease. Disease-a-Month, 2015, 61, 396-402.	0.4	4
826	Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial. Drugs and Aging, 2015, 32, 1055-1065.	1.3	16

#	ARTICLE	IF	CITATIONS
827	Association between higher rates of cardioprotective drug use and survival in patients on dialysis. Research in Social and Administrative Pharmacy, 2015, 11, 824-843.	1.5	11
829	Fixed-dose combination ezetimibe+atorvastatin lowers <sc>LDL</sc> equivalent to co-administered components in randomized trials: use of a dose-response model. Fundamental and Clinical Pharmacology, 2015, 29, 209-218.	1.0	6
830	Cardiovascular risk assessment in kidney transplantation. Kidney International, 2015, 87, 527-534.	2.6	70
831	KDOQI US Commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD. American Journal of Kidney Diseases, 2015, 65, 354-366.	2.1	93
833	Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives. Drug Discovery Today, 2015, 20, 332-346.	3.2	74
834	Euvolemia in Hemodialysis Patients: A Potentially Dangerous Goal?. Seminars in Dialysis, 2015, 28, 1-5.	0.7	25
835	HDL Cholesterol, Apolipoproteins, and Cardiovascular Risk in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2015, 26, 484-492.	3.0	37
836	Alterations of plant sterols, lathosterol, oxidative stress and inflammatory markers after the combination therapy of ezetimibe and statin drugs in type 2 diabetic patients. Obesity Research and Clinical Practice, 2015, 9, 67-74.	0.8	5
837	Canadian Society of Nephrology Commentary on the KDIGO Clinical Practice Guideline for CKD Evaluation and Management. American Journal of Kidney Diseases, 2015, 65, 177-205.	2.1	98
838	The New Dyslipidemia Guidelines: What Is the Debate?. Canadian Journal of Cardiology, 2015, 31, 605-612.	0.8	46
839	Chronic Kidney Disease and Hypertension. , 2015, , .		0
840	Contrasting Cholesterol Management Guidelines for Adults with CKD. Journal of the American Society of Nephrology: JASN, 2015, 26, 1173-1180.	3.0	52
841	Planning for Hemodialysis. , 2015, , 751-764.		0
842	Chronic Kidney Disease in Children. , 2015, , 813-824.		0
843	Approach to Chronic Kidney Disease in the Diabetic Patient. , 2015, , 523-533.		0
844	Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. Seminars in Dialysis, 2015, 28, 35-47.	0.7	49
845	Neurologic Complications of Chronic Kidney Disease. , 2015, , 249-265.		1
846	Dyslipidemia and Chronic Kidney Disease. , 2015, , 706-710.		0

#	ARTICLE	IF	CITATIONS
847	PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels. , 2015, 145, 58-66.		44
848	Cardiovascular Disease and Chronic Kidney Disease. , 2015, , 181-198.		2
849	Clinical Assessment and Management of Chronic Kidney Disease Across its Stages. , 2015, , 43-54.		0
850	The Interdisciplinary Chronic Kidney Disease Clinic. , 2015, , 587-597.		0
851	Slowing Progression of Chronic Kidney Disease. , 2015, , 598-612.		2
852	Muscle- and skeletal-related side-effects of statins: tip of the iceberg?. European Journal of Preventive Cardiology, 2016, 23, 88-110.	0.8	58
853	China Patient-centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction. Chinese Medical Journal, 2016, 129, 72-80.	0.9	18
854	DoenÃ§a coronÃ¡ria no paciente com doenÃ§a renal crÃ³nica. Revista Da Faculdade De CiÃªncias MÃ©dicas De Sorocaba, 2016, 18, 6-10.	0.2	0
855	Eligibility for Statin Treatment in Korean Subjects with Reduced Renal Function: An Observational Study. Endocrinology and Metabolism, 2016, 31, 402.	1.3	4
856	Recent advances in managing and understanding diabetic nephropathy. F1000Research, 2016, 5, 1044.	0.8	29
857	Coronary artery disease (CAD) in chronic kidney disease patients. Giornale De Tecniche Nefrologiche & Dialitiche, 2016, 28, 44-52.	0.1	1
858	Overview of guidelines for the management of dyslipidemia: EU perspectives. Vascular Health and Risk Management, 2016, Volume 12, 357-369.	1.0	16
859	Editorial (Thematic Issue: Sex, Environment, Physical Activity, Diet, and Obesity in Cardiovascular) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	2
860	Disorders of Lipid Metabolism. , 2016, , 1660-1700.		7
861	2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation). Korean Circulation Journal, 2016, 46, 275.	0.7	106
862	Lipids in Coronary Heart Disease. , 2016, , 67-80.		0
863	Chronic Heart Failure and Comorbid Renal Dysfunction - A Focus on Type 2 Cardiorenal Syndrome. Current Cardiology Reviews, 2016, 12, 186-194.	0.6	12
864	Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies. BMC Cancer, 2016, 16, 488.	1.1	78

#	ARTICLE	IF	CITATIONS
865	PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR. PLoS ONE, 2016, 11, e0146920.	1.1	35
866	Soy-based renoprotection. World Journal of Nephrology, 2016, 5, 233.	0.8	32
867	Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. World Journal of Cardiology, 2016, 8, 201.	0.5	47
868	Diabetes Mellitus and Intestinal Niemann-Pick C1-like 1 Gene Expression. , 2016, , 277-290.		2
869	Enzyme Replacement Therapy for Fabry Disease. FIRE Forum for International Research in Education, 2016, 4, 232640981667942.	0.7	1
870	Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy. Diabetes, Obesity and Metabolism, 2016, 18, 1120-1127.	2.2	9
871	Coronary Revascularization in Chronic and End-Stage Renal Disease. American Journal of Therapeutics, 2016, 23, e16-e28.	0.5	16
872	Electronegative Low-density Lipoprotein Increases Coronary Artery Disease Risk in Uremia Patients on Maintenance Hemodialysis. Medicine (United States), 2016, 95, e2265.	0.4	12
873	Cardiovascular calcifications in chronic kidney disease: Potential therapeutic implications. Nefrologia, 2016, 36, 597-608.	0.2	15
874	Different effect of hypercholesterolemia on mortality in hemodialysis patients based on coronary artery disease or myocardial infarction. Lipids in Health and Disease, 2016, 15, 211.	1.2	12
875	Using pharmacists to improve risk stratification and management of stage 3A chronic kidney disease: a feasibility study. BMC Nephrology, 2016, 17, 168.	0.8	22
876	iTRAQ-based proteomic analysis of plasma reveals abnormalities in lipid metabolism proteins in chronic kidney disease-related atherosclerosis. Scientific Reports, 2016, 6, 32511.	1.6	21
879	Are statins useful in patients with advanced chronic kidney disease? Authors' reply. Lancet Diabetes and Endocrinology, 2016, 4, 971-972.	5.5	7
880	Delphi consensus on the diagnosis and management of dyslipidaemia in chronic kidney disease patients: A post hoc analysis of the DIANA study. Nefrologia, 2016, 36, 679-686.	0.2	0
881	Clearance of cardiovascular medications during hemodialysis. Current Opinion in Nephrology and Hypertension, 2016, 25, 257-267.	1.0	4
882	Statins, renal function and homocysteine. Pharmacological Reports, 2016, 68, 1093.	1.5	0
883	Opponent's comments. Nephrology Dialysis Transplantation, 2016, 31, 880-881.	0.4	2
884	Association of statin use and the risk of end-stage renal disease: A nationwide Asian population-based case-control study. European Journal of Internal Medicine, 2016, 31, 68-72.	1.0	9

#	ARTICLE	IF	CITATIONS
885	Pro: Meta-analysis: the case<i>for</i>. Nephrology Dialysis Transplantation, 2016, 31, 875-880.	0.4	6
886	Discontinuation of Statins: What Are the Risks?. Current Atherosclerosis Reports, 2016, 18, 41.	2.0	9
887	Statin-centered treatment of dyslipidemia. New evidence-based paradigm, or only part of the evidence?. EndocrinologÃa Y NutriciÃ³n (English Edition), 2016, 63, 1-3.	0.5	2
888	Viejos y nuevos hipolipemiantes. FMC Formacion Medica Continuada En Atencion Primaria, 2016, 23, 172-184.	0.0	0
889	The heart and vascular system in dialysis. Lancet, The, 2016, 388, 276-284.	6.3	219
890	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. Nature Reviews Endocrinology, 2016, 12, 467-484.	4.3	28
891	Clinical management of the uraemic syndrome in chronic kidney disease. Lancet Diabetes and Endocrinology,the, 2016, 4, 360-373.	5.5	78
892	Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD. American Journal of Kidney Diseases, 2016, 67, 965-977.	2.1	16
893	2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statins Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. Journal of the American College of Cardiology, 2016, 68, 92-125.	1.2	371
894	Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. Kidney International, 2016, 89, 1144-1152.	2.6	139
895	Statin combination therapy and cardiovascular risk reduction. Future Cardiology, 2016, 12, 289-315.	0.5	13
896	Development and validation of cardiovascular risk scores for haemodialysis patients. International Journal of Cardiology, 2016, 216, 68-77.	0.8	44
897	Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clinical and Experimental Nephrology, 2016, 20, 342-370.	0.7	85
898	The macrophage and its related cholesterol efflux as a HDL function index in atherosclerosis. Clinica Chimica Acta, 2016, 457, 117-122.	0.5	21
899	Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 695-712.	1.4	129
900	Impaired postprandial lipemic response in chronic kidney disease. Kidney International, 2016, 90, 172-180.	2.6	14
901	Influence of Renal Insufficiency on the Prescription of Evidence-Based Medicines in Patients With Coronary Artery Disease and Its Prognostic Significance. Medicine (United States), 2016, 95, e2740.	0.4	3
902	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis, 2016, 253, 281-344.	0.4	1,189

#	ARTICLE	IF	CITATIONS
903	Calcificaciones cardiovasculares en la enfermedad renal cr�nica: Potenciales implicaciones terap�uticas. Nefrologia, 2016, 36, 597-608.	0.2	18
904	�timibe : plus de preuves pour un effet sur la r�duction du risque cardiovasculaire. Medecine Des Maladies Metaboliques, 2016, 10, 430-433.	0.1	0
905	Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes. Heart Lung and Circulation, 2016, 25, 1051-1054.	0.2	0
906	The predictive value of different equations for estimation of glomerular filtration rate in patients with coronary artery disease � Results from the AtheroGene study. International Journal of Cardiology, 2016, 221, 908-913.	0.8	6
907	Consenso Delphi sobre el diagn�stico y manejo de la dislipidemia en pacientes con enfermedad renal cr�nica: an�lisis post-hoc del estudio DIANA. Nefrologia, 2016, 36, 679-686.	0.2	2
908	Ezetimibe and cholesterol: how low should you go?. British Journal of Cardiac Nursing, 2016, 11, 288-289.	0.0	0
909	Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1794-1801.	2.2	22
910	Data Monitoring Committees � Expect the Unexpected. New England Journal of Medicine, 2016, 375, 1365-1371.	13.9	46
911	The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2017, 32, gfw312.	0.4	40
912	Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III � rationale, trial design and baseline data. Nephrology Dialysis Transplantation, 2017, 32, gfw321.	0.4	24
913	Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease. Journal of Clinical and Translational Endocrinology, 2016, 6, 8-14.	1.0	34
914	Prescription Rates of Cardiovascular Medications in a Large UK Primary Care Chronic Kidney Disease Cohort. Nephron, 2016, 133, 15-22.	0.9	6
915	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes and Endocrinology,the, 2016, 4, 829-839.	5.5	234
916	Knowing what we do not know: statin therapy in advanced chronic kidney disease. Lancet Diabetes and Endocrinology,the, 2016, 4, 801-803.	5.5	3
917	Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?. Nephron, 2016, 133, 147-158.	0.9	8,212
918	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 2016, 37, 2999-3058.	1.0	2,393
919	Sources of Mortality on Dialysis with an Emphasis on Microemboli. Seminars in Dialysis, 2016, 29, 442-446.	0.7	10
920	Pharmacological treatment of primary membranous nephropathy in 2016. Expert Review of Clinical Pharmacology, 2016, 9, 1463-1478.	1.3	23

#	ARTICLE	IF	CITATIONS
921	The efficacy of ezetimibe does not seem a credible real effect. International Journal of Cardiology, 2016, 222, 795-796.	0.8	2
923	Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis. Clinical Science, 2016, 130, 1147-1163.	1.8	167
924	<scp>PCSK</scp>9 in diabetic kidney disease. European Journal of Clinical Investigation, 2016, 46, 779-786.	1.7	21
925	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2016, 32, 1263-1282.	0.8	775
926	Treatment of Hyperlipidemia Changes With Level of Kidney Functionâ€™Rationale. Advances in Chronic Kidney Disease, 2016, 23, 247-254.	0.6	8
927	LDL-Cholesterol: Standards of Treatment 2016: A German Perspective. American Journal of Cardiovascular Drugs, 2016, 16, 323-336.	1.0	18
928	Gene Polymorphisms Affect the Effectiveness of Atorvastatin in Treating Ischemic Stroke Patients. Cellular Physiology and Biochemistry, 2016, 39, 630-638.	1.1	23
929	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East. International Journal of Cardiology, 2016, 225, 268-283.	0.8	17
930	Very low LDLâ€™C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. International Journal of Clinical Practice, 2016, 70, 886-897.	0.8	20
931	Clinical Update on Nursing Home Medicine: 2016. Journal of the American Medical Directors Association, 2016, 17, 978-993.	1.2	9
932	Pathophysiology of Diabetic Nephropathy. , 2016, , 41-65.		2
934	Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study. Nephrology Dialysis Transplantation, 2016, 33, gfw360.	0.4	14
937	Hormone therapy and clinical and surrogate cardiovascular endpoints in women with chronic kidney disease: a systematic review and meta-analysis. Menopause, 2016, 23, 1028-1037.	0.8	9
938	The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy. Current Opinion in Nephrology and Hypertension, 2016, 25, 314-324.	1.0	47
939	Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications. Wiener Klinische Wochenschrift, 2016, 128, 216-228.	1.0	8
940	Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2994-3001.	1.8	17
941	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 68, 371-380.	2.1	57
942	Statins for hemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D Study. Kidney International, 2016, 89, 1189-1191.	2.6	6

#	ARTICLE	IF	CITATIONS
943	Cardiac Events After Kidney Transplantation According to Pretransplantation Coronary Artery Disease and Coronary Revascularization Status. <i>Transplantation Proceedings</i> , 2016, 48, 65-73.	0.3	15
944	Dyslipidemia in diabetic nephropathy. <i>Renal Replacement Therapy</i> , 2016, 2, .	0.3	53
945	Core Concepts in Dialysis and Continuous Therapies. , 2016, , .		3
946	Effect of colestilan on serum phosphorus in dialysis patients: A meta-analysis of the literature. <i>Nephrology</i> , 2016, 21, 229-235.	0.7	0
947	Balancing the Evidence: How to Reconcile the Results of Observational Studies vs. Randomized Clinical Trials in Dialysis. <i>Seminars in Dialysis</i> , 2016, 29, 342-346.	0.7	2
948	The Current State of Peritoneal Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3238-3252.	3.0	366
949	Cholesterol trials and mortality. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 168-177.	1.1	17
950	Might ezetimibe be considered an expensive placebo?. <i>International Journal of Cardiology</i> , 2016, 207, 48-49.	0.8	1
951	The Role of Ezetimibe in the Treatment of Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2016, 18, 8.	2.0	3
952	The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis. <i>Pharmacological Research</i> , 2016, 105, 74-83.	3.1	48
953	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). <i>Canadian Journal of Cardiology</i> , 2016, 32, S35-S65.	0.8	194
954	Cardiovascular Pharmacogenomics Implications for Patients With CKD. <i>Advances in Chronic Kidney Disease</i> , 2016, 23, 82-90.	0.6	12
955	Recent advances in the pharmacological management of hypercholesterolaemia. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 436-446.	5.5	28
956	Effect of Different Statin Intensity in Chronic Kidney Disease Patients. <i>American Journal of Medicine</i> , 2016, 129, e53.	0.6	1
957	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. <i>American Journal of Kidney Diseases</i> , 2016, 67, 31-39.	2.1	42
958	Dyslipidemia Part 2. <i>Vascular and Endovascular Surgery</i> , 2016, 50, 119-135.	0.3	4
959	Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 59-71.	2.3	10
961	The Success Story of LDL Cholesterol Lowering. <i>Circulation Research</i> , 2016, 118, 721-731.	2.0	48

#	ARTICLE	IF	CITATIONS
962	Special considerations for the treatment of chronic kidney disease in the elderly. Expert Review of Clinical Pharmacology, 2016, 9, 727-737.	1.3	5
963	Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis. Kidney International, 2016, 89, 1380-1387.	2.6	27
964	From Lipids to Inflammation. Circulation Research, 2016, 118, 732-749.	2.0	180
965	A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. Journal of Clinical Lipidology, 2016, 10, 240-264.	0.6	3
966	Reply to: Ezetimibe: A real effect?. International Journal of Cardiology, 2016, 209, 337-338.	0.8	1
967	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 67, 576-584.	2.1	19
969	Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease. Circulation, 2016, 133, 518-536.	1.6	149
970	An Informed and Activated Patient: Addressing Barriers in the Pathway From Education to Outcomes. American Journal of Kidney Diseases, 2016, 67, 1-4.	2.1	49
972	Modulation of stroke risk in chronic kidney disease. CKJ: Clinical Kidney Journal, 2016, 9, 29-38.	1.4	23
973	Dyslipidemia in Obesity. , 2016, , 525-540.		4
974	Efficacy of ezetimibe: A real effect?. International Journal of Cardiology, 2016, 209, 335-336.	0.8	1
975	The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. Expert Opinion on Drug Safety, 2016, 15, 559-569.	1.0	14
976	Considerations in Applying the Results of Randomized Controlled Clinical Trials to the Care of Older Adults With Kidney Disease in the Clinical Setting: The SHARP Trial. Advances in Chronic Kidney Disease, 2016, 23, 29-35.	0.6	2
977	The β -Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2016, 67, 902-911.	2.1	36
978	Should all surgery patients get statins pre-operatively? Clear or blurry VISION?. European Heart Journal, 2016, 37, 186-188.	1.0	2
979	Tratamiento estatino-céntrico de la dislipemia. ¿Nuevo paradigma basado en la evidencia o solo parte de la evidencia?. Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion, 2016, 63, 1-3.	0.8	1
980	Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. Expert Opinion on Pharmacotherapy, 2016, 17, 369-380.	0.9	43
981	Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 539-546.	2.2	20

#	ARTICLE	IF	CITATIONS
982	Prevalence, Predictors, and Outcomes of Pulmonary Hypertension in CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 877-886.	3.0	71
983	Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician. American Journal of Medicine, 2016, 129, 153-162.e7.	0.6	161
984	Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 944-952.	0.4	23
985	Evidence, Guidelines, and Gut Checks: Musings on Entering the Post-Statins Era of Lipid Management. Canadian Journal of Cardiology, 2016, 32, 271-274.	0.8	1
986	Neurological complications in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2016, 31, 1606-1614.	0.4	54
987	Impact of non-invasive cardiovascular screening programs as a predictor of cardiovascular events among asymptomatic chronic kidney disease patients. Clinical and Experimental Nephrology, 2016, 20, 416-424.	0.7	4
988	Defining end-stage renal disease in clinical trials: a framework for adjudication: Table 1. Nephrology Dialysis Transplantation, 2016, 31, 864-867.	0.4	60
989	Guideline Confusion for the Clinician. Angiology, 2016, 67, 5-9.	0.8	4
990	Remnant lipoproteinemia predicts cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Journal of Cardiology, 2017, 69, 529-535.	0.8	24
991	Individualized lipid-lowering therapy to further reduce residual cardiovascular risk. Journal of Steroid Biochemistry and Molecular Biology, 2017, 169, 198-201.	1.2	8
993	Management of coronary artery disease and acute coronary syndrome in the chronic kidney disease population: A review of the current literature. Hemodialysis International, 2017, 21, 472-482.	0.4	11
994	A Randomized Open-Label Trial to Assess the Effect of Plant Sterols Associated with Ezetimibe in Low-Density Lipoprotein Levels in Patients with Coronary Artery Disease on Statin Therapy. Journal of Medicinal Food, 2017, 20, 30-36.	0.8	12
995	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation, 2018, 33, gfw396.	0.4	6
996	Clinical Treatment of Vascular Diseases. , 2017, , 233-251.		0
997	Lipid and other management to improve arterial disease and survival in end stage renal disease. Expert Opinion on Pharmacotherapy, 2017, 18, 343-349.	0.9	3
999	Statistical significance versus clinical relevance. Nephrology Dialysis Transplantation, 2017, 32, gfw385.	0.4	19
1000	Genetics for the Identification of Lipid Targets Beyond PCSK9. Canadian Journal of Cardiology, 2017, 33, 334-342.	0.8	8
1001	PCSK9 in chronic kidney disease. International Urology and Nephrology, 2017, 49, 1015-1024.	0.6	41

#	ARTICLE	IF	CITATIONS
1002	Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations. <i>International Journal of Cardiology</i> , 2017, 232, 12-23.	0.8	64
1003	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Studyâ€“Renal (<sc>CANVASâ€“R</sc>): A randomized, placeboâ€“controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 387-393.	2.2	139
1004	Sudden Cardiac Death Among Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2017, 69, 684-695.	2.1	107
1005	Effectiveness of a combination of ezetimibe and statins in patients with acute coronary syndrome and multiple comorbidities: A 6-year population-based cohort study. <i>International Journal of Cardiology</i> , 2017, 233, 43-51.	0.8	10
1006	Ezetimibe: an update on its clinical usefulness in specific patient groups. <i>Therapeutic Advances in Chronic Disease</i> , 2017, 8, 4-11.	1.1	44
1007	Statin use and all-cause and cancer mortality: BioBank Japan cohort. <i>Journal of Epidemiology</i> , 2017, 27, S84-S91.	1.1	25
1008	Cardiovascular disease in haemodialysis: role of the intravascular innate immune system. <i>Nature Reviews Nephrology</i> , 2017, 13, 285-296.	4.1	75
1009	2017 Taiwan lipid guidelines for high risk patients. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 217-248.	0.8	123
1010	Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 422-431.e2.	0.6	18
1011	Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 591-602.	2.2	42
1013	New approaches to trials in glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i1-i6.	0.4	3
1014	The impact of renal protection clinics on prescription of and adherence to cardioprotective drug therapy in chronic kidney disease patients. <i>CKJ: Clinical Kidney Journal</i> , 2017, 10, 375-380.	1.4	0
1015	Global Cardiovascular and Renal Outcomes of Reduced GFR. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2167-2179.	3.0	194
1016	Evolution of Cardiovascular Disease During the Transition to End-Stage Renal Disease. <i>Seminars in Nephrology</i> , 2017, 37, 120-131.	0.6	30
1017	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. <i>Lancet, The</i> , 2017, 390, 1888-1917.	6.3	662
1018	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	1.0	2,292
1019	Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy. <i>American Journal of Kidney Diseases</i> , 2017, 70, 611-618.	2.1	56
1020	Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations. <i>Current Atherosclerosis Reports</i> , 2017, 19, 29.	2.0	11

#	ARTICLE	IF	CITATIONS
1021	American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. <i>Endocrine Practice</i> , 2017, 23, 1-87.	1.1	766
1022	Maintenance of Hemodialysis Vascular Access and Prevention of Access Dysfunction: A Review. <i>Annals of Vascular Surgery</i> , 2017, 43, 318-327.	0.4	20
1023	Coronary artery calcification predicts risk of CVD in patients with CKD. <i>Nature Reviews Nephrology</i> , 2017, 13, 324-326.	4.1	27
1024	The Role of Emerging Risk Factors in Cardiovascular Outcomes. <i>Current Atherosclerosis Reports</i> , 2017, 19, 28.	2.0	43
1025	How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. <i>Atherosclerosis Supplements</i> , 2017, 26, 16-24.	1.2	24
1026	Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective. <i>Kidney International</i> , 2017, 92, 192-200.	2.6	33
1027	A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels. <i>Postgraduate Medical Journal</i> , 2017, 93, 205-208.	0.9	1
1028	Lipid-Lowering Therapy in CKD: Should We Use It and in Which Patients. <i>Blood Purification</i> , 2017, 43, 196-199.	0.9	8
1029	Quality of Care for Patients With Chronic Kidney Disease in the Primary Care Setting: A Retrospective Cohort Study From Ontario, Canada. <i>Canadian Journal of Kidney Health and Disease</i> , 2017, 4, 205435811770305.	0.6	20
1030	Evidence for more intensive cholesterol lowering. <i>Current Opinion in Lipidology</i> , 2017, 28, 291-299.	1.2	13
1031	Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3034-3043.	3.0	30
1032	Two-year outcome and risk factors for mortality in patients with coronary artery disease and renal failure: The prospective, observational CAD-REF Registry. <i>International Journal of Cardiology</i> , 2017, 243, 65-72.	0.8	20
1033	Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 919-926.	1.0	4
1034	Still a reasonable goal: Targeting cholesterol in dialysis and advanced chronic kidney disease patients. <i>Seminars in Dialysis</i> , 2017, 30, 390-394.	0.7	11
1035	Favourable impact of statin use on diastolic blood pressure levels. <i>Journal of Hypertension</i> , 2017, 35, 2086-2094.	0.3	13
1036	Considerations and controversies in managing chronic kidney disease: An update. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 795-810.	0.5	10
1037	A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial. <i>American Heart Journal</i> , 2017, 191, 37-46.	1.2	10
1038	Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. <i>Nature Reviews Nephrology</i> , 2017, 13, 393-409.	4.1	200

#	ARTICLE	IF	CITATIONS
1039	Meta-analysis of statins in chronic kidney disease: who benefits?. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 493-500.	0.2	39
1040	Medication adherence in randomized controlled trials evaluating cardiovascular or mortality outcomes in dialysis patients: A systematic review. BMC Nephrology, 2017, 18, 42.	0.8	27
1041	From the Editor: Preventing cardiovascular death. Journal of Clinical Lipidology, 2017, 11, 313-314.	0.6	0
1042	Statins and the Kidney: Friend or Foe?. Blood Purification, 2017, 43, 91-96.	0.9	14
1043	Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study. International Journal of Cardiology, 2017, 238, 72-78.	0.8	22
1044	Chronic kidney disease and dyslipidaemia. Clínica E Investigaci3n En Arteriosclerosis (English Edition), 2017, 29, 22-35.	0.1	6
1045	Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrology Dialysis Transplantation, 2017, 32, 1373-1386.	0.4	159
1046	The public health dimension of chronic kidney disease: what we have learnt over the past decade. Nephrology Dialysis Transplantation, 2017, 32, ii113-ii120.	0.4	22
1047	Association of very Low-density Lipoprotein Cholesterol with All-cause and Cardiovascular Mortality in Peritoneal Dialysis. Kidney and Blood Pressure Research, 2017, 42, 52-61.	0.9	14
1048	Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. The Cochrane Library, 2017, , .	1.5	2
1049	A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin. International Journal of Cardiology, 2017, 235, 49-55.	0.8	24
1050	Cholesterol Levels Are Associated with 30-day Mortality from Ischemic Stroke in Dialysis Patients. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 1349-1356.	0.7	6
1051	Dyslipidemia in patients with chronic kidney disease. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 29-40.	2.6	139
1052	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. Hypertension, 2017, 69, 314-322.	1.3	30
1053	Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review. Kidney International, 2017, 91, 797-807.	2.6	102
1054	Does statins promote vascular calcification in chronic kidney disease?. European Journal of Clinical Investigation, 2017, 47, 137-148.	1.7	62
1055	Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Expert Opinion on Emerging Drugs, 2017, 22, 1-26.	1.0	45
1056	Vascular Diseases for the Non-Specialist. , 2017, , .		3

#	ARTICLE	IF	CITATIONS
1057	Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia. American Journal of Cardiovascular Drugs, 2017, 17, 169-181.	1.0	19
1058	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes, 2017, 66, 241-255.	0.3	454
1059	Statin treatment in dialysis patients after acute myocardial infarction improves overall mortality. Atherosclerosis, 2017, 267, 156-157.	0.4	5
1060	Closing the gap between evidence and practice in chronic kidney disease. Kidney International Supplements, 2017, 7, 114-121.	4.6	14
1061	Femoral Neck X-Ray Absorptiometry Parameters and Peripheral Quantitative Computer Tomography Tibial Cortical Density Predict Survival in Dialysis Patients. Nephron, 2017, 136, 183-192.	0.9	2
1062	Cardiac Pre-operative Evaluation as an Opportunity to Optimize Risk Factors in Kidney Transplant Candidates. , 2017, , 229-233.		0
1063	Dyslipidemias in CKD and ESKD: Outcomes and Management. , 2017, , 369-375.		0
1064	RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in Japan. Therapeutic Apheresis and Dialysis, 2017, 21, 326-333.	0.4	2
1065	Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?. Diabetes Care, 2017, 40, 1144-1151.	4.3	50
1066	New perspectives on CKD-induced dyslipidemia. Expert Opinion on Therapeutic Targets, 2017, 21, 967-976.	1.5	31
1067	Is High-Volume Online Hemodiafiltration Associated With Malnutrition?. Therapeutic Apheresis and Dialysis, 2017, 21, 361-369.	0.4	12
1068	Strategies for the use of nonstatin therapies. Current Opinion in Lipidology, 2017, 28, 458-464.	1.2	2
1070	Prevention of renal apoB retention is protective against diabetic nephropathy: role of TGF- β 2 inhibition. Journal of Lipid Research, 2017, 58, 2264-2274.	2.0	13
1071	Statin and ezetimibe combination therapy: New therapeutic options for lowering Low-Density Lipoprotein Cholesterol. International Journal of Cardiology, 2017, 247, 49.	0.8	0
1072	Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. Kidney International Supplements, 2017, 7, 122-129.	4.6	106
1073	Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1099-1104.	1.5	16
1074	2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. Journal of the American College of Cardiology, 2017, 70, 1785-1822.	1.2	313
1075	Improving Care for Patients With or at Risk for Chronic Kidney Disease Using Electronic Medical Record Interventions: A Pragmatic Cluster-Randomized Trial Protocol. Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811769983.	0.6	9

#	ARTICLE	IF	CITATIONS
1076	Low-density lipoprotein cholesterol variability increases the risk of cardiovascular events. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, e91-e93.	0.6	1
1078	The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Medicine (United States)</i> , 2017, 96, e7351.	0.4	7
1079	The role of trimethylamine N-oxide as a mediator of cardiovascular complications in chronic kidney disease. <i>Kidney International</i> , 2017, 92, 809-815.	2.6	81
1080	Chronic kidney disease. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17088.	18.1	558
1081	Apparent Treatment-Resistant Hypertension and Chronic Kidney Disease: Another Cardiovascular "Renal Syndrome?". , 2017, , 25-38.		1
1082	Adjuvant Therapy for Incremental Low-Density Lipoprotein Cholesterol Reduction With Ezetimibe. <i>Clinical Medicine Insights Therapeutics</i> , 2017, 9, 1179559X1769555.	0.4	0
1083	Study of Cardiovascular Outcomes in Renal Transplantation: A Prospective, Multicenter Study to Determine the Incidence of Cardiovascular Events in Renal Transplant Recipients in Ontario, Canada. <i>Canadian Journal of Kidney Health and Disease</i> , 2017, 4, 205435811771372.	0.6	16
1084	Electronegative low-density lipoprotein increases the risk of ischemic lower-extremity peripheral artery disease in uremia patients on maintenance hemodialysis. <i>Scientific Reports</i> , 2017, 7, 4654.	1.6	10
1086	Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection. <i>BMC Nephrology</i> , 2017, 18, 147.	0.8	12
1087	Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis. <i>BMC Nephrology</i> , 2017, 18, 187.	0.8	73
1088	Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects. <i>Lipids in Health and Disease</i> , 2017, 16, 122.	1.2	16
1089	Effect of statin use on clinical outcomes in ischemic stroke patients with atrial fibrillation. <i>Medicine (United States)</i> , 2017, 96, e5918.	0.4	15
1090	Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer. <i>International Journal of Epidemiology</i> , 2017, 46, 1777-1785.	0.9	10
1091	Arterial and Cellular Inflammation in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1278-1285.	3.0	46
1092	Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 546-552.	2.2	41
1093	Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis. <i>Free Radical Research</i> , 2017, 51, 14-23.	1.5	9
1094	mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 367-385.	1.5	9
1095	Determinant Effects of Average Fasting Plasma Glucose on Mortality in Diabetic End-Stage Renal Disease Patients on Maintenance Hemodialysis. <i>Kidney International Reports</i> , 2017, 2, 18-26.	0.4	0

#	ARTICLE	IF	CITATIONS
1096	Management of Overt Diabetic Kidney Disease and Uremia. , 2017, , 77-115.		0
1097	Does an Aspirin a Day Keep the Doctor Away?. American Journal of Kidney Diseases, 2017, 69, 337-340.	2.1	2
1098	Opinions of nephrologists on the efficacy and tolerance of statins in hemodialysis patients. Renal Failure, 2017, 39, 277-282.	0.8	6
1099	The importance of accurate measurement of aortic stiffness in patients with chronic kidney disease and end-stage renal disease. CKJ: Clinical Kidney Journal, 2017, 10, 503-515.	1.4	17
1100	Diabetic Microvascular Disease: An Endocrine Society Scientific Statement. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4343-4410.	1.8	323
1101	Simultaneous inference of phenotype-associated genes and relevant tissues from GWAS data via Bayesian integration of multiple tissue-specific gene networks. Journal of Molecular Cell Biology, 2017, 9, 436-452.	1.5	10
1102	ANMCO Scientific Statement: clinical management of hypercholesterolaemia in patients with acute coronary syndromes. European Heart Journal Supplements, 2017, 19, D64-D69.	0.0	2
1103	A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. Heart, 2017, 103, 1880-1890.	1.2	21
1104	Serum Non-High-Density Lipoprotein Cholesterol and Risk of Cardiovascular Disease in Community Dwellers with Chronic Kidney Disease: the Hisayama Study. Journal of Atherosclerosis and Thrombosis, 2017, 24, 706-715.	0.9	18
1105	Lipid lowering in renal disease. Australian Prescriber, 2017, 40, 141-146.	0.5	6
1107	Una historia resumida. Impacto de los avances en el control lipídico. Revista Espanola De Cardiología Suplementos, 2017, 17, 7-9.	0.2	0
1108	ISCHEMIC HEART DISEASE AND RENAL DYSFUNCTION. Rational Pharmacotherapy in Cardiology, 2017, 13, 409-415.	0.3	1
1109	Effects of Statins on Cardiovascular Outcomes in Patients With Chronic Kidney Disease. Clinical Medicine Insights Therapeutics, 2017, 9, 1179559X1771902.	0.4	2
1110	Risk of Stroke in Elderly Dialysis Patients. Journal of Korean Medical Science, 2017, 32, 1460.	1.1	3
1111	PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Archives of Medical Science, 2017, 1, 1-45.	0.4	70
1112	What Happens to the Heart in Chronic Kidney Disease?. Journal of the Royal College of Physicians of Edinburgh, The, 2017, 47, 76-82.	0.2	18
1113	Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). Diabetology and Metabolic Syndrome, 2017, 9, 53.	1.2	34
1114	Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction. Diabetology and Metabolic Syndrome, 2017, 9, 71.	1.2	7

#	ARTICLE	IF	CITATIONS
1115	Cardiovascular risk and dyslipidemia among persons living with HIV: a review. <i>BMC Infectious Diseases</i> , 2017, 17, 551.	1.3	112
1116	Cardiovascular Disease in Patients with End-Stage Renal Disease on Hemodialysis. <i>Annals of Vascular Diseases</i> , 2017, 10, 327-337.	0.2	29
1117	The Effect of High-Dose Simvastatin Therapy on Patients with Acute Cerebral Infarction. <i>Journal of Clinical & Experimental Cardiology</i> , 2017, 08, .	0.0	0
1119	Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome. <i>Oncotarget</i> , 2017, 8, 41582-41589.	0.8	16
1120	Advances in Hypercholesterolemia. , 2017, , 663-693.		1
1121	Cardiovascular Pathophysiology in Chronic Kidney Disease: Opportunities to Transition from Disease to Health. <i>Annals of Global Health</i> , 2018, 80, 69.	0.8	26
1122	Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?. <i>American Journal of Kidney Diseases</i> , 2018, 72, 728-744.	2.1	58
1123	Contribution of non-traditional lipid profiles to reduced glomerular filtration rate in H-type hypertension population of rural China. <i>Annals of Medicine</i> , 2018, 50, 249-259.	1.5	6
1124	Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease. <i>Heart</i> , 2018, 104, 1455-1460.	1.2	23
1125	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. <i>Kidney International</i> , 2018, 93, 1397-1408.	2.6	83
1126	Can We Eliminate Low-Density Lipoprotein Cholesterol-Related Cardiovascular Events Through More Aggressive Primary Prevention Therapy?. <i>Canadian Journal of Cardiology</i> , 2018, 34, 546-551.	0.8	3
1127	Polymorphisms in CYP450 Genes and the Therapeutic Effect of Atorvastatin on Ischemic Stroke: A Retrospective Cohort Study in Chinese Population. <i>Clinical Therapeutics</i> , 2018, 40, 469-477.e2.	1.1	13
1128	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1566.	3.8	339
1129	Is the management of diabetes different in dialysis patients?. <i>Seminars in Dialysis</i> , 2018, 31, 367-376.	0.7	6
1130	Impact of Chronic Kidney Disease on Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusions (from the Japanese Multicenter Registry). <i>American Journal of Cardiology</i> , 2018, 121, 1519-1523.	0.7	8
1131	A Province-wide, Cross-sectional Study of Demographics and Medication Use of Patients in Hemodialysis Units Across Ontario. <i>Canadian Journal of Kidney Health and Disease</i> , 2018, 5, 205435811876083.	0.6	21
1132	Hemodialysis-induced cardiovascular disease. <i>Seminars in Dialysis</i> , 2018, 31, 258-267.	0.7	97
1133	Dyslipidemia. <i>Canadian Journal of Diabetes</i> , 2018, 42, S178-S185.	0.4	50

#	ARTICLE	IF	CITATIONS
1134	Simultaneous Risk Factor Control Using Telehealth to sLOw Progression of Diabetic Kidney Disease (STOP-DKD) study: Protocol and baseline characteristics of a randomized controlled trial. Contemporary Clinical Trials, 2018, 69, 28-39.	0.8	18
1135	Dyslipidemia and risk of renal replacement therapy or death in incident pre-dialysis patients. Scientific Reports, 2018, 8, 3130.	1.6	6
1136	The role of lipoprotein (a) in chronic kidney disease. Journal of Lipid Research, 2018, 59, 577-585.	2.0	77
1137	Lipid-lowering treatment in peripheral artery disease. Current Opinion in Pharmacology, 2018, 39, 19-26.	1.7	19
1138	Eicosapentaenoic Acid as a Potential Therapeutic Approach to Reduce Cardiovascular Risk in Patients with End-Stage Renal Disease on Hemodialysis: A Review. CardioRenal Medicine, 2018, 8, 18-30.	0.7	7
1139	Evolving Role of Non-Statins for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. Pharmacotherapy, 2018, 38, 164-171.	1.2	7
1140	Impact of CKD on Household Income. Kidney International Reports, 2018, 3, 610-618.	0.4	25
1141	Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients. Endocrinology and Metabolism Clinics of North America, 2018, 47, 237-257.	1.2	28
1142	Associations of lipoproteins with cardiovascular and infection-related outcomes in patients receiving hemodialysis. Journal of Clinical Lipidology, 2018, 12, 481-487.e14.	0.6	8
1143	Beyond the traditional lipid parameters in chronic kidney disease. Nefrologia, 2018, 38, 109-113.	0.2	4
1144	Roxadustat in the treatment of anaemia in chronic kidney disease. Expert Opinion on Investigational Drugs, 2018, 27, 125-133.	1.9	35
1145	A Novel Type 2 Diabetes Mouse Model of Combined Diabetic Kidney Disease and Atherosclerosis. American Journal of Pathology, 2018, 188, 343-352.	1.9	14
1146	Dyslipidaemia in the elderly: to treat or not to treat?. Expert Review of Clinical Pharmacology, 2018, 11, 259-278.	1.3	7
1147	Strategies to manage cardiovascular risk in chronic kidney disease. Nephrology Dialysis Transplantation, 2018, 33, 23-25.	0.4	13
1148	Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Drugs, 2018, 78, 215-229.	4.9	33
1149	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	1.0	262
1150	Do statins induce or protect from acute kidney injury and chronic kidney disease: An update review in 2018. Journal of Translational Internal Medicine, 2018, 6, 21-25.	1.0	34
1151	Disorders of Lipid Metabolism in Chronic Kidney Disease. Blood Purification, 2018, 46, 144-152.	0.9	95

#	ARTICLE	IF	CITATIONS
1152	Variations in time to benefit among clinical trials of cholesterol-lowering drugs. <i>Journal of Clinical Lipidology</i> , 2018, 12, 857-862.	0.6	21
1153	<scp>ESRD</scp>â€”induced dyslipidemiaâ€”Should management of lipid disorders differ in dialysis patients?. <i>Seminars in Dialysis</i> , 2018, 31, 398-405.	0.7	19
1154	De Novo Heart Failure After Kidney Transplantation: Trends in Incidence and Outcomes. <i>American Journal of Kidney Diseases</i> , 2018, 72, 223-233.	2.1	6
1155	Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes. <i>Annals of Medicine</i> , 2018, 50, 303-311.	1.5	15
1156	An update on trials of novel lipid-lowering drugs. <i>Current Opinion in Cardiology</i> , 2018, 33, 416-422.	0.8	5
1157	Multiple potency of ezetimibe in a patient with macroproteinuric chronic kidney disease and statin-intolerant dyslipidemia. <i>Journal of Cardiology Cases</i> , 2018, 17, 204-207.	0.2	2
1158	Lipids, inflammation, and chronic kidney disease: a SHARP perspective. <i>Kidney International</i> , 2018, 93, 784-786.	2.6	4
1159	A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 844-853.	0.8	43
1160	Increasing inclusion of patients with advanced chronic kidney disease in cardiovascular clinical trials. <i>Kidney International</i> , 2018, 93, 787-788.	2.6	4
1161	Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patientâ€™important outcomes. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 222-231.	0.9	7
1162	Impact of low-density lipoprotein cholesterol on decline in estimated glomerular filtration rate in apparently healthy young to middle-aged working men. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 15-27.	0.7	25
1163	Regional evidence and international recommendations to guide lipid management in Asian patients with type 2 diabetes with special reference to renal dysfunction. <i>Journal of Diabetes</i> , 2018, 10, 200-212.	0.8	3
1164	Impaired Î²-Oxidation and Altered Complex Lipid Fatty Acid Partitioning with Advancing CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 295-306.	3.0	122
1165	Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. <i>Nature Reviews Nephrology</i> , 2018, 14, 57-70.	4.1	192
1166	Longitudinal Weight Change During CKD Progression and Its Association With Subsequent Mortality. <i>American Journal of Kidney Diseases</i> , 2018, 71, 657-665.	2.1	59
1167	Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 9-15.	1.5	13
1168	MÃ¡s allÃ¡ de los parÃ¡metros lipÃ¡dicos tradicionales en la enfermedad renal crÃ³nica. <i>NefrologÃ­a</i> , 2018, 38, 109-113.	0.2	5
1169	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , 2018, 93, 1000-1007.	2.6	32

#	ARTICLE	IF	CITATIONS
1170	Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 51-69.	0.7	8
1171	Serum apolipoprotein B is inversely associated with eccentric left ventricular hypertrophy in peritoneal dialysis patients. International Urology and Nephrology, 2018, 50, 155-165.	0.6	5
1172	The ABCs of chronic kidney disease. JAAPA: Official Journal of the American Academy of Physician Assistants, 2018, 31, 17-25.	0.1	4
1173	Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease – a randomized double blind crossover study. Renal Failure, 2018, 40, 700-709.	0.8	16
1174	Clinically feasible stratification of 1-year to 3-year post-myocardial infarction risk. Open Heart, 2018, 5, e000723.	0.9	3
1175	Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. The Cochrane Library, 2018, 2018, CD012502.	1.5	53
1176	Agrarian Crossings: Reformers and the Remaking of the U.S. and Mexican Countryside.. Journal of American History, 2018, 105, 441-442.	0.0	0
1177	OBSOLETE: Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease. , 2018, , .		0
1178	Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation. Clinical Transplantation, 2019, 33, e13452.	0.8	1
1179	Risk Stratification and Treatment of Coronary Disease in Chronic Kidney Disease and End-Stage Kidney Disease. Seminars in Nephrology, 2018, 38, 582-599.	0.6	15
1180	Le patient dialysé, ce que le pharmacien d'officine doit savoir. Actualites Pharmaceutiques, 2018, 57, 38-42.	0.0	0
1181	Documento de consenso de la Sociedad Española de Arteriosclerosis (SEA) para la prevención y tratamiento de la enfermedad cardiovascular en la diabetes mellitus tipo 2. Clínica E Investigación En Arteriosclerosis, 2018, 30, 1-19.	0.4	5
1182	Mechanisms and Modulation of Oxidative/Nitrative Stress in Type 4 Cardio-Renal Syndrome and Renal Sarcopenia. Frontiers in Physiology, 2018, 9, 1648.	1.3	42
1183	Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients. Journal of the American Heart Association, 2018, 7, e009876.	1.6	24
1184	Statins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation. International Journal of Environmental Research and Public Health, 2018, 15, 2733.	1.2	14
1185	Effects of Statin Use in Advanced Chronic Kidney Disease Patients. Journal of Clinical Medicine, 2018, 7, 285.	1.0	10
1186	Medication-based versus target-based lipid management. Journal of Diabetes, 2018, 10, 789-792.	0.8	1
1187	Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation, 2018, 138, 2908-2918.	1.6	88

#	ARTICLE	IF	CITATIONS
1188	The Role of Deprescribing in Older Adults with Chronic Kidney Disease. <i>Drugs and Aging</i> , 2018, 35, 973-984.	1.3	42
1189	Radial Pulse Spectrum Analysis as Risk Markers to Improve the Risk Stratification of Silent Myocardial Ischemia in Type 2 Diabetic Patients. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , 2018, 6, 1-9.	2.2	6
1190	Working Toward an Improved Understanding of Chronic Cardiorenal Syndrome Type 4. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 454-467.	0.6	5
1191	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. <i>Cmaj</i> , 2018, 190, E1192-E1206.	0.9	39
1192	Association of Continuation of Statin Therapy Initiated Before Transition to Chronic Dialysis Therapy With Mortality After Dialysis Initiation. <i>JAMA Network Open</i> , 2018, 1, e182311.	2.8	31
1193	Cardiovascular Risk Factors: The Old Ones and a Closer Look to the Mineral Metabolism. , 2018, , .		1
1194	New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 14-18.	2.2	19
1195	Statins at Dialysis Transition—Supportive but Not Sufficient. <i>JAMA Network Open</i> , 2018, 1, e182411.	2.8	2
1196	Effect of Statins on Renal Function in Chronic Kidney Disease Patients. <i>Scientific Reports</i> , 2018, 8, 16276.	1.6	19
1197	Managing Clinical Heterogeneity: An Argument for Benefit-Based Action Limits. <i>Journal of Engineering and Science in Medical Diagnostics and Therapy</i> , 2018, 1, .	0.3	4
1198	Lipid management in patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2018, 14, 727-749.	4.1	153
1199	Simvastatin Treatment Protects Myocardium in Noncoronary Artery Cardiac Surgery by Inhibiting Apoptosis Through miR-15a-5p Targeting. <i>Journal of Cardiovascular Pharmacology</i> , 2018, 72, 176-185.	0.8	14
1200	Circulating metabolic biomarkers of renal function in diabetic and non-diabetic populations. <i>Scientific Reports</i> , 2018, 8, 15249.	1.6	42
1201	Safety and efficacy of statin therapy. <i>Nature Reviews Cardiology</i> , 2018, 15, 757-769.	6.1	239
1202	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 846-984.	0.9	541
1203	Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk. <i>Atherosclerosis</i> , 2018, 278, 135-142.	0.4	20
1204	Further options for treating lipids in people with diabetes: targeting <sc>LDL</sc> cholesterol and beyond. <i>Diabetic Medicine</i> , 2018, 35, 1173-1180.	1.2	3
1205	Design of carboxymethyl chitosan-based heparin-mimicking cross-linked beads for safe and efficient blood purification. <i>International Journal of Biological Macromolecules</i> , 2018, 117, 392-400.	3.6	18

#	ARTICLE	IF	CITATIONS
1206	PCSK9 inhibition: ready for prime time in CKD?. <i>Kidney International</i> , 2018, 93, 1267-1269.	2.6	11
1208	Diabetes mellitus y riesgo cardiovascular. Actualización de las recomendaciones del Grupo de Trabajo de Diabetes y Riesgo Cardiovascular de la Sociedad Española de Diabetes (SED, 2018). <i>Clínica e Investigación En Arteriosclerosis</i> , 2018, 30, 137-153.	0.4	11
1209	Obesity Paradox in Advanced Kidney Disease: From Bedside to the Bench. <i>Progress in Cardiovascular Diseases</i> , 2018, 61, 168-181.	1.6	73
1210	Management of ADPKD Today. , 2018, , 243-262.		0
1211	On-treatment lipid profiles to predict the cardiovascular outcomes in ASCVD patients comorbid with chronic kidney disease – The multi-center T-SPARCLE registry study. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 814-824.	0.8	9
1212	Beneficial effect of statins in patients receiving chronic hemodialysis following percutaneous coronary intervention: A nationwide retrospective cohort study. <i>Scientific Reports</i> , 2018, 8, 9692.	1.6	11
1213	What every doctor needs to know about chronic kidney disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2018, 79, 438-443.	0.2	1
1214	Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease. <i>Seminars in Nephrology</i> , 2018, 38, 369-382.	0.6	4
1215	Detection of Atherosclerotic Cardiovascular Disease in Patients with Advanced Chronic Kidney Disease in the Cardiology and Nephrology Communities. <i>CardioRenal Medicine</i> , 2018, 8, 285-295.	0.7	5
1216	Adaptation of 2016 European Society of Cardiology/European Atherosclerosis Society guideline for lipid management to Indian patients – A consensus document. <i>Indian Heart Journal</i> , 2018, 70, 736-744.	0.2	4
1217	Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis. <i>Endocrinology and Metabolism</i> , 2018, 33, 219.	1.3	18
1218	Introduction: Precision Medicine in End-Stage Kidney Disease and Personalized Renal Replacement Therapy: Challenges and Unmet Need. <i>Seminars in Nephrology</i> , 2018, 38, 315-316.	0.6	1
1219	Comparison of the 2017 Taiwan lipid guidelines and the Western lipid guidelines for high risk patients. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 853-859.	0.6	7
1220	Effects of Cholesterol Levels on Mortality in Patients with Long-Term Peritoneal Dialysis Based on Residual Renal Function. <i>Nutrients</i> , 2018, 10, 300.	1.7	13
1221	Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). <i>Toxins</i> , 2018, 10, 237.	1.5	28
1222	Chronic kidney disease stage affects small, dense low-density lipoprotein but not glycated low-density lipoprotein in younger chronic kidney disease patients: a cross-sectional study. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 383-388.	1.4	13
1224	Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study. <i>Lipids in Health and Disease</i> , 2018, 17, 8.	1.2	8
1225	Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis. <i>Seminars in Dialysis</i> , 2018, 31, 487-499.	0.7	40

#	ARTICLE	IF	CITATIONS
1226	Cardiovascular Disease and Diabetic Kidney Disease. <i>Seminars in Nephrology</i> , 2018, 38, 217-232.	0.6	52
1227	Uremia increases QRS duration after β_2 -adrenergic stimulation in mice. <i>Physiological Reports</i> , 2018, 6, e13720.	0.7	6
1228	Differential association of ezetimibe-simvastatin combination with major adverse cardiovascular events in patients with or without diabetes: a retrospective propensity score-matched cohort study. <i>Scientific Reports</i> , 2018, 8, 11925.	1.6	8
1229	Global Risk Assessment. , 2018, , 234-249.		0
1230	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches—Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. <i>American Heart Journal</i> , 2018, 205, 42-52.	1.2	44
1231	Progress and perspectives in plant sterol and plant stanol research. <i>Nutrition Reviews</i> , 2018, 76, 725-746.	2.6	54
1232	Use of guideline-recommended management in established coronary heart disease in the observational DYSIS II study. <i>International Journal of Cardiology</i> , 2018, 270, 21-27.	0.8	16
1233	Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 339-344.	1.0	3
1234	Lowering <sc>LDL</sc>â€Cholesterol and <sc>CV</sc> Benefits: Is There a Limit to How Low <sc>LDL</sc>â€C Needs to be for Optimal Health Benefits?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 290-296.	2.3	6
1235	Diabetes mellitus and cardiovascular risk: Update of the recommendations of the Diabetes and Cardiovascular Disease working group of the Spanish Diabetes Society (SED, 2018). <i>ClÃnica E InvestigaciÃn En Arteriosclerosis (English Edition)</i> , 2018, 30, 137-153.	0.1	2
1236	Inverse Association Between Serum Nonâ€Highâ€Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	20
1237	Cardiovascular Outcomes Reported in Hemodialysis Trials. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2802-2810.	1.2	16
1238	Lipid levels are inversely associated with infectious and all-cause mortality: international MONDO study results. <i>Journal of Lipid Research</i> , 2018, 59, 1519-1528.	2.0	53
1239	Metabolic risk profile in kidney transplant candidates and recipients. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 388-400.	0.4	23
1240	Statins: Old drugs as new therapy for liver diseases?. <i>Journal of Hepatology</i> , 2019, 70, 194-202.	1.8	108
1242	Dyslipidemia. , 2019, , 150-155.		0
1244	Clinical management of chronic kidney disease. , 2019, , 162-168.		0
1245	Primary care of the kidney transplant recipient. , 2019, , 424-428.		0

#	ARTICLE	IF	CITATIONS
1246	Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 568-581.	2.3	6
1247	Optimal search strategies for identifying moderators and predictors of treatment effects in PubMed. <i>Health Information and Libraries Journal</i> , 2019, 36, 318-340.	1.3	3
1248	Low statin use in nondialysis-dependent chronic kidney disease in the absence of clinical atherosclerotic cardiovascular disease or diabetes. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 530-537.	1.4	4
1249	Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD. <i>Kidney International Reports</i> , 2019, 4, 1546-1554.	0.4	15
1250	Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. <i>Postgraduate Medicine</i> , 2019, 131, 390-396.	0.9	5
1251	Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2019, 8, e012428.	1.6	10
1252	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. <i>Lancet, The</i> , 2019, 394, 697-708.	6.3	67
1253	Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2007-2017.	0.9	21
1254	Sudden Cardiac Death in End-Stage Renal Disease. <i>Cardiology Clinics</i> , 2019, 37, 319-326.	0.9	4
1255	Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. <i>Current Cardiology Reports</i> , 2019, 21, 110.	1.3	24
1256	Atherosclerosis in Chronic Kidney Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1938-1966.	1.1	164
1257	High Cardiovascular Risk Profile in Young Patients on the Kidney Transplant Waiting List. <i>Transplantation Proceedings</i> , 2019, 51, 1717-1726.	0.3	1
1258	Diabetes and Atherogenic Dyslipidemia. , 2019, , 587-596.		3
1259	Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. <i>Atherosclerosis</i> , 2019, 288, 85-93.	0.4	16
1260	Impact of Lipid-Lowering Therapy on Mortality According to the Baseline Non-HDL Cholesterol Level: A Meta-Analysis. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 263-272.	1.0	7
1261	Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition. <i>Current Diabetes Reports</i> , 2019, 19, 61.	1.7	44
1262	Lipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a review. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 431-441.	0.3	3
1263	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2019, 31, 128-139.	0.1	6

#	ARTICLE	IF	CITATIONS
1264	The cost-effectiveness of lipid lowering for primary cardiovascular prevention in chronic kidney disease: moving beyond statins. <i>Kidney International</i> , 2019, 96, 22-25.	2.6	1
1265	Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARM α): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5537.	1.8	27
1266	Implications for REDUCE IT in clinical practice. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 395-400.	1.6	12
1267	Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease. <i>Nature Medicine</i> , 2019, 25, 1753-1760.	15.2	174
1268	Statins for primary prevention of cardiovascular disease and the risk of acute kidney injury. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1583-1590.	0.9	7
1269	Rationale and Strategies for Preserving Residual Kidney Function in Dialysis Patients. <i>American Journal of Nephrology</i> , 2019, 50, 411-421.	1.4	36
1270	The Association of Atrial Fibrillation and Ischemic Stroke in Patients on Hemodialysis: A Competing Risk Analysis. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811987871.	0.6	12
1271	2018 Guidelines for the Management of Dyslipidemia in Korea. <i>Journal of Lipid and Atherosclerosis</i> , 2019, 8, 78.	1.1	100
1272	Redefining Medication Management in Dialysis: A Kidney Pharmacy Quality Pyramid. <i>Kidney Medicine</i> , 2019, 1, 307-314.	1.0	6
1273	Elevated Triglycerides (≥ 150 mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of Hospitalization for New-Onset Kidney Disease: A Real-World Analysis of High-Risk Statin-Treated Patients. <i>CardioRenal Medicine</i> , 2019, 9, 400-407.	0.7	14
1274	Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75). <i>Circulation</i> , 2019, 140, 992-1003.	1.6	132
1275	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.4	1,753
1276	Lipid lowering and risk of haemorrhagic stroke in CKD. <i>Nature Reviews Nephrology</i> , 2019, 15, 667-669.	4.1	1
1278	Revascularization Strategies in Patients with Chronic Kidney Disease and Acute Coronary Syndromes. <i>Current Cardiology Reports</i> , 2019, 21, 113.	1.3	1
1279	Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. <i>Pharmacoeconomics</i> , 2019, 37, 1451-1468.	1.7	24
1280	Chronic Kidney Disease and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1823-1838.	1.2	403
1281	Pravastatin Versus Fluvastatin After Statin Intolerance: The PRUV-Intolerance Study With Propensity Score Matching. <i>American Journal of Medicine</i> , 2019, 132, 1320-1326.e1.	0.6	4
1282	Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e030596.	0.8	12

#	ARTICLE	IF	CITATIONS
1283	Antihypertensive Agents in the Dialysis Patient. <i>Current Hypertension Reports</i> , 2019, 21, 5.	1.5	5
1284	Longitudinal lipid trends and adverse outcomes in patients with CKD: a 13-year observational cohort study. <i>Journal of Lipid Research</i> , 2019, 60, 648-660.	2.0	21
1285	Abordaje del paciente con insuficiencia renal cr�nica. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2019, 26, 1-26.	0.0	0
1286	Lipid-Lowering Agents. <i>Circulation Research</i> , 2019, 124, 386-404.	2.0	124
1287	Cholesterol-Lowering Agents. <i>Circulation Research</i> , 2019, 124, 364-385.	2.0	45
1288	Cholesterol-Lowering Agents. <i>Circulation Research</i> , 2019, 124, 354-363.	2.0	33
1289	A cross-sectional survey of coronary plaque composition in individuals on non-statin lipid lowering drug therapies and undergoing coronary computed tomography angiography. <i>Journal of Cardiovascular Computed Tomography</i> , 2019, 13, 99-104.	0.7	2
1290	Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD. <i>American Journal of Kidney Diseases</i> , 2019, 73, 827-836.	2.1	43
1291	Associations between Hemodialysis Facility Practices to Manage Fluid Volume and Intradialytic Hypotension and Patient Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 385-393.	2.2	50
1292	The Use of Risk-Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-Society Cholesterol Guidelines. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	14
1293	Determinants and Prevention of Coronary Disease in Patients With Chronic Kidney Disease. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1181-1187.	0.8	5
1294	Identification of hepatic NPC1L1 as an NAFLD risk factor evidenced by ezetimibe-mediated steatosis prevention and recovery. <i>FASEB BioAdvances</i> , 2019, 1, 283-295.	1.3	17
1295	Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure. <i>Renal Replacement Therapy</i> , 2019, 5, .	0.3	6
1296	Indicaciones de los inhibidores de PCSK9 en la pr�ctica cl�nica. <i>Recomendaciones de la Sociedad Espa�ola de Arteriosclerosis (SEA)</i> , 2019. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2019, 31, 128-139.	0.4	28
1297	An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 619-630.	1.5	29
1298	Cholesterol-Lowering Treatment in Chronic Kidney Disease: Multistage Pairwise and Network Meta-Analyses. <i>Scientific Reports</i> , 2019, 9, 8951.	1.6	18
1299	Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. <i>Current Atherosclerosis Reports</i> , 2019, 21, 32.	2.0	17
1300	Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2961-2970.	1.2	115

#	ARTICLE	IF	CITATIONS
1301	Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.3	16
1302	Determinants of inertia with lipid-lowering treatment in patients with type 2 diabetes mellitus. <i>Endocrinología Diabetes Y Nutrición (English Ed)</i> , 2019, 66, 223-231.	0.1	2
1303	Proprotein convertase subtilisin/kexin type 9 and mortality in patients starting hemodialysis. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13113.	1.7	7
1304	Attainment of Guideline-Directed Medical Treatment in Stable Ischemic Heart Disease Patients With and Without Chronic Kidney Disease. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 443-451.	1.3	4
1305	High convective volumes are associated with improvement in metabolic profile in diabetic patients on online haemodiafiltration. <i>Nefrologia</i> , 2019, 39, 168-176.	0.2	2
1306	IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 702-711.	2.2	22
1307	Statin therapy among chronic kidney disease patients presenting with acute coronary syndrome. <i>Atherosclerosis</i> , 2019, 286, 14-19.	0.4	7
1308	Vitamin D and Cardiovascular Complications of CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 932-934.	2.2	10
1309	Predicting, preventing, and managing cardiovascular and chronic kidney disease progression in people with type 2 diabetes: How to improve on traditional strategies. <i>Journal of Diabetes</i> , 2019, 11, 619-622.	0.8	4
1310	Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia. <i>Medicine (United States)</i> , 2019, 98, e14400.	0.4	29
1311	Efficacy and Safety of Ezetimibe in Combination with Atorvastatin for Acute Coronary Syndrome Patients Accompanied with Type 2 Diabetes: A Single-Center, Non-randomized Cohort Study. <i>Chemical and Pharmaceutical Bulletin</i> , 2019, 67, 419-425.	0.6	4
1312	Impact of chronic kidney disease on recurrent ventricular tachyarrhythmias in ICD recipients. <i>Heart and Vessels</i> , 2019, 34, 1811-1822.	0.5	6
1313	An updated review of lipid-modifying therapy. <i>Medical Journal of Australia</i> , 2019, 211, 87-92.	0.8	9
1315	Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. <i>Atherosclerosis</i> , 2019, 285, 40-48.	0.4	39
1316	Arterial Stiffness in the Heart Disease of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 918-928.	3.0	128
1317	Clinical care gaps and solutions in diabetes and advanced chronic kidney disease: a patient-oriented qualitative research study. <i>CMAJ Open</i> , 2019, 7, E258-E263.	1.1	9
1318	Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2019, 8, e010827.	1.6	17
1319	Physical Stability and Viscoelastic Properties of Co-Amorphous Ezetimibe/Simvastatin System. <i>Pharmaceuticals</i> , 2019, 12, 40.	1.7	18

#	ARTICLE	IF	CITATIONS
1320	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. <i>Kidney International</i> , 2019, 96, 170-179.	2.6	13
1321	The emerging concept of "individualized cholesterol-lowering therapy": A change in paradigm. , 2019, 199, 111-116.		34
1322	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 140, e596-e646.	1.6	1,789
1323	Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication. <i>Journal of Endovascular Therapy</i> , 2019, 26, 402-410.	0.8	2
1324	Statin Therapy Before Transition to End-Stage Renal Disease With Posttransition Outcomes. <i>Journal of the American Heart Association</i> , 2019, 8, e011869.	1.6	13
1325	Statins and antiplatelet agents are associated with changes in the circulatory markers of endothelial dysfunction in chronic kidney disease. <i>Nefrologia</i> , 2019, 39, 287-293.	0.2	3
1326	Sudden Cardiac Death in Dialysis: Arrhythmic Mechanisms and the Value of Non-invasive Electrophysiology. <i>Frontiers in Physiology</i> , 2019, 10, 144.	1.3	17
1327	Impact of Glucose Exposure on Outcomes of a Nation-Wide Peritoneal Dialysis Cohort " Results of the BRAZPD II Cohort. <i>Frontiers in Physiology</i> , 2019, 10, 150.	1.3	3
1328	Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 917-928.	0.9	17
1329	Cardiovascular adaptations associated with exercise in patients on hemodialysis. <i>Seminars in Dialysis</i> , 2019, 32, 361-367.	0.7	7
1330	Statin use and the risk of acute kidney injury in older adults. <i>BMC Nephrology</i> , 2019, 20, 103.	0.8	21
1331	Modifying Effect of Statins on Fatal Outcomes in Chronic Kidney Disease Patients in the Systolic Blood Pressure Intervention Trial: A Post Hoc Analysis. <i>American Journal of Nephrology</i> , 2019, 49, 297-306.	1.4	2
1332	Systolic Blood Pressure Intervention Trial and Statins, a Story of Statistical Interaction. <i>American Journal of Nephrology</i> , 2019, 49, 294-296.	1.4	0
1333	Treatment of Central Nervous System Complications of Renal Dialysis and Transplantation. <i>Current Treatment Options in Neurology</i> , 2019, 21, 13.	0.7	4
1334	Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. <i>Nature Medicine</i> , 2019, 25, 569-574.	15.2	200
1335	Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage " A Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 1703-1709.	0.7	31
1336	Elevated Serum Non-HDL (High-Density Lipoprotein) Cholesterol and Triglyceride Levels as Residual Risks for Myocardial Infarction Recurrence Under Statin Treatment. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 934-944.	1.1	25
1337	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1376-1414.	1.2	820

#	ARTICLE	IF	CITATIONS
1338	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Journal of the American College of Cardiology, 2019, 74, e177-e232.	1.2	1,038
1339	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 140, e563-e595.	1.6	1,676
1340	Drugs for Treatment of Dyslipidemia Available in the USA. , 2019, , 171-195.		0
1341	Guidelines impact cholesterol management. Journal of Clinical Lipidology, 2019, 13, 432-442.	0.6	6
1342	Serum indoxyl sulfate predicts adverse cardiovascular events in patients with chronic kidney disease. Journal of the Formosan Medical Association, 2019, 118, 1099-1106.	0.8	28
1343	Lipid Accumulation and Chronic Kidney Disease. Nutrients, 2019, 11, 722.	1.7	207
1344	Guideline attainment and morbidity/mortality rates in a large cohort of European haemodialysis patients (EURODOPPS). Nephrology Dialysis Transplantation, 2019, 34, 2105-2110.	0.4	11
1345	Brain white matter microstructure in end-stage kidney disease, cognitive impairment, and circulatory stress. Hemodialysis International, 2019, 23, 356-365.	0.4	27
1347	Clinical practice guidelines for the provision of renal service in Hong Kong: General Nephrology. Nephrology, 2019, 24, 9-26.	0.7	4
1348	Current pharmacotherapies for atherosclerotic cardiovascular diseases. Archives of Pharmacal Research, 2019, 42, 206-223.	2.7	10
1349	Dual inhibition of endothelial miR-92a-3p and miR-489-3p reduces renal injury-associated atherosclerosis. Atherosclerosis, 2019, 282, 121-131.	0.4	55
1350	El uso de estatinas y antiagregantes se asocia con cambios en los marcadores de disfunción endotelial en la enfermedad renal crónica. Nefrología, 2019, 39, 287-293.	0.2	3
1351	New agents to reduce cholesterol levels: implications for nephrologists. Nephrology Dialysis Transplantation, 2019, 35, 213-218.	0.4	3
1352	Statin use among Veterans with dialysis-dependent chronic kidney disease. Hemodialysis International, 2019, 23, 206-213.	0.4	3
1353	Screening coronary angiography in patients with long-standing diabetes mellitus undergoing kidney transplant evaluation. Clinical Transplantation, 2019, 33, e13501.	0.8	4
1354	The China Patient-centred Evaluative Assessment of Cardiac Events (PEACE) prospective heart failure study design. BMJ Open, 2019, 9, e025144.	0.8	26
1355	2018 Guidelines for the management of dyslipidemia. Korean Journal of Internal Medicine, 2019, 34, 723-771.	0.7	144
1356	Dyslipidemia in Special Populations, the Elderly, Women, HIV, Chronic Kidney Disease and ESRD, and Minority Groups. , 0, , .		6

#	ARTICLE	IF	CITATIONS
1357	Improving coding and primary care management for patients with chronic kidney disease: an observational controlled study in East London. <i>British Journal of General Practice</i> , 2019, 69, e454-e461.	0.7	16
1358	The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 375-383.	1.6	32
1359	Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old Tale. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 314.	1.8	62
1360	Impact of prior stroke on major clinical outcome in chronic kidney disease: the Salford kidney cohort study. <i>BMC Nephrology</i> , 2019, 20, 432.	0.8	8
1361	Cardiovascular Disease in Renal Transplantation. , 2019, , 496-516.		0
1362	Change in Dyslipidemia with Declining Glomerular Filtration Rate and Increasing Proteinuria in Children with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1711-1718.	2.2	20
1363	Cholesterol Disturbances and the Role of Proper Nutrition in CKD Patients. <i>Nutrients</i> , 2019, 11, 2820.	1.7	14
1364	Protocol for the Study of Heart and Renal Protection-Extended Review: Additional 5-Year Follow-up of the Australian, New Zealand, and Malaysian SHARP Cohort. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811987989.	0.6	4
1365	Prognostic impact of chronic kidney disease and renal replacement therapy in ventricular tachyarrhythmias and aborted cardiac arrest. <i>Clinical Research in Cardiology</i> , 2019, 108, 669-682.	1.5	13
1366	Cardiovascular Screening and Early Detection of Heart Disease in Adults With Chronic Kidney Disease. <i>Journal for Nurse Practitioners</i> , 2019, 15, 34-40.	0.4	3
1367	Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. <i>Cellular Signalling</i> , 2019, 55, 53-64.	1.7	23
1368	Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. <i>Cardiology and Therapy</i> , 2019, 8, 5-20.	1.1	17
1369	Beyond a Measure of Liver Functionâ€”Bilirubin Acts as a Potential Cardiovascular Protector in Chronic Kidney Disease Patients. <i>International Journal of Molecular Sciences</i> , 2019, 20, 117.	1.8	23
1370	Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 113-131.	1.0	4
1371	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. <i>Journal of the American College of Cardiology</i> , 2019, 73, e285-e350.	1.2	1,550
1372	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1046-e1081.	1.6	361
1373	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1082-e1143.	1.6	2,380
1374	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3168-3209.	1.2	1,128

#	ARTICLE	IF	CITATIONS
1375	Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. <i>Kidney International</i> , 2019, 95, 973-982.	2.6	70
1376	Los altos volúmenes convectivos se asocian a la mejoría del perfil metabólico en los pacientes diabéticos en hemodiafiltración online. <i>Nefrología</i> , 2019, 39, 168-176.	0.2	3
1377	Complications of Solid Organ Transplantation. <i>Critical Care Clinics</i> , 2019, 35, 169-186.	1.0	39
1378	Changes in QTc interval in long-term hemodialysis patients. <i>PLoS ONE</i> , 2019, 14, e0209297.	1.1	14
1379	Cardiovascular Disease in Chronic Kidney Disease. , 2019, , 176-193.e9.		0
1380	Determinantes de la inercia en el tratamiento hipolipemiente de pacientes con diabetes mellitus tipo 2. <i>Endocrinología, Diabetes Y Nutrición</i> , 2019, 66, 223-231.	0.1	4
1381	Trends in Statin Use Among US Adults With Chronic Kidney Disease, 1999–2014. <i>Journal of the American Heart Association</i> , 2019, 8, e010640.	1.6	27
1382	Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, e38-e81.	1.1	431
1383	Management of Diabetes Mellitus. <i>Contemporary Cardiology</i> , 2019, , 113-177.	0.0	0
1384	Chronic Kidney Disease in the Primary Care Setting: Cardiovascular Disease Risk and Management. <i>Contemporary Cardiology</i> , 2019, , 179-216.	0.0	0
1385	The effect of chronic kidney disease on lipid metabolism. <i>International Urology and Nephrology</i> , 2019, 51, 265-277.	0.6	32
1386	Dietary n-3 polyunsaturated fatty acid intake and all-cause and cardiovascular mortality in adults on hemodialysis: The DIET-HD multinational cohort study. <i>Clinical Nutrition</i> , 2019, 38, 429-437.	2.3	16
1387	Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. <i>European Heart Journal</i> , 2019, 40, 880-886.	1.0	34
1388	Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials. <i>Clinical Nutrition</i> , 2020, 39, 358-368.	2.3	45
1389	Association of non-invasive measures of subclinical atherosclerosis and arterial stiffness with mortality and major cardiovascular events in chronic kidney disease: systematic review and meta-analysis of cohort studies. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 842-854.	1.4	21
1390	Clinical Assessment and Management of Chronic Kidney Disease Across Its Stages. , 2020, , 55-71.		0
1391	Cardiovascular Disease and Chronic Kidney Disease. , 2020, , 337-353.		0
1392	Slowing Progression of Chronic Kidney Disease. , 2020, , 937-959.		2

#	ARTICLE	IF	CITATIONS
1394	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	1.0	4,871
1395	Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 827-836.	0.4	23
1396	Neurologic Complications of Chronic Kidney Disease. , 2020, , 441-461.		0
1397	Dyslipidemia and Chronic Kidney Disease. , 2020, , 1093-1101.		0
1398	Preparing for Hemodialysis. , 2020, , 1157-1173.		1
1399	Chronic Kidney Disease in Children. , 2020, , 1239-1253.		0
1400	Approach to Chronic Kidney Disease in the Diabetic Patient. , 2020, , 831-847.		0
1401	The Interdisciplinary Clinic for Chronic Kidney Disease. , 2020, , 921-935.		0
1402	Prevention and treatment of stroke in patients with chronic kidney disease: an overview of evidence and current guidelines. <i>Kidney International</i> , 2020, 97, 266-278.	2.6	33
1403	Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 47-60.	2.2	41
1404	Do virtual renal clinics improve access to kidney care? A preliminary impact evaluation of a virtual clinic in East London. <i>BMC Nephrology</i> , 2020, 21, 10.	0.8	15
1405	Comment on "Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies" <i>Clinical Rheumatology</i> , 2020, 39, 615-616.	1.0	0
1406	Failure of Statins to Improve Outcomes in Dialysis Patients: Does Peritonitis Modify the Impact of Lipids on Cardiovascular Events?. <i>Canadian Journal of Cardiology</i> , 2020, 36, 22-23.	0.8	0
1407	Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerations. , 2020, 207, 107459.		7
1408	Detailed Review of Chronic Kidney Disease. <i>Kidney Diseases (Basel, Switzerland)</i> , 2020, 6, 85-91.	1.2	25
1409	Cardiovascular actions of parathyroid hormone/parathyroid hormone-related protein signaling. , 2020, , 623-644.		0
1410	Peritonitis Affects the Relationship Between Low-Density Lipoprotein Cholesterol and Cardiovascular Events in Peritoneal Dialysis Patients. <i>Canadian Journal of Cardiology</i> , 2020, 36, 92-99.	0.8	3
1411	Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 36-49.	5.5	115

#	ARTICLE	IF	CITATIONS
1412	Waiting List and Kidney Transplant Vascular Risk: An Ongoing Unmet Concern. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 1-27.	0.9	12
1413	Increased risk of developing peripheral artery disease in hemodialysis patients receiving statin treatments: a population-based cohort study in Taiwan. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1753-1760.	0.4	6
1414	The short-term effects of angiotensin II receptor blockers on albuminuria and renal function in Korean patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 424-431.	1.2	0
1415	Cardiovascular Risk Assessment Using Ultrasonographic Surrogate Markers of Atherosclerosis and Arterial Stiffness in Patients With Chronic Renal Impairment: A Narrative Review of the Evidence and a Critical View of Their Utility in Clinical Practice. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812095493.	0.6	4
1416	IMPROVE-IT. <i>JACC: CardioOncology</i> , 2020, 2, 397-399.	1.7	0
1417	Prevalence of chronic kidney disease in adults in England: comparison of nationally representative cross-sectional surveys from 2003 to 2016. <i>BMJ Open</i> , 2020, 10, e038423.	0.8	23
1418	Pre β 1-high-density lipoprotein metabolism is delayed in patients with chronic kidney disease not on hemodialysis. <i>Journal of Clinical Lipidology</i> , 2020, 14, 730-739.	0.6	5
1419	Chronic kidney disease as a cardiovascular risk factor. <i>Journal of Hypertension</i> , 2020, 38, 2110-2121.	0.3	21
1421	Prerandomization run-in periods in randomized controlled trials of chronic diseases: a methodological study. <i>Journal of Clinical Epidemiology</i> , 2020, 128, 148-156.	2.4	4
1422	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020, 98, 849-859.	2.6	65
1423	Efectividad y seguridad del uso de inhibidores de PCSK9 en el tratamiento de la dislipidemia en el paciente con insuficiencia renal. <i>Nefrología</i> , 2020, 40, 499-505.	0.2	7
1424	Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives. <i>Cardiology Research and Practice</i> , 2020, 2020, 1-9.	0.5	14
1425	Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 334.	0.7	14
1426	Possible Differential Diagnosis of the Degrees of Rheological Disturbances in Patients with Type 2 Diabetes Mellitus by Dielectrophoresis of Erythrocytes. <i>Journal of Personalized Medicine</i> , 2020, 10, 60.	1.1	7
1427	Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?. <i>Diabetes</i> , 2020, 69, 2578-2580.	0.3	1
1428	Epidemiology of kidney disease: consolidating and integrating the evidence to improve kidney care from early childhood to adulthood. <i>Kidney International</i> , 2020, 98, 1378-1381.	2.6	1
1429	Hyperlipidemia and mortality associated with diabetes mellitus co-existence in Chinese peritoneal dialysis patients. <i>Lipids in Health and Disease</i> , 2020, 19, 234.	1.2	9
1430	Hitos hist β ricos en el tratamiento hipolipemiante antes de la era de los inhibidores de la proproteína convertasa subtilisina/kexina tipo 9. <i>Revista Espanola De Cardiología Suplementos</i> , 2020, 20, 8-14.	0.2	0

#	ARTICLE	IF	CITATIONS
1431	Anticuerpos monoclonales inhibidores de la proproteína convertasa subtilisina/kexina tipo 9: nuevas evidencias. Revista Espanola De Cardiología Suplementos, 2020, 20, 15-20.	0.2	1
1433	Coronary artery calcium progresses rapidly and discriminates incident cardiovascular events in chronic kidney disease regardless of diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis, 2020, 310, 75-82.	0.4	6
1434	Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. Expert Opinion on Pharmacotherapy, 2020, 21, 2137-2151.	0.9	7
1435	Japanese Clinical Practice Guideline for Diabetes 2019. Journal of Diabetes Investigation, 2020, 11, 1020-1076.	1.1	159
1436	Prognostic significance of carotid plaque presence in peritoneal dialysis patients and its association with the apolipoprotein B/apolipoprotein A1 ratio. Nephrology, 2020, 25, 919-928.	0.7	3
1437	The current and future landscape of dialysis. Nature Reviews Nephrology, 2020, 16, 573-585.	4.1	252
1438	There is a U shaped association between non high density lipoprotein cholesterol with overall and cardiovascular mortality in chronic kidney disease stage 3-5. Scientific Reports, 2020, 10, 12749.	1.6	8
1439	Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies. Journal of the American Heart Association, 2020, 9, e016506.	1.6	8
1440	Japanese Clinical Practice Guideline for Diabetes 2019. Diabetology International, 2020, 11, 165-223.	0.7	266
1441	Hit or miss: the new cholesterol targets. BMJ Evidence-Based Medicine, 2020, 26, bmjebm-2020-111413.	1.7	9
1442	Elevated TG/HDL-C and non-HDL-C/HDL-C ratios predict mortality in peritoneal dialysis patients. BMC Nephrology, 2020, 21, 324.	0.8	17
1443	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Advanced Drug Delivery Reviews, 2020, 159, 4-33.	6.6	113
1444	Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMs): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?. Current Atherosclerosis Reports, 2020, 22, 43.	2.0	8
1445	LDL-cholesterol reduction in chronic kidney disease: options beyond statins. Current Opinion in Nephrology and Hypertension, 2020, 29, 480-488.	1.0	3
1446	Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease. Biomolecules, 2020, 10, 1348.	1.8	23
1447	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3613-3682.	1.8	63
1448	Contribution of Predictive and Prognostic Biomarkers to Clinical Research on Chronic Kidney Disease. International Journal of Molecular Sciences, 2020, 21, 5846.	1.8	29
1449	Treatment to reduce vascular calcification in hemodialysis patients using vitamin K (Trevasc-HDK). Medicine (United States), 2020, 99, e21906.	0.4	22

#	ARTICLE	IF	CITATIONS
1450	Statins ameliorate cholesterol-induced inflammation and improve AQP2 expression by inhibiting NLRP3 activation in the kidney. <i>Theranostics</i> , 2020, 10, 10415-10433.	4.6	25
1451	Quantification of left ventricular mass by echocardiography compared to cardiac magnet resonance imaging in hemodialysis patients. <i>Cardiovascular Ultrasound</i> , 2020, 18, 39.	0.5	7
1452	Chronic kidney disease: a high-risk group that deserves intensive lipid lowering. <i>European Heart Journal</i> , 2020, 41, 4124-4126.	1.0	4
1453	Improved Detection of Potentially Pleiotropic Genes in Coronary Artery Disease and Chronic Kidney Disease Using GWAS Summary Statistics. <i>Frontiers in Genetics</i> , 2020, 11, 592461.	1.1	4
1454	Targeting Uremic Toxins to Prevent Peripheral Vascular Complications in Chronic Kidney Disease. <i>Toxins</i> , 2020, 12, 808.	1.5	5
1455	Strategies for enhancing the initiation of cholesterol lowering medication among patients at high cardiovascular disease risk: a qualitative descriptive exploration of patient and general practitioners' perspectives on a facilitated relay intervention in Alberta, Canada. <i>BMJ Open</i> , 2020, 10, e038469.	0.8	6
1456	Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease. <i>Nefrologia</i> , 2020, 40, 499-505.	0.2	3
1457	Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo. <i>JACC: CardioOncology</i> , 2020, 2, 385-396.	1.7	7
1459	Effect of statins on cardiovascular complications in chronic kidney disease patients. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 T</i>	0.4	8
1460	Mode of Death Among Japanese Adults With Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. <i>JAMA Network Open</i> , 2020, 3, e204296.	2.8	32
1461	Clinical Pharmacology of Statins: an Update. <i>Current Atherosclerosis Reports</i> , 2020, 22, 26.	2.0	31
1462	Are statins back for patients on hemodialysis?. <i>European Journal of Preventive Cardiology</i> , 2020, 28, 834-837.	0.8	0
1463	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2020, 76, 109-120.	2.1	10
1464	CKD Increases Carbonylation of HDL and Is Associated with Impaired Antiaggregant Properties. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1462-1477.	3.0	14
1465	Cerebrovascular Disease and Cognition in Chronic Kidney Disease Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 96.	1.1	39
1466	The association of repeatedly measured low-density lipoprotein cholesterol and all-cause mortality and cardiovascular disease in dyslipidemic patients: A longitudinal study. <i>International Journal of Cardiology</i> , 2020, 311, 97-103.	0.8	5
1467	The predictive study of the relation between elevated low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and mortality in peritoneal dialysis. <i>Lipids in Health and Disease</i> , 2020, 19, 51.	1.2	11
1468	Clinical Potential of Targeting Fibroblast Growth Factor α 23 and β Klotho in the Treatment of Uremic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2020, 9, e016041.	1.6	20

#	ARTICLE	IF	CITATIONS
1469	Progress in using the electronic health record to improve primary care. <i>British Journal of General Practice</i> , 2020, 70, e215-e220.	0.7	8
1470	Si-Miao-Yong-An (SMYA) Decoction May Protect the Renal Function Through Regulating the Autophagy-Mediated Degradation of Ubiquitinated Protein in an Atherosclerosis Model. <i>Frontiers in Pharmacology</i> , 2020, 11, 837.	1.6	2
1471	Renal Medicine and Clinical Pharmacy. <i>Advanced Clinical Pharmacy</i> — Research, Development and Practical Applications, 2020, , .	0.0	2
1472	Adverse Drug Reactions in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1090-1102.	2.2	47
1473	Data from the ERA-EDTA Registry were examined for trends in excess mortality in European adults on kidney replacement therapy. <i>Kidney International</i> , 2020, 98, 999-1008.	2.6	27
1474	Management of metabolic alterations in adult kidney transplant recipients: A joint position statement of the Italian Society of Nephrology (SIN), the Italian Society for Organ Transplantation (SITO) and the Italian Diabetes Society (SID). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1427-1441.	1.1	6
1475	Statins and All-cause Mortality in Patients Undergoing Hemodialysis. <i>Journal of the American Heart Association</i> , 2020, 9, e014840.	1.6	20
1476	A scoring system for predicting individual treatment effects of statins in type 2 diabetes patients on haemodialysis. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 838-851.	0.8	6
1477	Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 753-757.	1.4	20
1478	Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology. <i>Journal of Nephrology</i> , 2020, 33, 417-430.	0.9	8
1479	Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2020, 21, 50.	0.8	8
1480	Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. <i>Journal of the American College of Cardiology</i> , 2020, 75, 835-837.	1.2	1
1481	Should We Consider the Cardiovascular System While Evaluating CKD-MBD?. <i>Toxins</i> , 2020, 12, 140.	1.5	7
1483	Statin-Associated Muscle Symptoms. <i>Contemporary Cardiology</i> , 2020, , .	0.0	0
1484	The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 601.	1.8	54
1485	Access to CKD Care in Rural Communities of India: a qualitative study exploring the barriers and potential facilitators. <i>BMC Nephrology</i> , 2020, 21, 26.	0.8	17
1486	LDL-Cholesterol-Lowering Therapy. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	0.9	8
1487	Targeting Vascular Calcification in Chronic Kidney Disease. <i>JACC Basic To Translational Science</i> , 2020, 5, 398-412.	1.9	95

#	ARTICLE	IF	CITATIONS
1488	Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1945-1955.	1.2	47
1490	Cardiovascular risk factors and cardiovascular disease in patients with type 1 diabetes and end-stage renal disease candidates for kidney-pancreas transplantation: Trends from 1999 to 2017. <i>Diabetes Research and Clinical Practice</i> , 2020, 163, 108135.	1.1	11
1491	An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 3-15.	2.2	278
1492	Not even a peripheral role for statins in end-stage renal disease?. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1645-1647.	0.4	2
1493	Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 833-843.	2.3	13
1494	Second revolution in cardiovascular prevention. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 327-336.	0.6	6
1495	Trimethylamine-N-oxide acutely increases cardiac muscle contractility. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 318, H1272-H1282.	1.5	17
1496	Renal Function-Dependent Associations of Statins with Outcomes of Ischemic Stroke. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 146-156.	0.9	1
1497	Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 479-489.	1.3	11
1498	Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 905-916.	0.8	13
1499	High low-density lipoprotein cholesterol as an independent risk factor for coronary restenosis in hemodialysis patients undergoing percutaneous coronary interventions. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 296-303.	0.4	0
1500	Association between serum lipids, polyunsaturated fatty acids, and prognosis in maintenance hemodialysis patients. <i>Hemodialysis International</i> , 2021, 25, 104-112.	0.4	1
1501	Cardiac Imaging for Coronary Heart Disease Risk Stratification in Chronic Kidney Disease. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 669-682.	2.3	32
1502	Association of renal insufficiency with treatments and outcomes in patients with acute coronary syndrome in China. <i>International Journal of Cardiology</i> , 2021, 323, 7-12.	0.8	7
1503	Chronic kidney disease and statin eligibility. <i>Journal of Clinical Lipidology</i> , 2021, 15, 173-180.	0.6	6
1504	Elevated atherogenic index and higher triglyceride increase risk of kidney function decline: a 7-year cohort study in Chinese adults. <i>Renal Failure</i> , 2021, 43, 32-39.	0.8	9
1505	Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 87-94.	0.4	259
1506	Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. <i>Diabetology International</i> , 2021, 12, 1-51.	0.7	6

#	ARTICLE	IF	CITATIONS
1507	LDL-Cholesterol versus Glucose in Microvascular and Macrovascular Disease. <i>Clinical Chemistry</i> , 2021, 67, 167-182.	1.5	7
1508	Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease. <i>American Heart Journal</i> , 2021, 231, 36-44.	1.2	9
1509	Association between atherosclerotic cardiovascular diseases risk and renal outcome in patients with type 2 diabetes mellitus. <i>Renal Failure</i> , 2021, 43, 477-487.	0.8	9
1510	The Cardiovascular Status of Pediatric Dialysis Patients. , 2021, , 559-588.		0
1511	Ezetimibe. <i>Stroke Revisited</i> , 2021, , 91-101.	0.2	1
1512	Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis. <i>Renal Failure</i> , 2021, 43, 718-728.	0.8	10
1513	Uraemic Cardiomyopathy: A Review of Current Literature. <i>Clinical Medicine Insights: Cardiology</i> , 2021, 15, 117954682199834.	0.6	22
1514	Peritoneal Dialysis in Diabetic Patients. , 2021, , 247-258.		0
1515	FGF23â€”resolved issues, remaining controversies, and future questionsâ€”a clinician's perspective. , 2021, , 215-224.		0
1516	The cardiovascularâ€”dialysis nexus: the transition to dialysis is a treacherous time for the heart. <i>European Heart Journal</i> , 2021, 42, 1244-1253.	1.0	14
1517	Public Health and Nephrology: Contributions of Epidemiology to the Study, Understanding, Prevention and Treatment of Kidney Disease. <i>Contributions To Nephrology</i> , 2021, 199, 1-14.	1.1	0
1518	Stroke and Chronic Kidney Disease. <i>Contributions To Nephrology</i> , 2021, 199, 80-90.	1.1	6
1520	Management of dyslipidemia in chronic kidney disease. <i>Journal of Indira Gandhi Institute of Medical Sciences</i> , 2021, 7, 2.	0.1	1
1521	Usefulness of statins in end-stage renal disease. <i>Baylor University Medical Center Proceedings</i> , 2021, 34, 361-363.	0.2	0
1522	Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS). <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1629-1639.	0.4	73
1523	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <i>Atherosclerosis</i> , 2021, 319, 51-61.	0.4	37
1524	Diabetes, Cardiovascular Disease, and Cardiovascular Risk in Patients with Chronic Kidney Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 159-165.	1.0	5
1525	Chronic kidney disease detection, staging and treatment in cardiovascular disease prevention. <i>Heart</i> , 2021, 107, 1282-1288.	1.2	18

#	ARTICLE	IF	CITATIONS
1526	Treatment rationale for coronary heart disease in advanced CKD. <i>Herz</i> , 2021, 46, 221-227.	0.4	1
1527	Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 120-129.	0.7	41
1528	Ethereal Extract of Pepper: Preventing Atherosclerosis and Left Ventricle Remodeling in LDL Receptor Knockout Mice. <i>Preventive Nutrition and Food Science</i> , 2021, 26, 51-57.	0.7	0
1529	Associations between Circulating Markers of Cholesterol Homeostasis and Macrovascular Events among Patients Undergoing Hemodialysis. <i>Nutrients</i> , 2021, 13, 1014.	1.7	1
1530	Invasive Management of Coronary Artery Disease in Advanced Renal Disease. <i>Kidney International Reports</i> , 2021, 6, 1513-1524.	0.4	5
1531	Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. <i>European Heart Journal</i> , 2021, 42, 1216-1227.	1.0	75
1532	The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs. <i>Health Technology Assessment</i> , 2021, 25, 1-62.	1.3	6
1533	Ten things to know about ten cardiovascular disease risk factors. <i>American Journal of Preventive Cardiology</i> , 2021, 5, 100149.	1.3	87
1534	Cardiovascular Disease in Chronic Kidney Disease. <i>Circulation</i> , 2021, 143, 1157-1172.	1.6	680
1535	Medical Therapy Versus Revascularization in Patients with Stable Ischemic Heart Disease and Advanced Chronic Kidney Disease. <i>Current Cardiology Reports</i> , 2021, 23, 23.	1.3	3
1536	Stage A Heart Failure. <i>Heart Failure Clinics</i> , 2021, 17, 167-177.	1.0	4
1537	Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation. <i>Life</i> , 2021, 11, 315.	1.1	8
1539	A narrative review of new treatment options for chronic kidney disease in type 2 diabetes. <i>Annals of Translational Medicine</i> , 2021, 9, 716-716.	0.7	5
1540	Umbrella Review on Non-Statin Lipid-Lowering Therapy. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 107424842110029.	1.0	11
1541	Understanding and Overcoming the Challenges Related to Cardiovascular Trials Involving Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1435-1444.	2.2	6
1542	Diabetic kidney disease in type 2 diabetes: a review of pathogenic mechanisms, patient-related factors and therapeutic options. <i>PeerJ</i> , 2021, 9, e11070.	0.9	6
1543	Association of baseline as well as change in lipid levels with the risk of cardiovascular diseases and all-cause deaths. <i>Scientific Reports</i> , 2021, 11, 7381.	1.6	11
1544	A titan of Cardiovascular Research: Professor Peter Sleight (1929–2020). <i>Cardiovascular Research</i> , 2021, 117, e64-e66.	1.8	0

#	ARTICLE	IF	CITATIONS
1545	Colesterol LDL y aterosclerosis: evidencias. Clínica E Investigaci3n En Arteriosclerosis, 2021, 33, 25-32.	0.4	13
1546	Does Statin Therapy Reduce the Risks of Mortality and Major Adverse Cardiac and Cerebrovascular Events in Young Adults with End-Stage Renal Disease? Population-Based Cohort Study. Journal of Clinical Medicine, 2021, 10, 2097.	1.0	6
1547	Prediction of premature all-cause mortality in patients receiving peritoneal dialysis using modified artificial neural networks. Aging, 2021, 13, 14170-14184.	1.4	2
1548	Time-dependent lipid profile inversely associates with mortality in hemodialysis patients " independent of inflammation/malnutrition. Journal of Internal Medicine, 2021, 290, 910-921.	2.7	8
1549	Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk. Expert Review of Clinical Pharmacology, 2021, 14, 793-806.	1.3	8
1550	Statin-induced liver dysfunction triggering fatal myonecrosis. Internal Medicine Journal, 2021, 51, 812-813.	0.5	1
1551	New Trends in Dyslipidemia Treatment. Circulation Journal, 2021, 85, 759-768.	0.7	16
1552	Lipid Optimization in Lower Extremity Peripheral Arterial Disease. Annals of Vascular Surgery, 2021, 76, 542-554.	0.4	3
1553	Remnant cholesterol predicts progression of diabetic nephropathy and retinopathy in type 1 diabetes. Journal of Internal Medicine, 2021, 290, 632-645.	2.7	32
1554	Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nature Reviews Nephrology, 2021, 17, 528-542.	4.1	70
1555	Association between baseline LDL-C and prognosis among patients with coronary artery disease and advanced kidney disease. BMC Nephrology, 2021, 22, 168.	0.8	10
1556	Markers of cholesterol synthesis to cholesterol absorption across the spectrum of non-dialysis CKD: An observational study. Pharmacology Research and Perspectives, 2021, 9, e00801.	1.1	3
1557	Special Considerations for Lipid-Lowering Therapy in Women Reflecting Recent Randomized Trials. Current Atherosclerosis Reports, 2021, 23, 42.	2.0	2
1558	The Impact of Atherosclerotic Cardiovascular Risk on Graft Failure in Deceased-Donor Renal Transplantation. Progress in Transplantation, 2021, 31, 201-210.	0.4	0
1559	Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients Receiving Maintenance Hemodialysis. American Journal of Kidney Diseases, 2021, 77, 920-930.e1.	2.1	23
1560	Metabolic Acidosis and Cardiovascular Disease in CKD. Kidney Medicine, 2021, 3, 753-761.e1.	1.0	13
1562	Management of Kidney Failure in Patients with Diabetes Mellitus: What Are the Best Options?. Journal of Clinical Medicine, 2021, 10, 2943.	1.0	4
1563	Is a treat-to-target approach to lipid-lowering therapy appropriate in patients with chronic kidney disease? A prospective French cohort study. Journal of Nephrology, 2021, 34, 1467-1477.	0.9	3

#	ARTICLE	IF	CITATIONS
1564	Management of Dyslipidemia in Women and Men with Coronary Heart Disease: Results from POLASPIRE Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2594.	1.0	4
1565	Hyperphosphatemia in chronic kidney disease exacerbates atherosclerosis via a mannosidases-mediated complex-type conversion of SCAP N-glycans. <i>Kidney International</i> , 2021, 99, 1342-1353.	2.6	17
1566	Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 107424842110236.	1.0	4
1567	Atherosclerotic Cardiovascular Disease Events in Adults With CKD Taking a Moderate- or High-Intensity Statin: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Kidney Medicine</i> , 2021, 3, 722-731.e1.	1.0	3
1568	Polypharmacy and medication use in patients with chronic kidney disease with and without kidney replacement therapy compared to matched controls. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2497-2523.	1.4	18
1569	Chronic Kidney Disease and Cerebrovascular Disease. <i>Stroke</i> , 2021, 52, e328-e346.	1.0	56
1570	Intersection Between Chronic Kidney Disease and Cardiovascular Disease. <i>Current Cardiology Reports</i> , 2021, 23, 117.	1.3	12
1571	Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2021, 100, 35-48.	2.6	26
1573	Cardiorenal Syndrome: Emerging Role of Medical Imaging for Clinical Diagnosis and Management. <i>Journal of Personalized Medicine</i> , 2021, 11, 734.	1.1	8
1574	The Impact of Chronic Kidney Disease on Peripheral Artery Disease and Peripheral Revascularization. <i>International Journal of General Medicine</i> , 2021, Volume 14, 3749-3759.	0.8	12
1575	Association of Kidney Function With NMR-Quantified Lipids, Lipoproteins, and Metabolic Measures in Mexican Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2828-2839.	1.8	10
1576	Evaluation of Statin Use and Prescribing in Patients with Chronic Kidney Disease Not Receiving Treatment with Kidney Transplant or Dialysis. <i>Canadian Journal of Hospital Pharmacy</i> , 2021, 74, 219-226.	0.1	0
1577	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	1.0	2,517
1578	Perfil cl�nico de los pacientes tratados con evolocumab en unidades hospitalarias de nefrolog�a en Espa�a (RETOSS-NEFRO). <i>Nefrolog�a</i> , 2022, 42, 301-310.	0.2	1
1579	Triglyceride-Rich Lipoproteins, Apolipoproteins, and Atherosclerotic Cardiovascular Events Among Patients with Diabetes Mellitus and End-Stage Renal Disease on Hemodialysis. <i>American Journal of Cardiology</i> , 2021, 152, 63-68.	0.7	5
1580	Klotho as a biomarker of subclinical atherosclerosis in patients with moderate to severe chronic kidney disease. <i>Scientific Reports</i> , 2021, 11, 15877.	1.6	17
1581	Dyslipidemia in Patients with Kidney Disease. <i>Cardiology Clinics</i> , 2021, 39, 353-363.	0.9	14
1582	Efficacy of Statin Treatment according to Baseline Renal Function in Korean Patients with Acute Myocardial Infarction Not Requiring Dialysis Undergoing Newer-Generation Drug-Eluting Stent Implantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 3504.	1.0	1

#	ARTICLE	IF	CITATIONS
1583	Statin initiation and all-cause mortality in incident statin-naïve dialysis patients. <i>Atherosclerosis</i> , 2021, 337, 59-65.	0.4	9
1584	Inflammation Alters Relationship Between High-Density Lipoprotein Cholesterol and Cardiovascular Risk in Patients With Chronic Kidney Disease: Results From KNOWCKD. <i>Journal of the American Heart Association</i> , 2021, 10, e021731.	1.6	9
1585	Arterial Remodelling in Chronic Kidney Disease: Impact of Uraemic Toxins and New Pharmacological Approaches. <i>Journal of Clinical Medicine</i> , 2021, 10, 3803.	1.0	8
1586	Diabetic dyslipidaemia. <i>Practical Laboratory Medicine</i> , 2021, 26, e00248.	0.6	14
1587	Nonatherosclerotic Vascular Abnormalities Associated with Chronic Kidney Disease. <i>Cardiology Clinics</i> , 2021, 39, 415-425.	0.9	0
1588	Circulating Microbial Signatures and Cardiovascular Death in Patients With ESRD. <i>Kidney International Reports</i> , 2021, 6, 2617-2628.	0.4	7
1589	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.	0.8	220
1590	Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes) <i>Tj ETQq b.30.7843i1 4 rgBT</i>		
1591	Controversies: Stroke Prevention in Chronic Kidney Disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105679.	0.7	4
1592	Shifting the focus away from binary thinking of statistical significance and towards education for key stakeholders: revisiting the debate on whether it's time to de-emphasize or get rid of statistical significance. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 104-112.	2.4	9
1593	Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives. <i>American Journal of Nephrology</i> , 2021, 52, 693-701.	1.4	18
1594	AtualizaÃ§Ã£o da Diretriz Brasileira de Hipercolesterolemia Familiar â€” 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 782-844.	0.3	10
1595	Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 141-155.	1.0	10
1596	Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis. <i>International Journal of Women's Dermatology</i> , 2021, 7, 560-575.	1.1	7
1597	Relation of renal function to mid-term prognosis of stable angina patients with high- or low-dose pitavastatin treatment: REAL-CAD substudy. <i>American Heart Journal</i> , 2021, 240, 89-100.	1.2	3
1598	Cardiovascular Disease and Inflammation. , 2021, , 1-22.		0
1600	Lipoproteins in chronic kidney disease: from bench to bedside. <i>European Heart Journal</i> , 2021, 42, 2170-2185.	1.0	32
1601	Association Between BMI and Cardiovascular Benefits After More Intensive LDL-C Lowering Strategy: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1604	High-Density Lipoprotein: Structural and Functional Changes Under Uremic Conditions and the Therapeutic Consequences. Handbook of Experimental Pharmacology, 2015, 224, 423-453.	0.9	7
1605	CKD as CAD Equivalent: Inflammatory Milieu and Vascular Oxidative Stress. , 2017, , 61-70.		2
1606	Lipidsenkende Mittel. , 2011, , 683-698.		1
1607	Reactive Oxygen Species and Chronic Kidney Disease. , 2014, , 2645-2658.		1
1608	Metabolic Effects of Peritoneal Dialysis. , 2017, , 468-472.e1.		1
1609	Kidney Disease. , 2012, , 1523-1607.		5
1610	Risk Factors and Chronic Kidney Disease. , 2011, , 758-781.		4
1611	Adaptation to Nephron Loss and Mechanisms of Progression in Chronic Kidney Disease. , 2011, , 1918-1971.		5
1612	Cardiovascular Aspects of Kidney Disease. , 2012, , 2059-2080.		5
1613	Colesterol LDL, cuanto más bajo mejor. Clínica E Investigaci3n En Arteriosclerosis, 2019, 31, 16-27.	0.4	16
1614	Diabetic Kidney Disease. , 2019, , 277-286.		1
1615	Prevalence, Detection, Evaluation and Management of Chronic Kidney Disease. BMJ, The, 2014, 348, bmj.f7688-bmj.f7688.	3.0	11
1616	Estatinas en enfermedad renal cr3nica. Ars Medica, 2017, 42, .	0.1	2
1617	Saturated phosphatidic acids mediate saturated fatty acid-induced vascular calcification and lipotoxicity. Journal of Clinical Investigation, 2015, 125, 4544-4558.	3.9	59
1618	Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes. A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society. Circulation Journal, 2020, 85, 82-125.	0.7	16
1619	Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease. F1000prime Reports, 2014, 6, 72.	5.9	13
1620	Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors. Journal of Lipid and Atherosclerosis, 2019, 8, 183.	1.1	16
1621	Statin use and risk of liver cancer: A meta-analysis of 7 studies involving more than 4.7 million patients. World Journal of Meta-analysis, 2013, 1, 130.	0.1	2

#	ARTICLE	IF	CITATIONS
1622	Dyslipidemias in chronic kidney disease: Current guidelines and future perspectives. <i>OA Nephrology</i> , 2013, 1, .	0.2	1
1623	Association of Dyslipidemia with Renal Outcomes in Chronic Kidney Disease. <i>PLoS ONE</i> , 2013, 8, e55643.	1.1	68
1624	The Effects of Comorbidity on the Benefits and Harms of Treatment for Chronic Disease: A Systematic Review. <i>PLoS ONE</i> , 2014, 9, e112593.	1.1	15
1625	Increased Risks of Mortality and Atherosclerotic Complications in Incident Hemodialysis Patients Subsequently with Bone Fractures: A Nationwide Case-Matched Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0121705.	1.1	18
1626	Reduction of Oxidative Stress in Chronic Kidney Disease Does Not Increase Circulating β_2 -Microglobulin Concentrations. <i>PLoS ONE</i> , 2016, 11, e0144121.	1.1	13
1627	Effect of Statins on the Progression of Coronary Calcification in Kidney Transplant Recipients. <i>PLoS ONE</i> , 2016, 11, e0151797.	1.1	17
1628	Low cholesterol level associated with severity and outcome of spontaneous intracerebral hemorrhage: Results from Taiwan Stroke Registry. <i>PLoS ONE</i> , 2017, 12, e0171379.	1.1	25
1629	The atherogenic index of plasma and the risk of mortality in incident dialysis patients: Results from a nationwide prospective cohort in Korea. <i>PLoS ONE</i> , 2017, 12, e0177499.	1.1	22
1630	Poststatin Lipid Therapeutics: A Review. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 32.	0.5	8
1631	Management of lipids in adults with diabetes mellitus and nephropathy and/or chronic kidney disease: summary of joint guidance from the Association of British Clinical Diabetologists (ABCD) and the Renal Association (RA). <i>British Journal of Diabetes</i> , 2017, 17, 64.	0.1	17
1632	Cardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes. <i>British Journal of Diabetes</i> , 2018, 18, 101-105.	0.1	4
1634	Beyond confusion and controversy, can we evaluate the real efficacy and safety of cholesterol-lowering with statins?. <i>Journal of Controversies in Biomedical Research</i> , 2015, 1, 67-92.	0.5	6
1636	The Kidney in Type 2 Diabetes Therapy. <i>Review of Diabetic Studies</i> , 2011, 8, 392-402.	0.5	66
1637	Dyslipoproteinemia and Impairment of Renal Function in Diabetic Kidney Disease: An Analysis of Animal Studies, Observational Studies, and Clinical Trials. <i>Review of Diabetic Studies</i> , 2013, 10, 110-120.	0.5	16
1638	Choosing statins: a review to guide clinical practice. <i>Archives of Endocrinology and Metabolism</i> , 2020, 64, 639-653.	0.3	7
1639	Anti-hypercholesterolemia effects and quality of eel (<i>Anguilla bicolor</i>) oil. <i>International Journal of Science and Applied Science Conference Series</i> , 2017, 2, 174.	0.1	2
1640	Risk of Cardiovascular Death in the Remote Period after Myocardial Revascularization and in Association with Renal Dysfunction. <i>International Journal of Biomedicine</i> , 2016, 6, 12-17.	0.1	2
1641	The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: An Update. <i>Current Pharmaceutical Design</i> , 2014, 20, 3665-3674.	0.9	38

#	ARTICLE	IF	CITATIONS
1642	Ezetimibe Therapy for Dyslipidemia: An Update. <i>Current Pharmaceutical Design</i> , 2013, 19, 3107-3114.	0.9	40
1643	Metabolic Syndrome and Non-Cardiac Vascular Diseases: An Update from Human Studies. <i>Current Pharmaceutical Design</i> , 2014, 20, 4944-4952.	0.9	41
1644	Could Antioxidant Supplementation Delay Progression of Cardiovascular Disease in End-Stage Renal Disease Patients?. <i>Current Vascular Pharmacology</i> , 2020, 19, 41-54.	0.8	8
1645	Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease. <i>Current Cardiology Reviews</i> , 2015, 11, 261-269.	0.6	27
1646	The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature. <i>Current Cardiology Reviews</i> , 2017, 13, 209-216.	0.6	132
1647	Statins for Early Stage Chronic Kidney Disease: An Overview of Reviews. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2014, 14, 205-211.	0.2	2
1648	The Treatment of Disorders of Lipid Metabolism. <i>Deutsches A&#x0308;rztblatt International</i> , 2016, 113, 261-8.	0.6	55
1649	Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults. <i>Nefrologia</i> , 2013, 33 Suppl 1, 1-28.	0.2	15
1651	Effect of revascularization strategy in patients with acute myocardial infarction and renal insufficiency with multivessel disease. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 177.	0.7	3
1652	Stroke in patients with chronic kidney disease: How do we approach and manage it?. <i>Indian Journal of Nephrology</i> , 2017, 27, 167.	0.2	36
1653	Statins in clinical medicine. <i>Swiss Medical Weekly</i> , 2011, 141, w13310.	0.8	16
1654	Dietary Management in Japan Atherosclerosis Society (JAS) Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases in Japanese ^ ^mdash;2012 Version^ ^mdash;. <i>The Japanese Journal of Nutrition and Dietetics</i> , 2013, 71, 3-13.	0.1	5
1655	Dyslipidemia, statins, and CKD patientsâ€™ outcomes â€“ review of the evidence in the post-sharp era. <i>Journal of Nephrology</i> , 2012, 25, 460-472.	0.9	16
1656	Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT. <i>Clinical Nephrology</i> , 2013, 80, 235-248.	0.4	4
1657	Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease. <i>Clinical Nephrology</i> , 2014, 81, 75-85.	0.4	16
1658	Vascular calcification, bone and mineral metabolism after kidney transplantation. <i>World Journal of Transplantation</i> , 2015, 5, 222.	0.6	14
1659	Vascular calcification: When should we interfere in chronic kidney disease patients and how?. <i>World Journal of Nephrology</i> , 2016, 5, 398.	0.8	18
1660	Diabetes Mellitus. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 93-98.	0.9	16

#	ARTICLE	IF	CITATIONS
1661	Chronic Kidney Disease. Journal of Atherosclerosis and Thrombosis, 2014, 21, 173-174.	0.9	3
1662	The Elderly. Journal of Atherosclerosis and Thrombosis, 2014, 21, 180-185.	0.9	1
1663	WpÅ,yw krÅ³tkotrwaÅ,ego leczenia skojarzonego simwastatynÄ... i ezetimibem na stÄ™Å¼enie adipokin w osoczu pacjentÅ³w na izolowanÄ... hipercholesterolemiÄ™. Endokrynologia Polska, 2014, 65, 275-280.	0.3	2
1666	Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiologica Sinica, 2016, 32, 631-639.	0.1	203
1667	Inflammation and Endothelial Dysfunction in the Initiation and Propagation of Cardiovascular Disease in Patients with Chronic Kidney Disease. British Journal of Medicine and Medical Research, 2014, 4, 2568-2580.	0.2	1
1668	Statin initiation in dialysis patients: The hardship of non-prescription. Atherosclerosis, 2021, 337, 53-56.	0.4	1
1669	Slowing Chronic Kidney Disease Progression. , 2022, , 51-68.		0
1670	Research Priorities for Kidney-Related Research“An Agenda to Advance Kidney Care: A Position Statement From the National Kidney Foundation. American Journal of Kidney Diseases, 2022, 79, 141-152.	2.1	10
1671	Lipid lowering in patients 75 years and older. World Journal of Cardiology, 2021, 13, 526-532.	0.5	2
1672	Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 713007.	1.6	6
1673	Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?. Current Atherosclerosis Reports, 2021, 23, 74.	2.0	0
1674	Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 410-419.	1.1	8
1675	State of the Care, Definition, and Epidemiology of Chronic Kidney Disease. , 2022, , 11-24.		1
1676	A Modern Approach to Dyslipidemia. Endocrine Reviews, 2022, 43, 611-653.	8.9	110
1677	Stratification Analysis of Statin Effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Hemodialysis. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	0.8	0
1678	Ezetimibe in the Treatment of Patients with Metabolic Diseases. European Endocrinology, 2010, 9, 55.	0.8	0
1679	ĩ¼“ĩ¼Ž è,,è³ä½Žä,è--ã«ã,ã,é€æžæ,èè€...ã®ã•è,,^ç;¬ãĒ-æ€Šã,ãf™ãf³ãf^æŠ^ã^¶. Nihon Toseki Igakkai Zasshi, 2011, 44, 1136-113		20
1680	Disorders of Lipid Metabolism. , 2011, , 1633-1674.		5

#	ARTICLE	IF	CITATIONS
1681	Risk Factors Associated with Arterial Stiffness in Diabetic Nephropathy in an Asian Population Cohort. Journal of the ASEAN Federation of Endocrine Societies, 2011, 26, 163-167.	0.1	0
1682	New Treatments for Diabetic Chronic Kidney Disease. Journal of Nephrology & Therapeutics, 2012, s2, .	0.1	1
1683	Management of Diabetic Nephropathy in the Elderly: Special Considerations. Journal of Nephrology & Therapeutics, 2012, 02, .	0.1	2
1684	Lipidsenkende Mittel. , 2012, , 697-711.		0
1686	Medical therapy in patients with chronic kidney disease. Journal of the Korean Medical Association, 2012, 55, 381.	0.1	3
1687	A Stepped Care Approach to the Management of Chronic Kidney Disease. , 2012, , 2205-2239.		1
1688	Drugs that affect lipid metabolism. Side Effects of Drugs Annual, 2012, , 723-730.	0.6	0
1689	Statin of Preference to Treat Dyslipidaemia in Patients with Renal Dysfunction : Cues from Saturn. Sultan Qaboos University Medical Journal, 2012, 12, 245-246.	0.3	0
1691	Renal Disease in Diabetes Mellitus: Recent Studies and Potential Therapies. Journal of Diabetes & Metabolism, 2013, 01, .	0.2	2
1692	Uso de estatinas y riesgo de diabetes. Revista Chilena De Cardiología, 2013, 32, 161-162.	0.0	0
1693	Ezetimibe in Combination With a Statin Does Not Reduce All-Cause Mortality. Journal of Clinical Medicine Research, 2013, 5, 275-80.	0.6	12
1694	Lipidsenkende Mittel. , 2013, , 687-702.		0
1695	The Analysis of Risk Factor Management Programs for Patients with Coronary Artery Disease. The Korean Journal of Rehabilitation Nursing, 2013, 16, 27-36.	0.1	4
1697	The EVOLVE Study: Another Disappointment for Nephrologists?. Giornale De Tecniche Nefrologiche & Dialitiche, 2013, 25, 261-265.	0.1	2
1698	EXPERT CONSENSUS. ROLE OF COMBINATION LIPID-LOWERING THERAPY (SIMVASTATIN/EZETIMIBE 20/10 MG) IN THE CORRECTION OF LIPID METABOLISM DISTURBANCES IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Cardiovascular Therapy and Prevention (Russian Federation), 2013, 12, 75-78.	0.4	0
1700	Dyslipidemia. , 2014, , 489-502.		1
1701	How Lipid-Lowering Agents Work: The Good, the Bad, and the Ugly. , 2014, , 45-65.		0
1702	Chronic Kidney Disease: Management. , 2014, , 547-562.		0

#	ARTICLE	IF	CITATIONS
1703	Dyslipidemia and Chronic Kidney Disease. , 2014, , 71-82.		0
1704	Chronic Kidney Disease: Cardiovascular Complications. , 2014, , 589-601.		0
1708	Non-statin Therapies for CKD with Dyslipidemia. , 2014, , 153-178.		0
1709	Dyslipidemia in Dialysis. , 2014, , 179-202.		0
1710	Dyslipidemia in Nephrotic Syndrome. , 2014, , 213-229.		0
1711	Review of Clinical Trials Pertaining to Dyslipidemias in CKD. , 2014, , 111-127.		0
1712	Dyslipidemias in the Geriatric Chronic Kidney Disease Patients. , 2014, , 255-267.		0
1713	Lipid-Lowering Drugs. , 2014, , 1-19.		0
1714	Treatment of Hyperlipidemia in the Statin-Intolerant Patient. , 2014, , 111-117.		0
1715	Dyslipidemia After Kidney Transplantation. , 2014, , 199-204.		0
1716	Epidemiology/Prevalence of Dyslipidemia in the General Population and in Patients with Chronic Kidney Disease. , 2014, , 1-8.		0
1717	Diabetes and the Kidney. , 2014, , 345-357.		0
1718	Review of Current Guidelines: National Cholesterol Education Program and Kidney Disease Outcomes Quality Initiative as They Apply to CKD with Dyslipidemias. , 2014, , 287-299.		0
1719	Pharmacokinetics of Lipid-Lowering Medications in Chronic Kidney Disease. , 2014, , 129-152.		0
1721	Chronische nierschade, implementatie richtlijnen en transmurale afstemming. , 2014, , 89-95.		0
1722	Cardiovascular Disease in Renal Transplantation. , 2014, , 472-490.		1
1724	Las nuevas guías de hipertensi3n arterial y dislipidemia, m3s all3 de la controversia, 3son gu3as confiables?. Revista Peruana De Medicina De Experimental Y Salud Publica, 2014, 31, .	0.1	0
1726	The role of the food lipid component in the progression of chronic renal failure. Giornale De Technice Nefrologiche & Dialitiche, 2015, 27, 4-8.	0.1	0

#	ARTICLE	IF	CITATIONS
1728	Statins in Chronic Kidney Disease. , 2015, , 187-199.		0
1729	Diseases of Renal Microcirculation: Diabetic Nephropathy. , 2015, , 3739-3768.		0
1730	Progression of Chronic Kidney Disease and Nephroprotective Therapy. , 2016, , 1399-1423.		1
1732	Do We Need A Wider Therapeutic Paradigm For Heart Failure With Comorbidities?: A Remote Australian Perspective. Health Care Current Reviews, 2016, 4, .	0.1	3
1733	Special Problems in Caring for Patients on Peritoneal Dialysis. , 2016, , 155-167.		0
1735	Statins, Targets and Chronic Kidney Disease. Journal of Cardiology & Current Research, 2016, 6, .	0.1	0
1737	Whatâ€™s the Optimal Lipids Level for Dialysis Patients? A Cohort Study from a Chinese Dialysis Center in a University Hospital. PLoS ONE, 2016, 11, e0167258.	1.1	2
1738	Management of Dyslipidemia in Long-Term Dialysis Patients. , 2017, , 655-659.e2.		0
1739	Coronary Artery Disease in CKD: Traditional and Nontraditional Risk Factors, Diagnosis and Management. , 2017, , 35-43.		0
1740	III. Management for Patients with Chronic Kidney Disease in Light of Preventing Cognitive Impairment and Cerebrovascular Disease. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 926-935.	0.0	0
1741	Effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction: A propensity score-matched analysis. PLoS ONE, 2017, 12, e0183059.	1.1	2
1742	Beyond the Lipid-lowering Effects of Statins: Renal Effects. KoÅŸuyolu Heart Journal, 2017, 20, 240-247.	0.1	0
1743	Fall 20: SpÃ¡tschÃ¡den â€“ 58 Jahre, â™€DM Typ 1, drohende Dialyse. , 2018, , 75-77.		0
1744	Diabetic dyslipidemia and microvascular complications of diabetes. Vnitri Lekarstvi, 2018, 64, 17-24.	0.1	5
1745	Coronary Intervention in the Chronic Kidney Disease, Diabetic and Elderly Populations. , 2018, , 291-303.		0
1746	Research Progress of Application of Novel Li-pid-Regulating Drugs. Pharmacy Information, 2018, 07, 74-78.	0.1	0
1747	Chronic Kidney Disease Ð°s a Common Medical Problem. UkraÃ­nsâ¼urnal Medicini BÃ¡-ologÃ¡-Ã¡ Ta Sportu, 2018, 3, 185-193.	0.0	0
1748	PÅ™nos novÃ© fixnÃ©-kombinace rosuvastatinu s ezetimibem k lÃ©bÅ› dyslipidemiÃ¡ ke snÃ¡enÃ©-celkovÃ©ho kardiovaskulÃ¡rnoho rizika. Vnitri Lekarstvi, 2018, 64, 457-460.	0.1	0

#	ARTICLE	IF	CITATIONS
1749	New clinical and pharmacological aspects of the use of atorvastatin for primary and secondary prevention of complications of cardiovascular diseases. Meditsinskiy Sovet, 2018, , 110-117.	0.1	0
1750	Combined lipid-lowering therapy. Vnitri Lekarstvi, 2018, 64, 1177-1184.	0.1	0
1752	Diabetes and Cardiovascular Disease. , 2019, , 709-730.		1
1753	Lipids and Renal Disease. Methodist DeBakey Cardiovascular Journal, 2021, 15, 88.	0.5	3
1754	Statins and the Kidney. , 2019, , 1330-1333.e2.		0
1755	Slowing Progression of Chronic Kidney Disease. , 2019, , 125-136.		0
1756	Cardiovascular Protection in Chronic Kidney Disease. , 2019, , 295-308.		0
1757	Pharmacologic Renal Protection. , 2019, , 101-112.		0
1759	Ezetimibe in the treatment of hypercholesterolaemia. Interni Medicina Pro Praxi, 2019, 21, 112-116.	0.0	0
1761	Diagnosis and treatment of myocardial infarction in patient with end - stage renal disease on chronic hemodialysis. Terapevticheski Arkhiv, 2019, 91, 137-144.	0.2	0
1762	Heart Failure in a Patient with End-Stage Kidney Disease on Renal Replacement Therapy. , 2020, , 107-120.		0
1763	Chronic kidney disease referrals from general practitioners pre- and post National Institute for Health and Care Excellence guidance 2014. Clinical Medicine, 2019, 19, 490-493.	0.8	0
1764	Investigating the Effect of Telenursing on Health Promoting Behaviours of Haemodialysis Patients in Education Hospitals in Zahedan in 2017-2018. Journal of Evolution of Medical and Dental Sciences, 2019, 8, 3326-3331.	0.1	5
1766	Chronic Kidney Disease and End Stage Renal Disease. Advanced Clinical Pharmacy Research, Development and Practical Applications, 2020, , 45-115.	0.0	0
1767	Cholesterol Levels. , 2020, , 1-7.		0
1768	The Burden of Coronary Artery Disease in Chronic Kidney Disease. , 2020, , 3-18.		0
1770	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS,) Tj ETQq0 0 0 rgBT /Overlo TREATMENT OF ATHEROSCLEROSIS (2020). Eurasian Heart Journal, 2020, , 6-29.	0.2	28
1771	Lipid-lowering therapy in selected specific groups of patients. MedicĀna Pro Praxi, 2020, 17, 151-156.	0.0	0

#	ARTICLE	IF	CITATIONS
1772	Efficacy of Ezetimibe/Simvastatin (10/10 mg) versus High Dose Statin in Dyslipidemia Patients: A Meta-Analysis of Randomized Controlled Trials. Iranian Journal of Public Health, 0, , .	0.3	0
1773	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation, 2021, 144, 1750-1759.	1.6	36
1775	Nutritional Management of Cardiovascular Disease. , 2020, , 223-236.		0
1776	Diabetic Kidney Disease and Cardiovascular Disease. , 2021, , 31-45.		0
1777	Intestinally Active Therapies for Hypercholesterolemia: Ezetimibe, Bile Acid Resins, and Plant Sterols. Contemporary Cardiology, 2021, , 219-268.	0.0	0
1778	Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. Contemporary Cardiology, 2021, , 611-651.	0.0	0
1779	Fixed-dose combination of rosuvastatin and ezetimibe. Vnitri Lekarstvi, 2020, 66, 513-517.	0.1	0
1780	Prevention and management of cardiovascular disease in kidney disease and kidney failure. , 2022, , 207-223.		0
1781	Nutritional management of maintenance hemodialysis patients. , 2022, , 557-591.		0
1782	Altered lipid metabolism and serum lipids in chronic kidney disease. , 2022, , 43-60.		2
1783	Chronische Nierenerkrankungen. , 2020, , 77-103.		0
1785	Uremic Toxin-Related Systemic Disorders. , 2020, , 53-67.		0
1786	Nephrology Consultative Approach and Risk Stratification Prior to Revascularization in Chronic Kidney Disease. , 2020, , 165-179.		0
1787	The Canadian Consensus Working Group's Approach to Identifying and Managing Statin-Associated Muscle and Other Symptoms. Contemporary Cardiology, 2020, , 137-150.	0.0	1
1788	The History of Prevention and Treatment of Diabetic Nephropathy. Frontiers in Diabetes, 2020, , 242-256.	0.4	2
1789	Intensity of statin therapy and renal outcome in chronic kidney disease: Results from the Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease. Kidney Research and Clinical Practice, 2020, 39, 93-102.	0.9	6
1790	Dyslipidemia in diabetic kidney disease classified by proteinuria and renal dysfunction: A cross-sectional study from a regional diabetes cohort. Journal of Diabetes Investigation, 2022, 13, 657-667.	1.1	18
1791	Comparison of using fractionated and unfractionated heparins after primary hip and knee arthroplasty in patients receiving programmed hemodialysis. Nephrology (Saint-Petersburg), 2020, 24, 55-64.	0.1	1

#	ARTICLE	IF	CITATIONS
1793	Reviewing the medical literature: five notable articles in general internal medicine from 2010 and 2011. <i>Open Medicine</i> , 2012, 6, e17-23.	1.5	0
1794	Twenty four-hour ambulatory blood pressure monitoring and lipid levels before, 3, 6 and 12 months after the onset of hemodialysis in chronic kidney disease patients: a pilot study. <i>Hippokratia</i> , 2012, 16, 154-8.	0.3	0
1795	Management of Diabetic Nephropathy in the Elderly: Special Considerations. <i>Journal of Nephrology & Therapeutics</i> , 2012, 2, .	0.1	1
1796	Pediatric patients with renal disease and cardiovascular complications: A literature review. <i>ARYA Atherosclerosis</i> , 2014, 10, 118-28.	0.4	1
1797	Does ezetimibe modify clinical outcomes?. <i>Canadian Family Physician</i> , 2015, 61, 251.	0.1	1
1798	Contemporary Management of Coronary Artery Disease and Acute Coronary Syndrome in Patients with Chronic Kidney Disease and End-Stage Renal Disease. <i>Acta Cardiologica Sinica</i> , 2013, 29, 132-41.	0.1	8
1799	ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy. <i>European Heart Journal Supplements</i> , 2017, 19, D163-D189.	0.0	0
1800	Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients. <i>Acta Cardiologica Sinica</i> , 2018, 34, 371-378.	0.1	12
1801	Modernization of Chronic Allograft Injury Research: Better Biomarkers, Better Studies, Better Outcomes. <i>Clinical Transplants</i> , 2015, 31, 211-225.	0.2	0
1802	Significant reduction in the LDL cholesterol increases the risk of intracerebral hemorrhage: a systematic review and meta-analysis of 33 randomized controlled trials. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 463-477.	0.0	6
1803	Efficacy of Ezetimibe/Simvastatin (10/10 mg) versus High Dose Statin in Dyslipidemia Patients: A Meta-Analysis of Randomized Controlled Trials. <i>Iranian Journal of Public Health</i> , 2019, 48, 1405-1417.	0.3	0
1804	Chinese Guideline on the Primary Prevention of Cardiovascular Diseases. <i>Cardiology Discovery</i> , 2021, 1, 70-104.	0.6	13
1805	Impact of Renal Insufficiency on Prognosis of Patients with Acute Coronary Syndrome. <i>International Journal of General Medicine</i> , 2021, Volume 14, 8919-8927.	0.8	2
1806	The Effect of Statins in Cancer Risk Reduction in Patients on Dialysis: A Population-Based Case-Control Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5602.	1.0	2
1807	Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 789931.	1.1	32
1808	2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. <i>Diagnostyka Laboratoryjna i Wiadomości PTDL</i> , 2021, 57, 1-99.	0.0	0
1809	Guía de unidades de hemodiálisis 2020. <i>Nefrología</i> , 2021, 41, 1-77.	0.2	5
1810	Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. <i>Advances in Therapy</i> , 2022, 39, 148-164.	1.3	41

#	ARTICLE	IF	CITATIONS
1811	Statin effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Haemodialysis. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, .	0.8	0
1812	Idiopathic chronic pancreatitis: Beyond antioxidants. <i>World Journal of Gastroenterology</i> , 2021, 27, 7423-7432.	1.4	4
1813	PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. <i>Archives of Medical Science</i> , 2021, 17, 1447-1547.	0.4	78
1814	A Matched Case-Control Study of Noncholesterol Sterols and Fatty Acids in Chronic Hemodialysis Patients. <i>Metabolites</i> , 2021, 11, 774.	1.3	2
1815	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 291-303.	3.0	10
1816	Cholesterol Levels. , 2021, , 970-976.		0
1817	Prevalence of statin intolerance: a meta-analysis. <i>European Heart Journal</i> , 2022, 43, 3213-3223.	1.0	151
1818	Cholesterol-Lowering Drugs. , 2020, , 233-248.		0
1819	The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. , 2021, 12, 1857.		2
1820	A Prognostic Merit of Statins in Patients with Chronic Hemodialysis after Percutaneous Coronary Interventionâ€”A 10-Year Follow-Up Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 390.	1.0	3
1821	Relationship between Low-Density Lipoprotein Cholesterol, Lipid Lowering Agents and the Risk of Stroke: A meta-analysis of Observational studies (n=355,591) and Randomized Controlled Trials (n=165,988).. <i>Archives of Medical Science</i> , 2022, , .	0.4	2
1822	Assessing the Validity of the Criteria for the Extreme Risk Category of Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Study. <i>Journal of Lipid and Atherosclerosis</i> , 2022, 11, 73.	1.1	6
1823	Fatty kidney: A possible future for chronic kidney disease research. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13748.	1.7	6
1824	The Protective Effects of Lipid-Lowering Agents on Cardiovascular Disease and Mortality in Maintenance Dialysis Patients: Propensity Score Analysis of a Population-Based Cohort Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 804000.	1.6	2
1825	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update. <i>Atherosclerosis</i> , 2022, 343, 28-50.	0.4	12
1826	The Effect of Statins on Mortality of Patients With Chronic Kidney Disease Based on Data of the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) and Korea National Health Insurance Claims Database. , 2022, 1, .		2
1828	Barriers to prescribing proprotein convertase subtilisinâ€”kexin type 9 inhibitors after coronary revascularisation. <i>Internal Medicine Journal</i> , 2022, , .	0.5	2
1829	Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021). <i>CL�nica E Investigaci�n En Arteriosclerosis (English Edition)</i> , 2022, , .	0.1	0

#	ARTICLE	IF	CITATIONS
1830	Chronic kidney disease as a risk factor for acute stroke. <i>Transplantologia</i> , 2021, 13, 382-397.	0.1	0
1832	Hemodialysis Centers Guide 2020. <i>Nefrologia</i> , 2021, 41, 1-77.	0.2	1
1834	Pan-European risk factor for a comprehensive cardiovascular health management. <i>Journal of Diabetes</i> , 2022, 14, 179-191.	0.8	2
1835	Uso de estatinas Ã© associado Ã menor mortalidade de causa cardiovascular em pacientes em diÃ¡lise candidatos ao transplante renal. <i>Revista Da Faculdade De CiÃªncias MÃ©dicas De Sorocaba</i> , 2022, 22, 106-111.	0.2	0
1836	JCS 2022 Guideline Focused Update on Diagnosis and Treatment in Patients With Stable Coronary Artery Disease. <i>Circulation Journal</i> , 2022, 86, 882-915.	0.7	37
1837	Contemporary Management of Dyslipidemia. <i>Drugs</i> , 2022, 82, 559-576.	4.9	14
1838	Association of Ratio of Apolipoprotein B to Apolipoprotein A1 With Survival in Peritoneal Dialysis. <i>Frontiers in Nutrition</i> , 2022, 9, 801979.	1.6	0
1839	A PON for All Seasons: Comparing Paraoxonase Enzyme Substrates, Activity and Action including the Role of PON3 in Health and Disease. <i>Antioxidants</i> , 2022, 11, 590.	2.2	10
1840	Could Phosphate Provide a Second Chance for Statin Therapy in Kidney Failure?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 478-480.	2.2	0
1841	Premature Death in Kidney Transplant Recipients: The Time for Trials is Now. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 665-673.	3.0	4
1842	Findings from 4C-T Study demonstrate an increased cardiovascular burden in girls with end stage kidney disease and kidney transplantation. <i>Kidney International</i> , 2022, 101, 585-596.	2.6	16
1843	Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease. <i>JAMA Network Open</i> , 2022, 5, e221169.	2.8	24
1844	Impacts of ezetimibe on risks of various types of cancers: a meta-analysis and systematic review. <i>European Journal of Cancer Prevention</i> , 2023, 32, 89-97.	0.6	4
1845	Association between changes in lipid indexes and early progression of kidney dysfunction in participants with normal estimated glomerular filtration rate: a prospective cohort study. <i>Endocrine</i> , 2022, , 1.	1.1	3
1846	Results of a pilot feasibility randomised controlled trial exploring the use of an electronic patient-reported outcome measure in the management of UK patients with advanced chronic kidney disease. <i>BMJ Open</i> , 2022, 12, e050610.	0.8	4
1847	Triglycerides and glucose index and the risk of cardiovascular events in persons with non-diabetic chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1705-1712.	1.4	7
1848	Low-density lipoprotein and blood pressure are important risk factors for vasculopathy in children on dialysis: A single center study. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 1220-1225.	0.4	1
1849	Ten things to know about ten cardiovascular disease risk factors â€” 2022. <i>American Journal of Preventive Cardiology</i> , 2022, 10, 100342.	1.3	34

#	ARTICLE	IF	CITATIONS
1850	Trimming the fat: is there a health economic case for the use of new lipid-lowering drugs in chronic kidney disease? A scoping review. CKJ: Clinical Kidney Journal, 0, , .	1.4	0
1851	Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms. Trends in Cardiovascular Medicine, 2023, 33, 170-179.	2.3	2
1852	Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials. Advances in Therapy, 2022, 39, 193-220.	1.3	12
1853	Higher Serum Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio Is Associated with Increased Mortality among Incident Peritoneal Dialysis Patients. Nutrients, 2022, 14, 144.	1.7	8
1854	Management of Adults with Newly Diagnosed Atrial Fibrillation with and without CKD. Journal of the American Society of Nephrology: JASN, 2022, 33, 442-453.	3.0	3
1855	Coronary Artery Disease in Chronic Kidney Disease: Need for a Heart-Kidney Team-Based Approach. European Cardiology Review, 2021, 16, e48.	0.7	3
1856	High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study. European Journal of Preventive Cardiology, 2022, 29, 1731-1739.	0.8	3
1857	Topical issues concerning modern lipid-lowering therapy. Consilium Medicum, 2022, 24, 20-27.	0.1	1
1858	Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease. Trials, 2022, 23, 331.	0.7	8
1859	GuÃa ESC 2021 sobre la prevenciÃn de la enfermedad cardiovascular en la prÃctica clÃnica. Revista Espanola De Cardiologia, 2022, 75, 429.e1-429.e104.	0.6	27
1860	Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, 101161CIRCOUTCOMES121008552.	0.9	21
1861	Cardiorenal Syndrome Triggered by Slowly Progressive Drugs Toxicity-Induced Renal Failure along with Minimal Mitral Disease: A Case Report. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2022, 22, 970-977.	0.6	3
1872	Prognosis and risk factors for cardiac valve calcification in Chinese end-stage kidney disease patients on combination therapy with hemodialysis and hemodiafiltration. Renal Failure, 2022, 44, 224-232.	0.8	7
1875	Safety and Efficacy of the Surgical Management of Hemodialysis Patients with Gastric Cancer. Acta Medica Okayama, 2017, 71, 333-339.	0.1	6
1876	Consensus document on the management of renal disease in HIV-infected patients. Nefrologia, 2014, 34 Suppl 2, 1-81.	0.2	8
1877	Kynurenine pathway metabolites predict subclinical atherosclerotic disease and new cardiovascular events in chronic kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 1952-1965.	1.4	4
1878	PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ, The, 2022, 377, e069116.	3.0	32
1879	Soluble Î±-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease. Kidney International, 2022, 102, 261-279.	2.6	16

#	ARTICLE	IF	CITATIONS
1880	Comparison of Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement and Lipid-Lowering Therapy in the Patients With Coronary Artery Disease With Different Renal Functions. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	0
1881	Cardiovascular Complications of Chronic Kidney Disease: An Introduction. <i>European Cardiology Review</i> , 0, 17, .	0.7	7
1882	Clinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database. <i>Journal of Nephrology</i> , 2022, , 1.	0.9	0
1883	Lipid-modifying and antiatherosclerotic drugs. , 2013, , 398-435.		3
1884	Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies. , 2022, 1, e000134.		13
1887	Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and) Tj ETQq1 1 0.784314 rgBT /Overlock 100483.	1.0	8
1888	Dyslipidemia in Renal Transplant Recipients. <i>Transplantology</i> , 2022, 3, 188-199.	0.3	2
1891	Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease. <i>American Heart Journal</i> , 2022, 251, 78-90.	1.2	7
1892	The Risk of Cardiovascular Events in Individuals With Primary Glomerular Diseases. <i>American Journal of Kidney Diseases</i> , 2022, 80, 740-750.	2.1	10
1893	Hydrophilic Versus Lipophilic Statin Treatments in Patients With Renal Impairment After Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	2
1894	Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1895	Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS) Tj ETQq1 1 0.784314 rgBT /Overlock 0.2	0.2	0
1896	NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. <i>Journal of Clinical Lipidology</i> , 2022, 16, 361-375.	0.6	56
1897	Acupuncture Combined with Traditional Chinese Medicine and Drug Therapy for the Treatment of Cerebral Infarction (Phlegm-Blood Stasis Syndrome) and Carotid Atherosclerotic Plaque: A Preliminary Randomized Controlled Study. <i>Applied Bionics and Biomechanics</i> , 2022, 2022, 1-6.	0.5	1
1898	Signaling pathways of chronic kidney diseases, implications for therapeutics. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	71
1899	2022 Taiwan lipid guidelines for primary prevention. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 2393-2407.	0.8	10
1900	Effect of Pemafibrate on Serum Creatinine in Patients with Chronic Kidney Disease. <i>JMA Journal</i> , 2022, 5, 328-333.	0.6	4
1901	The 2021â€“2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	3

#	ARTICLE	IF	CITATIONS
1902	Cardiovascular Risk Stratification and Appropriate Use of Statins in Patients with Chronic Kidney Disease According to Different Strategies. High Blood Pressure and Cardiovascular Prevention, 0, , .	1.0	1
1903	Statin use before and after the KDIGO Lipids in chronic kidney disease guideline: A populationâ€based interrupted time series analysis. Basic and Clinical Pharmacology and Toxicology, 0, , .	1.2	5
1904	Safety of Statins and Nonstatins for Treatment of Dyslipidemia. Endocrinology and Metabolism Clinics of North America, 2022, 51, 655-679.	1.2	7
1905	New Therapeutic Approaches in Treatment of Dyslipidaemiaâ€”A Narrative Review. Pharmaceuticals, 2022, 15, 839.	1.7	15
1906	Is Our Increasing Understanding of PCSK9 and Lp(a) Metabolism the Key to Unlocking the Paradox of Statins Ineffectiveness in Reducing Cardiovascular Events in Advanced CKD?. SN Comprehensive Clinical Medicine, 2022, 4, .	0.3	1
1907	Trajectory of low-density lipoprotein cholesterol in patients with chronic kidney disease and its association with cardiovascular disease. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
1908	Low-Density Lipoprotein Cholesterol and Mortality in Peritoneal Dialysis. Frontiers in Nutrition, 0, 9, .	1.6	2
1909	2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. Journal of the American College of Cardiology, 2022, 80, 1366-1418.	1.2	147
1910	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Planâ€”2022 Update. Endocrine Practice, 2022, 28, 923-1049.	1.1	146
1911	Extent of Low-density Lipoprotein Cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: A Systematic Review and Meta-analysis. Journal of Cardiovascular Pharmacology, 2023, 81, 35-44.	0.8	2
1912	LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgraduate Medicine, 2022, 134, 752-762.	0.9	9
1913	Management of Dyslipidemia in Long-Term Dialysis Patients. , 2023, , 430-433.		0
1914	Metabolic Complications of Peritoneal Dialysis. , 2023, , 296-299.		0
1915	Cardiovascular Disease Assessment Prior to Kidney Transplantation. Methodist DeBakey Cardiovascular Journal, 2022, 18, 50-61.	0.5	2
1916	Statin uses in adults with non-dialysis advanced chronic kidney disease: Focus on clinical outcomes of infectious and cardiovascular diseases. Frontiers in Pharmacology, 0, 13, .	1.6	1
1917	Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations. Journal of Human Hypertension, 2023, 37, 1-19.	1.0	19
1918	Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nature Reviews Nephrology, 2022, 18, 696-707.	4.1	101
1919	Non-High-Density Lipoprotein Cholesterol and Cardiovascular Outcomes in Chronic Kidney Disease: Results from KNOW-CKD Study. Nutrients, 2022, 14, 3792.	1.7	3

#	ARTICLE	IF	CITATIONS
1920	Statin Therapy in Persons Receiving Dialysis—Does Peripheral Artery Disease Change the Equation?. JAMA Network Open, 2022, 5, e2229713.	2.8	0
1921	Consider old and new approaches when treating dyslipidaemia. Drugs and Therapy Perspectives, 0, , .	0.3	0
1922	Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients. Cardiology Research and Practice, 2022, 2022, 1-9.	0.5	0
1923	Statins decrease overall mortality and cancer related mortality but are underutilized in NAFLD: a longitudinal analysis of 12,538 individuals. Expert Review of Gastroenterology and Hepatology, 2022, 16, 895-901.	1.4	7
1924	Lipidic profiles of patients starting peritoneal dialysis suggest an increased cardiovascular risk beyond classical dyslipidemia biomarkers. Scientific Reports, 2022, 12, .	1.6	5
1925	Hypercholesterolemia diagnosis, treatment patterns and target achievement in patients with acute coronary syndromes in Germany. Clinical Research in Cardiology, 2023, 112, 299-311.	1.5	7
1926	Association of Statin Therapy With Major Adverse Cardiovascular and Limb Outcomes in Patients With End-stage Kidney Disease and Peripheral Artery Disease Receiving Maintenance Dialysis. JAMA Network Open, 2022, 5, e2229706.	2.8	5
1927	Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care, 2022, 45, 3075-3090.	4.3	161
1928	Aspirin for Primary and Secondary Prevention of Mortality, Cardiovascular Disease, and Kidney Failure in the Chronic Renal Insufficiency Cohort (CRIC) Study. Kidney Medicine, 2022, 4, 100547.	1.0	2
1929	Association of Low-Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease. Journal of the American Heart Association, 2022, 11, .	1.6	4
1930	Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International, 2022, 102, 974-989.	2.6	65
1931	Combined impacts of low apolipoprotein A-I levels and reduced renal function on long-term prognosis in patients with coronary artery disease undergoing percutaneous coronary intervention. Clinica Chimica Acta, 2022, , .	0.5	0
1932	Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	0.9	5
1933	Pathogenesis of Coronary Artery Disease in Chronic Kidney Disease: Strategies to Identify and Target Specific Populations. , 2022, , 189-198.		0
1934	Hyperlipidemia and mortality in patients on peritoneal dialysis. BMC Nephrology, 2022, 23, .	0.8	3
1935	The Contribution of Lipotoxicity to Diabetic Kidney Disease. Cells, 2022, 11, 3236.	1.8	14
1936	Adherence to multidisciplinary care in a prospective chronic kidney disease cohort is associated with better outcomes. PLoS ONE, 2022, 17, e0266617.	1.1	2
1937	Antihyperlipidemic Treatment Options in Statin Resistance and Intolerance. Cardiology in Review, 0, Publish Ahead of Print, .	0.6	1

#	ARTICLE	IF	CITATIONS
1938	Emerging Evidence on Coronary Heart Disease Screening in Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2022, 146, .	1.6	38
1939	Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review. <i>Cureus</i> , 2022, , .	0.2	1
1940	The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function. <i>BMC Medicine</i> , 2022, 20, .	2.3	5
1941	Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors. <i>Drugs</i> , 2022, 82, 1565-1589.	4.9	17
1942	Non-High-Density Lipoprotein Cholesterol and Progression of Chronic Kidney Disease: Results from the KNOW-CKD Study. <i>Nutrients</i> , 2022, 14, 4704.	1.7	1
1948	European, Russian and American Clinical Guidelines on dyslipidemias management “ where do we stand? European, Russian, and US guidelines on dyslipidemias. , 2022, 1, 48-53.		0
1949	Digital health interventions in chronic kidney disease: levelling the playing field?. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 763-767.	1.4	3
1950	Lipidâ€Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Metaâ€Analysis of Exclusion Criteria. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	11
1951	Antidyslipidemia Pharmacotherapy in Chronic Kidney Disease: A Systematic Review and Bayesian Network Meta-Analysis. <i>Pharmaceutics</i> , 2023, 15, 6.	2.0	0
1952	Nontraditional Risk Factors for Progression Through Chronic Kidney Disease Risk Categories: The Coronary Artery Risk Development in Young Adults Study. <i>American Journal of Medicine</i> , 2023, 136, 380-389.e10.	0.6	5
1953	Albuminuria postâ€liver transplant is a predictor of kidney disease progression and mortality. <i>Canadian Liver Journal</i> , 2023, 6, 2-13.	0.3	1
1954	Cardiovascular Risk Factor Burden and Association With CKD in Ghana and Nigeria. <i>Kidney International Reports</i> , 2023, 8, 658-666.	0.4	1
1955	Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 995-1009.	1.5	0
1956	Cardiovascular Risk Factor Burden and Treatment Control in Patients with Chronic Kidney Disease: A Cross-Sectional Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, 30, 1210-1288.	0.9	3
1957	Long-term visit-to-visit variability in low-density lipoprotein cholesterol is associated with poor cardiovascular and kidney outcomes in patients with primary nephrotic syndrome. <i>International Urology and Nephrology</i> , 2023, 55, 1565-1574.	0.6	1
1958	Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology. <i>Swiss Medical Weekly</i> , 2023, 153, 40004.	0.8	4
1959	Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?. <i>American Journal of Preventive Cardiology</i> , 2023, 13, 100451.	1.3	1
1960	Improvement of clinical outcomes in patients undergoing peritoneal dialysis using hydroxymethylglutaryl-CoA reductase inhibitors: A systematic review and meta-analysis. <i>Journal of the Chinese Medical Association</i> , 2023, 86, 155-165.	0.6	0

#	ARTICLE	IF	CITATIONS
1961	Current Understanding on the Role of Lipids in Macrophages and Associated Diseases. <i>International Journal of Molecular Sciences</i> , 2023, 24, 589.	1.8	7
1962	Is There an Interest in Implementing a Multidisciplinary Clinic or Renal Care Network to Improve the Prognosis of Patients with Chronic Kidney Disease?. , 0, , 60-67.		1
1963	Long-term statins administration exacerbates diabetic nephropathy via ectopic fat deposition in diabetic mice. <i>Nature Communications</i> , 2023, 14, .	5.8	17
1964	Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update. <i>Biomedicines</i> , 2023, 11, 291.	1.4	7
1965	Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. <i>New England Journal of Medicine</i> , 2023, 388, 203-213.	13.9	40
1966	Improving Cardiac Outcomes Among Patients With Severe Chronic Kidney Disease. <i>JACC: Cardiovascular Interventions</i> , 2023, 16, 219-221.	1.1	0
1967	Cardiovascular Disease and Inflammation. , 2023, , 575-596.		1
1968	Total hip arthroplasty complications in patients with chronic kidney disease: A comparison study. <i>Journal of Orthopaedics</i> , 2023, 39, 1-6.	0.6	0
1970	The U-shaped association of non-high-density lipoprotein cholesterol with all-cause and cardiovascular mortality in general adult population. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	0
1971	Low-density lipoprotein cholesterol to apolipoprotein B ratio predicts mortality and cardiovascular events in peritoneal dialysis patients. <i>International Urology and Nephrology</i> , 0, , .	0.6	0
1972	Systolic blood pressure, low-density lipoprotein cholesterol levels, and adverse kidney outcome: results from KNOW-CKD. <i>Hypertension Research</i> , 2023, 46, 1395-1406.	1.5	2
1974	Complex Interventions Across Primary and Secondary Care to Optimize Population Kidney Health. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2023, 18, 563-572.	2.2	3
1976	Development of the Anaerobic Microbiome in the Infant Gut. <i>Pediatric Infectious Disease Journal</i> , 0, Publish Ahead of Print, .	1.1	0
1977	Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2023, 34, 955-968.	3.0	1
1978	Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. <i>Frontiers in Clinical Drug Research Diabetes and Obesity</i> , 2023, , 117-167.	0.1	0
1979	Development and Progression of Chronic Kidney Disease. , 2018, , 466-475.e1.		0
1980	Cardiac Function and Cardiovascular Disease in Chronic Kidney Disease. , 2018, , 506-514.e1.		0
1981	Disparities in PCSK9 Initiation Among US Veterans with Peripheral Arterial Disease or Cerebrovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2023, 23, 311-321.	1.0	1

#	ARTICLE	IF	CITATIONS
1982	Higher Levels of Blood Selenium are Associated with Higher Levels of Serum Lipid Profile in US Adults with CKD: Results from NHANES 2013-2018. <i>Biological Trace Element Research</i> , 0, , .	1.9	3
1983	Diabetic Kidney Disease. <i>Medical Clinics of North America</i> , 2023, 107, 689-705.	1.1	12
1984	Prevention of Cardiovascular Events in Patients With Chronic Kidney Disease. <i>Annals of Pharmacotherapy</i> , 0, , 106002802311657.	0.9	2
1985	The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy. <i>Circulation Research</i> , 2023, 132, 902-914.	2.0	11
1986	ADAM10 and ADAM17, Major Regulators of Chronic Kidney Disease Induced Atherosclerosis?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7309.	1.8	1
1995	Diabetes and Atherogenic Dyslipidemia. , 2023, , 645-656.		0
1996	Diabetes and Cardiovascular Disease. , 2023, , 813-835.		0
2004	Lipoproteins and Diabetic Kidney Disease. <i>Contemporary Diabetes</i> , 2023, , 407-438.	0.0	0
2006	About Randomized Clinical Trials Related to Lipoproteins in Diabetes Mellitus. <i>Contemporary Diabetes</i> , 2023, , 525-553.	0.0	0
2008	Optimizing Pharmacotherapy in Older Patients: An Interdisciplinary Approach: Chronic Kidney Disease. <i>Practical Issues in Geriatrics</i> , 2023, , 405-426.	0.3	0
2010	Cholesterol Absorption Inhibitors. , 2024, , 161-168.e1.		0
2011	Special Populations. , 2024, , 367-374.e1.		0
2017	Knowledge landscapes and emerging trends of cardiorenal syndrome type 4: a bibliometrics and visual analysis from 2004 to 2022. <i>International Urology and Nephrology</i> , 0, , .	0.6	1
2037	Dyslipidemia in Metabolic Syndrome. , 2023, , 1-18.		0
2046	Hypertension and Dyslipidemia in Pediatric Obesity. , 2023, , 343-376.		0
2048	Nierenerkrankungen. , 2023, , 251-263.		0
2049	Cerebrovascular Disease and Chronic Kidney Disease. , 2023, , 199-213.		0
2050	Dyslipidaemia in Kidney Disease. , 2023, , 69-79.		0

#	ARTICLE	IF	CITATIONS
2051	Management of Cardiovascular Disease in Chronic Kidney Disease. , 2023, , 171-197.		0
2052	Lipid-lowering drugs and cancer: an updated perspective. Pharmacological Reports, 2024, 76, 1-24.	1.5	0
2071	Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy. Current Atherosclerosis Reports, 2024, 26, 103-109.	2.0	0
2072	Dyslipidemia in Metabolic Syndrome. , 2023, , 529-546.		0